<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="3888"><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Controlled Study to Evaluate the Long-Term Effects of Calcium Antagonists on Augmentation Index in Hypertensive Patients with Chronic Kidney Disease</ProtocolTitle><Sponsor>Astellas Pharma Inc, Bayer AG, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Kyowa Hakko Kirin Co Ltd, Pfizer Inc, Saitama Medical University, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90858"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of single-dose cerivastatin in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="175">Hyperlipidemia</Indication><HighestDevStatusForInd id="W">Withdrawn</HighestDevStatusForInd><Trial id="55035"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of bromerguride in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="299">Schizophrenia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="55739"></Trial><Drug id="2686">bromerguride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CFAR Study in Patients With Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50839"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Campath Maintenance in Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47859"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Fludarabine, Cytoxan and FCCAM (Alemtuzumab) in Untreated B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47855"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL</ProtocolTitle><Sponsor>Mahidol University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="45221"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Telmisartan Versus Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="20967"></Trial><Drug id="2773">valsartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib, Letrozole and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I to IV Breast Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="296462"></Trial><Drug id="2784">letrozole</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVERCE</ProtocolAcronym><ProtocolTitle>Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="156949"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="247284"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="3081">exemestane</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROGRESS</ProtocolAcronym><ProtocolTitle>Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="33547"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer</ProtocolTitle><Sponsor>Beth Israel Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58127"></Trial><Drug id="3311">bicalutamide</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Compare Double-Dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6932"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BENEFIT</ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, randomized study to evaluate the safety and efficacy of Betaseron in patients with multiple sclerosis (MS)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="61965"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ABOVE</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-Remitting MS</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="16573"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study of the safety, pharmacokinetics and preliminary efficacy of vatalanib in combination with oxaliplatin/5-FU/leucovorin (FOLFOX-4) in patients with treatment-naive metastatic colorectal cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38140"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52354"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PDE5 Inhibitor Use and Non-Arteritic Anterior Ischemic Optic Neuropathy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198958"></Trial><Drug id="4119">tadalafil</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REPLACE</ProtocolAcronym><ProtocolTitle>Riociguat Replacing PDE-5i Therapy Evaluated Against Continued PDE-5i Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271077"></Trial><Drug id="4119">tadalafil</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemia</ProtocolTitle><Sponsor>Nakakinen Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="584">Lipid metabolism disorder</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="180271"></Trial><Drug id="4155">pravastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="4259">saquinavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Birth Control Patch Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60670"></Trial><Drug id="4582">norelgestromin + ethinylestradiol (contraceptive patch) Cygnus/RW Johnson</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Telmisartan Versus Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="20967"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy of Acarbose, Metformin, Sitagliptin Combination Treatment in DM Patients</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83240"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EDIP</ProtocolAcronym><ProtocolTitle>Early Diabetes Intervention Program</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="82372"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effects of acarbose on incretins secretion in new diagnosed T2DM</ProtocolTitle><Sponsor>Bayer AG, Guangdong Provincial People's Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="174148"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Acarbose-Adiponectin Study</ProtocolAcronym><ProtocolTitle>Investigation of the Effects of Postprandial Glucose Reduction by Acarbose on Insulin Sensitivity and Cardiovascular Markers in the Subjects With Different Stages of Glucose Tolerance</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="120791"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3498">Glucose intolerance</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HOVON 68 CLL</ProtocolAcronym><ProtocolTitle>A Randomized, Phase III Study In Previously Untreated Patients With Biological High-Risk CLL: Fludarabine + Cyclophosphamide (FC) Versus FC + Low-Dose Alemtuzumab</ProtocolTitle><Sponsor>Rigshospitalet, Denmark</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="153416"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONKO-011</ProtocolAcronym><ProtocolTitle>Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="243750"></Trial><Drug id="6295">tinzaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Panther</ProtocolAcronym><ProtocolTitle>Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab in HER2-positive Breast Cancer</ProtocolTitle><Sponsor>All Ireland Cooperative Oncology Research Group, Cancer Trials Ireland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="255521"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, non-randomized, pilot study to assess whether natalizumab reduces cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis</ProtocolTitle><Sponsor>Bayer AG, Biogen Inc, Merck KGaA, Novartis AG, Sanofi SA, Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="146666"></Trial><Drug id="6692">natalizumab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43497"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28057"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28057"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI ND-C</ProtocolAcronym><ProtocolTitle>A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="320384"></Trial><Drug id="7413">darbepoetin alfa</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multi-center clinical trial comparing 99mTc-P280 to contrast venography (CV) for detection and localization of acute deep venous thrombosis (DVT)</ProtocolTitle><Sponsor>Diatide Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48938"></Trial><Drug id="7908">99mTc-apcitide injection</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An exploratory study to prospectively evaluate the safety and maximum standardized uptake values of 18F-FPPRGD2 positron emission tomography in patients with glioblastoma multiforme</ProtocolTitle><Sponsor>Bayer AG, GE Healthcare, General Electric Co, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="311550"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I to evaluate the safety, tolerability and efficacy of bendamustine in combination with thalidomide and prednisolone (BPT) in patients with refractory or relapsed multiple myeloma</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49474"></Trial><Drug id="8050">thalidomide, Celgene</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="8710">glatiramer acetate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Azelaic Acid Foam 15% in Papulopustular Rosacea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62385"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalation, phase I trial of vatalanib in patients with newly diagnosed or relapsed/refractory AML or advanced MDS</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="38016"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, non-randomized, non-blinded, single-group study to determine the effect of lanthanum carbonate on serum phosphate in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis (CAPD)</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52937"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II study of sorafenib with TS-1 for advanced hepatocellular carcinoma</ProtocolTitle><Sponsor>Bayer AG, Chiba University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="118704"></Trial><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib, Letrozole and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I to IV Breast Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="296462"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib/Cetuximab in Head and Neck Cancer</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="39672"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of tICAM-1-453 to assess tolerability in the treatment of common cold</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="292">Rhinovirus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="17267"></Trial><Drug id="11174">tICAM-1-453, Bayer/Genetic Therapy</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 24-week, randomized, open-label, multicenter, comparative study to determine the safety and efficacy of dienogest versus leuprolide acetate in patients with endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88731"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate the pharmacokinetics of progestogen dienogest in females</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="51531"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SORAML</ProtocolAcronym><ProtocolTitle>Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia &lt; 60 Years of Age</ProtocolTitle><Sponsor>Technische Universitat Dresden</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54207"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and tolerability of rapid injection and information on the signal reduction in the liver and spleen at various doses of SH-U-555-A</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="18417"></Trial><Drug id="11665">ferucarbotran (small superparamagnetic), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged &lt; 2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85375"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Gadobutrol 1.0 M (Gadavist) in Patients for Central Nervous System (CNS) Imaging</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40610"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, active-controlled, parallel-arm study to compare an improvement in diagnostic ability of 0.5 M gadobutrol with 0.5 M gadopentetate dimeglumine by the contrast enhancement effect in patients with CNS disease</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="345237"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A open-label, comparative, multicenter contrast-enhanced MRA study to show the diagnostic efficacy and the safety of SHL-562BB for contrast enhanced Magnetic Resonance Angiography (CEMRA) of body arteries by analyzing the rate of agreement between a CEMRA based diagnosis and the diagnosis achieved from the comparator procedure ia DSA</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75790"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, two parallel-arm study to compare the efficacy of SH-L-562 versus Omniscan in the diagnosis of patients with evidence of brain lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="343152"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, randomized, double-blind, two parallel-arm study to evaluate the efficacy of SH-L-562 in the diagnosis of patients with CNS (brain) tumors</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="343150"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LEADER75</ProtocolAcronym><ProtocolTitle>Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="347577"></Trial><Drug id="11862">gadoterate meglumine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Compare SH-T00658ID to Ortho Tri-Cyclen Lo (US/Canada)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32271"></Trial><Drug id="12171">norgestimate + ethinylestradiol, Ortho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled study evaluating safety and efficacy sorafenib in combination with capecitabine in patients with advanced metastatic HER-2 negative breast cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="59091"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open Psoriasis Plaque Test to Evaluate Efficacy of Different Comparator to Mapracorat</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="281">Psoriasis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="325659"></Trial><Drug id="12242">calcipotriol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A two-year, multicenter, randomized, double-blind, active-controlled, noninferiority study to evaluate the safety and efficacy of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62842"></Trial><Drug id="12343">estradiol (transdermal patch, vasomotor symptoms/ osteoporosis), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of metrifonate in patients with probable Alzheimer's disease</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8283"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled, safety, pharmacokinetic/pharmacodynamic study of metrifonate in patients with Alzheimer's disease</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8217"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, controlled trial to assess the anti-inflammatory effect of moxifloxacin or cefuroxime in patients exposed to cardiopulmonary bypass</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86327"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOXI</ProtocolAcronym><ProtocolTitle>Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection</ProtocolTitle><Sponsor>Saarland University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75176"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRAGON</ProtocolAcronym><ProtocolTitle>Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45053"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="13022">epirubicin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A placebo-controlled, phase I/II trial to evaluate the tolerability and efficacy of PapViRx vacccine, a potential treatment for precancerous cervical dysplasia</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, MediGene AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="41913"></Trial><Drug id="13441">PapViRx</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the effect of SH-543 and Mercilon on carbohydrate metabolism  in women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51982"></Trial><Drug id="13599">desogestrel + ethinylestradiol (monophasic), Organon/Merck &amp; Co/Barr</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III trial to evaluate the efficacy of Yasminelle compared to Mercilon in the prevention of pregnancy in subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46670"></Trial><Drug id="13599">desogestrel + ethinylestradiol (monophasic), Organon/Merck &amp; Co/Barr</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAGELLAN</ProtocolAcronym><ProtocolTitle>Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6337"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FOXTROT</ProtocolAcronym><ProtocolTitle>Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="312046"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS-12 versus Combined Oral Contraceptive (COC) User Satisfaction Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72841"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROFESS</ProtocolAcronym><ProtocolTitle>Prevention Regimen For Effectively Avoiding Second Strokes</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="8146"></Trial><Drug id="15574">dipyridamole + acetylsalicylic acid (stroke), Boehringer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LIPLONG</ProtocolAcronym><ProtocolTitle>BAY-79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31251"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5124"></Trial><Drug id="20137">treprostinil</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Proof-of-concept Study for the Combination BAY-60-4552/Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="68518"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONFIRMED</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, cross-over design study to compare the efficacy and safety of vardenafil to that of sildenafil when used on demand in a population of men with erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54419"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of vardenafil when co-administered with cimetidine or ranitidine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52957"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of vardenafil in healthy male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52939"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose versus Placebo in Males With Erectile Dysfunction (ED)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31434"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of Efficacy of Vardenafil, Influence on Self-Esteem and Self-Confidence in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31210"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31164"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31161"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2529">Hot flashes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44475"></Trial><Drug id="22274">estradiol + levonorgestrel transdermal combination patch (HRT), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of afeletecan for the treatment of cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="49158"></Trial><Drug id="27970">afeletecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29794"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="44479"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preoperative Trial of Sorafenib in Combination with Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="69878"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled study evaluating safety and efficacy sorafenib in combination with capecitabine in patients with advanced metastatic HER-2 negative breast cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59091"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="47137"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DECISION</ProtocolAcronym><ProtocolTitle>Nexavar Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60624"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47449"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Myelodysplastic Syndrome</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="26657"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROGRESS</ProtocolAcronym><ProtocolTitle>Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33547"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AUS1</ProtocolAcronym><ProtocolTitle>An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma (AUS1)</ProtocolTitle><Sponsor>Austin Health</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="145850"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="61575"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Mahidol University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="39419"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COTSOM</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="217823"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Open, Phase II Comparison Of The Safety And Efficacy Of A Reduced And Re-escalated Dose Of Sorafenib Versus A Reduced And Maintained Dose Of Sorafenib In Patients With Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Chiba University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="204469"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Anti-Viral Effect of Sorafenib in Hepatitis C-Related Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Human Genome Sciences Inc, National Institutes of Health</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="141501"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="124761"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, single-arm, open-label, non-randomized, multicenter study to evaluate the safety and efficacy of single-agent sorafenib in patients with advanced biliary tract carcinoma</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="63998"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="43543"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, non-randomized, mono-institutional, phase II, escalation study to assess both clinical and biological efficacy and toxicity of sorafenib in patients with metastatic renal cell carcinoma (mRCC) previously treated with an anti-angiogenic vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor</ProtocolTitle><Sponsor>American Italian Cancer Foundation, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85065"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)</ProtocolTitle><Sponsor>Mahidol University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46040"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MRI</ProtocolAcronym><ProtocolTitle>MRI Study of BAY-43-9006 in Metastatic Renal Cell Carcinoma</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43561"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43543"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer</ProtocolTitle><Sponsor>University of Nebraska</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28819"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Research Study for Patients With Metastatic Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28380"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TARGET</ProtocolAcronym><ProtocolTitle>Study of BAY-43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28247"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY-81-8973 and Advate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="233200"></Trial><Drug id="31620">octocog alfa, Baxalta</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VOYAGER PAD</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="235475"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Confirmatory Bridging Study in Total Knee Replacement</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="70594"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN-Extension</ProtocolAcronym><ProtocolTitle>Once-Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6696"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CASTA-DIVA</ProtocolAcronym><ProtocolTitle>Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="258814"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein Jr</ProtocolAcronym><ProtocolTitle>Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241991"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CASSINI</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241455"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>BARIVA</ProtocolAcronym><ProtocolTitle>Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="339268"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CASSINI</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241455"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN Jr</ProtocolAcronym><ProtocolTitle>Oral Rivaroxaban in Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210054"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CASSINI</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241455"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability, Transdermally Administered EE and GSD, Three Application Sites</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="67279"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="57015"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="39209">axitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="64317"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1772">Osteosarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="121819"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Placebo-Controlled, Phase II Study of Bone-Targeted Radium-223 in Symptomatic Hormone-Refractory Prostate Cancer</ProtocolTitle><Sponsor>Algeta ASA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40386"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Re-Treatment Safety of Radium-223 Dichloride in Castration-Resistant Prostate Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="153754"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety and pharmacokinetics study of iv solulin in healthy volunteers</ProtocolTitle><Sponsor>PAION AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="7145"></Trial><Drug id="40733">solulin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEINJr</ProtocolAcronym><ProtocolTitle>Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="217784"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="36139"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalating Study With BAY-43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64882"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the efficacy of moxifloxacin to ceftriaxone plus metronidzaole for the treatment of patients with complicated intraabdominal infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="16401"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, dose-escalating, safety and pharmacokinetic study of L19-IL-2 fusion protein in combination with DTIC (dacarbazine) chemotherapy in patients with metastatic melanoma</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="58180"></Trial><Drug id="45599">L19-IL-2 fusion protein, Philogen</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TU/TU study</ProtocolAcronym><ProtocolTitle>The Quality of Life Outcomes and the Pharmacokinetic and Pharmacodynamic Sequela of Testosterone Undecanoate Injections compared with Testosterone Implants for Androgen Replacement Therapy in men with Classical Male Hypogonadism</ProtocolTitle><Sponsor>Bayer AG, Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3494">Male hypogonadism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="123847"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, double-dummy, placebo-controlled, four-way, crossover study to investigate QT/QTc prolonging effects in 12-lead ECG after once daily oral dosing over four days of drug product SHT-00658M (containing 3 mg dienogest and 2 mg estradiol valerate) and a supra-therapeutic dose of 10 mg dienogest in comparison to placebo and to a single-dose of 400 mg moxifloxacin as an open-label positive control in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="345200"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open Psoriasis Plaque Test to Evaluate Efficacy of Different Comparator to Mapracorat</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="281">Psoriasis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="325659"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>HPA Axis Study in Japanese Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="79701"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation of Different Concentrations of ZK-245186 in Atopic Dermatitis</ProtocolTitle><Sponsor>Bayer AG, Intendis GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59066"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3">Acne</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="177060"></Trial><Drug id="46287">cyproterone acetate + ethinyl estradiol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized, placebo-controlled study of effects of low dose aprotinin in patients with thoracic surgical operations</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63116"></Trial><Drug id="46885">aprotinin, Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CARILLON study</ProtocolTitle><Sponsor>Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="154453"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-Inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-Inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47898"></Trial><Drug id="48140">doxycycline (once-daily, oral controlled release), CollaGenex</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Double-Blind, Placebo-Controlled, Multicenter Study comParing Ciprofloxacin DPI 32.5 Mg bid Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Noncystic Fibrosis Bronchiectasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="161610"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NEUTON</ProtocolAcronym><ProtocolTitle>Study to evaluate the effectiveness of aflibercept in patients with macular edema secondary to central retinal vein occlusion</ProtocolTitle><Sponsor>Fundacin Retinaplus+</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="292450"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Modified treat and extend regimen of aflibercept to central retinal vein occlusion with cystoid macular edema</ProtocolTitle><Sponsor>Aoki Eye Clinic, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Jichi Medical University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="277590"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DA VINCI</ProtocolAcronym><ProtocolTitle>DME And VEGF Trap-Eye: (Intravitreal Aflibercept Injection [IAI;EYLEA; BAY-86-5321]) Investigation of Clinical Impact</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="35495"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTRID</ProtocolAcronym><ProtocolTitle>Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients</ProtocolTitle><Sponsor>Hospices Civils De Lyon</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3138">Choroidal neovascularization</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="242527"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EyNeP</ProtocolAcronym><ProtocolTitle>Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)</ProtocolTitle><Sponsor>University Hospital, Bonn, University of Bonn</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3138">Choroidal neovascularization</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239264"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARIES</ProtocolAcronym><ProtocolTitle>Managing Neovascular (Known as 'Wet') Age-related Macular Degeneration Over Two Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="243768"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Eylea in Patients With Wet Age-Related Macular Degeneration</ProtocolTitle><Sponsor>Kagawa University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="138802"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy</ProtocolTitle><Sponsor>University of Colorado at Denver and Health Sciences Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="327478"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="178912"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONSIGN</ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85150"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>University of Rochester</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231609"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer</ProtocolTitle><Sponsor>University of California</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3462">Metastatic liver cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="329900"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Proof-of-concept Study for the Combination BAY-60-4552/Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="68518"></Trial><Drug id="59348">nelociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COSMOS</ProtocolAcronym><ProtocolTitle>Copanlisib and Gemcitabine in Relapsed/Refractory PTCL</ProtocolTitle><Sponsor>Bayer Korea Ltd, Chonnam National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="288180"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Chinese PK Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="336232"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II, Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="226848"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="373629"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2448">Rhabdomyosarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="331813"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="357065"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) Drug-Drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="212225"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-blind, active-control, parallel-group study to evaluate the safety and efficacy of estradiol valerate(E2V)/dienogest compared to estradiol/levonorgesterel in women with OC-associated sexual symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81320"></Trial><Drug id="64238">estradiol valerate + dienogest + levomefolic acid (contraception), Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the Positron Emission Tomography (PET) Tracer ZK-6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="62628"></Trial><Drug id="65279">18F-FEDAA-1106</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE 1</ProtocolAcronym><ProtocolTitle>A Fixed-dose, Correction/naive and Pre-dialysis (Europe and Asia Pacific)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="169818"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIa, proof-of-concept study to evaluate the safety and efficacy of vilaprisan in the treatment of patients with uterine fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="260534"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="385606"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Determine the Maximum Tolerable Dose of BAY-94-9343 in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="81044"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="249448"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine as Second-line Treatment for Malignant Pleural Mesothelioma (MPM)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="246511"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Determine the Maximum Tolerable Dose of BAY-94-9343 in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="81044"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessing the Analgesic Efficacy of Naproxen Sodium in Post-Surgical Dental Pain</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81717"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Phase Ib, Dose Escalation Study Of  OMP-54F28 In Combination With Sorafenib  In Patients With First-Line Locally Advanced or Metastatic Hepatocellular cancer</ProtocolTitle><Sponsor>Bayer AG, OncoMed Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="174083"></Trial><Drug id="76435">ipafricept</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>INDessa</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="340952"></Trial><Drug id="82773">levonorgesterol (3-year intrauterine contraceptive system), Bayer Healthcare</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY-1905254</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="353074"></Trial><Drug id="86786">BAY-1905254</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCOCO</ProtocolAcronym><ProtocolTitle>Phase I Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="338906"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="244510"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHIARA MIA 1</ProtocolAcronym><ProtocolTitle>A Single-blind, Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY-1142524 in Clinically Stable Patients With Left Ventricular Dysfunction</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="230127"></Trial><Drug id="91352">fulacimstat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-Man Clinical Trial of Emodepside (BAY-44-4400)</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2506">Onchocerciasis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="251576"></Trial><Drug id="92511">emodepside</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of Iberogast on heartburn in patients with indigestion</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="432">Dyspepsia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="296763"></Trial><Drug id="93023">iberogast N (ulcerative colitis), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="335">Trypanosoma cruzi infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="357182"></Trial><Drug id="100280">Nifurtimox, Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial of BAY-1251152 for Advanced Blood Cancers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2054">Hematological neoplasm</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="258786"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of BAY-2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="337620"></Trial><Drug id="101864">BAY-2287411</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1003803 Formulation Comparison in Open Psoriasis Plaque Test</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="281">Psoriasis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="276371"></Trial><Drug id="103866">BAY-1003803</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Food Effect, Oral and Intravenous Pharmacokinetics and Absolute Bioavailability of BAY-1834845 Including Drug-drug Interaction With Methotrexate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="188">Inflammatory disease</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="308334"></Trial><Drug id="105371">BAY-1834845</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SANDMAN</ProtocolAcronym><ProtocolTitle>Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3519">Obstructive sleep apnea</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="347818"></Trial><Drug id="106188">BAY-2253651</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="15254">atazanavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43497"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="374667"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Kontakt</ProtocolAcronym><ProtocolTitle>Naproxen Sodium/ASA Platelet Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="209557"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I single dose-escalating, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6120"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of two contrast agents for magnetic resonance imaging in patients with liver cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169693"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>End-stage Renal Disease (ESRD) Pilot Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2037">Kidney dialysis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="364726"></Trial><Drug id="94069">BAY-1213790</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2727">Gliosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="24791"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65750"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43433"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VINSOR</ProtocolAcronym><ProtocolTitle>Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract</ProtocolTitle><Sponsor>Karolinska University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="129696"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect on Primary Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="172041"></Trial><Drug id="12170">levonorgestrel + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MANTRA Study</ProtocolAcronym><ProtocolTitle>Regorafenib versus placebo as maintenance therapy in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer</ProtocolTitle><Sponsor>Azienda Ospedaliero-Universitaria di Parma</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="257779"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An interventional single site pilot study to determine the prophylactic alteplase in the prevention of line-associated thrombosis and infection in short bowel syndrome</ProtocolTitle><Sponsor>Alnylam Pharmaceuticals Inc, Bayer AG, BioMarin Pharmaceutical Inc, Biogen Inc, Nutricia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="356279"></Trial><Drug id="6893">alteplase</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing No or Only Mild Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169389"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="244510"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Effects of Two Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89865"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="82103"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of rivaroxaban granules for oral suspension and rivaroxaban tablets</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="318990"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm study to evaluate the efficacy of gadobutrol in the treatment of hospitalized patients with tumor in the liver, pelvis, or bone and soft tissue</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343144"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II trial to determine the safety and preliminary efficacy of oral vatalanib in patients with renal cell carcinoma (RCC)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38014"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29716"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate Compliance With the Oral Contraceptive SH-T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73000"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Native American Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, parallel-group, controlled, US trial to compare the safety, efficacy, and bioequivalence of Beyaz and Yaz in healthy women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71262"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Oral Contraceptive Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31941"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-man Dose-escalation Study of BAY-2010112 in Patients With Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="97491"></Trial><Drug id="68967">pasotuxizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm study to evaluate the brain and spinal cord enhancement by SH-L-562 in the treatment of hospitalized patients with known CNS lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="759">Central nervous system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342692"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45207"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EyNeP</ProtocolAcronym><ProtocolTitle>Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)</ProtocolTitle><Sponsor>University Hospital, Bonn, University of Bonn</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2159">Pseudoxanthoma elasticum</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239264"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TripleAXEL</ProtocolAcronym><ProtocolTitle>Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169341"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial Of Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY-43-9006) In Metastatic Melanoma</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="26276"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONFIRM 1</ProtocolAcronym><ProtocolTitle>Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37551"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, randomized, double-blind, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist in patients with known or suspected liver lesions and with independent blinded read and assessment of the truth standard</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75861"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>ARIADME</ProtocolAcronym><ProtocolTitle>Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects</ProtocolTitle><Sponsor>Orion Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="227379"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label, Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-Tumor Activity</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76673"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A non-randomized, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY-734506 in patients with advanced solid tumors refractory to standard treatment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38559"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of a continuous-combined HRT preparation containing DRSP 3 mg and E2 1 mg on blood pressure in mildly hypertensive postmenopausal women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78447"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, randomized, placebo-controlled, parallel group, single center study to determine the effect of estradiol and drospirenone on the coronary flow reserve of post-menopausal women with angina pectoris measured by PET and echocardiography (ECHO)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78381"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pharmacodynamic Study Comparing Zegerid and Prilosec OTC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48955"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pharmacodynamic Study Comparing Zegerid and Prilosec OTC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48954"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J-ROCKET AF</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1077">Embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4977"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Rifampin on the Pharmacokinetics of BAY-73-4506</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76140"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333956"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Measuring Brain Amyloid Plaque Load in Older Adults Using BAY-94-9172</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3122">Mild cognitive impairment</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71473"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222484"></Trial><Drug id="49721">denosumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="69">Renal failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75362"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of recAAT in patients with moderate-to-severe emphysema</ProtocolTitle><Sponsor>Bayer Corp, PPL Therapeutics plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="111">Emphysema</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="30491"></Trial><Drug id="2481">recAAT, PPL Therapeutics/Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGORA</ProtocolAcronym><ProtocolTitle>The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib</ProtocolTitle><Sponsor>Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263264"></Trial><Drug id="16026">esomeprazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="162134"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="793">Mouth tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single/Multiple Dose Bioavailability Trial</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="199514"></Trial><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of lanthanum carbonate on arterial stiffness in patients with CKD 3 to 5 not on dialysis</ProtocolTitle><Sponsor>Kurume University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223124"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-escalation Trial of BAY-1187982 in Subjects with Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223770"></Trial><Drug id="90875">BAY-1187982</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATTRACT</ProtocolAcronym><ProtocolTitle>Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="134991"></Trial><Drug id="6893">alteplase</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43497"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3442">Metrorrhagia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44480"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PEACE III</ProtocolAcronym><ProtocolTitle>Phase III Radium 223 mCRPC</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210276"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Phenylephrine Extended Release Tablets on Allergy Related Nasal Congestion</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1107">Allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="180146"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROMISE</ProtocolAcronym><ProtocolTitle>Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15274"></Trial><Drug id="12543">ertapenem</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LAVALIER</ProtocolAcronym><ProtocolTitle>Lanthanum versus Calcium Carbonate for Vascular Abnormalities in Patients with CKD and Hyperphosphatemia</ProtocolTitle><Sponsor>Osaka University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210182"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRAP</ProtocolAcronym><ProtocolTitle>A Trinity Antiplatelet Responsiveness (TRAP) study to assess the high on-treatment platelet reactivity on commonly prescribed anti-platelet agents following the transient ischemic attack or ischemic stroke</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Biogen Inc, Merck KGaA, Pfizer Inc, Relitech, Stanley Thomas Johnson Foundation, The European Union</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="151241"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="231217"></Trial><Drug id="17735">sipuleucel-T</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Patients With Advanced Neuroendocrine Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2538">Carcinoid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58975"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-DN</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Different Oral Doses of BAY-94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="138995"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY-86-4367 in Patients With Prostate Cancer and Healthy Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60298"></Trial><Drug id="64471">BAY-86-4367</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, single-dose, single-site, randomized, single-blind, placebo-controlled, two-fold crossover study to evaluate the safety, tolerability and pharmacokinetics of ciprofloxacin DPI in healthy male subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150058"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole (ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C] Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="230626"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="245">Osteoarthritis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="344505"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare Omeprazole Administered as Zegerid Powder and as Prilosec Capsule in Healthy Participants (P08050 AM1)(CL2010-12)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="432">Dyspepsia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="182323"></Trial><Drug id="45877">omeprazole (powder for suspension), Salix/GlaxoSmithKline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of Long-term Treatment With Testosterone Undecanoate in Males With Hypogonadism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="33681"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multinational, randomized, non-blinded study of moxifloxacin, compared to co-amoxiclav in adult patients with acute exacerbations of chronic bronchitis (AECB)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1488">Chronic bronchitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50281"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="5321">indinavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CKD-FGF23</ProtocolAcronym><ProtocolTitle>CKD-FGF23 Study</ProtocolTitle><Sponsor>Daikosunadabashi Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212377"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose Escalation and Expansion of Oral BAY-1143269 in Combination With Intravenous Docetaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="228971"></Trial><Drug id="96499">BAY-1143269</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MATCHBOX</ProtocolAcronym><ProtocolTitle>Study of FVIIa Variant BAY-86-6150 (B-0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150246"></Trial><Drug id="52200">BAY-86-6150</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rivaroxaban Hypericum Trial</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="365829"></Trial><Drug id="8860">fexofenadine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54662">ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Research for the Adheerence and QOL for Oral Anti-coagulants(OAC) in Patients With Atrial Fibrillation</ProtocolTitle><Sponsor>KKR Takamatsu Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="168764"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REWRAPS</ProtocolAcronym><ProtocolTitle>Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation</ProtocolTitle><Sponsor>Fujita Health University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="165487"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29597"></Trial><Drug id="9829">Busulfex</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of BAY-2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="337620"></Trial><Drug id="101864">BAY-2287411</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the efficacy of cerivastatin in treatment of patients with hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55048"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MRS</ProtocolAcronym><ProtocolTitle>Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/recurrent Germ Cell Carcinoma Refractory to Chemotherapy</ProtocolTitle><Sponsor>Fondation Wygrajmy Zdrowie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3737">Germ cell and embryonic cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="172391"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCKET AF</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer HealthCare AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4937"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="791">Burkitts lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Trial To Evaluate Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="80589"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT-CHILD</ProtocolAcronym><ProtocolTitle>Riociguat in Children With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1541">Congenital heart defect</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241682"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARASENS</ProtocolAcronym><ProtocolTitle>ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263277"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein Jr</ProtocolAcronym><ProtocolTitle>Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241991"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RASET</ProtocolAcronym><ProtocolTitle>Rivaroxaban Anticoagulation for Superficial Vein Thrombosis</ProtocolTitle><Sponsor>McMaster University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184048"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MARINER</ProtocolAcronym><ProtocolTitle>A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Janssen-Cilag Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="181560"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Roniciclib (BAY-1000394) Drug-drug Interaction (DDI) Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="230830"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cardiovascular Safety Study of Magnevist Injection at Two Dose Levels and Two Injection Rates in Normal Subjects</ProtocolTitle><Sponsor>Berlex Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5676"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TripleAXEL</ProtocolAcronym><ProtocolTitle>Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169341"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-VERT</ProtocolAcronym><ProtocolTitle>Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Non-valvular Atrial Fibrillation Scheduled for Cardioversion</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90547"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An interventional study to determine the anti-Xa activity and factors related to bleeding events in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban</ProtocolTitle><Sponsor>Astellas Pharma Inc, AstraZeneca plc, Bayer Pharmaceuticals Corp, Pfizer Japan Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="386368"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of rivaroxaban for hemodynamics in left atrium and thrombotic/thrombolytic biomarkers</ProtocolTitle><Sponsor>Jichi Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="252355"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Rivaroxaban</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239537"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239279"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study on Anticoagulant Therapy in Catheter Ablation for Atrial Fibrillation - Rivaroxaban versus Warfarin : A Comparative Study</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="183113"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IRIVASC</ProtocolAcronym><ProtocolTitle>Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="174098"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFIRE</ProtocolAcronym><ProtocolTitle>Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study</ProtocolTitle><Sponsor>Japan Cardiovascular Research Foundation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249714"></Trial><Drug id="19001">prasugrel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 3</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer (Malaysia) Sdn Bhd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="325833"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-risk Fever and Neutropenia in Children With Cancer: safety and Efficacy of Oral Antibiotics in an Outpatient Setting</ProtocolTitle><Sponsor>Swiss Pediatric Oncology Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1991">Neutropenia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32141"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PMS</ProtocolAcronym><ProtocolTitle>A phase IV, randomized, double-blind, multicenter, group-comparative clinical trial to evaluate the clinical effect and cost-effectiveness of Adalat CR and Norvasc for the treatment of patients with essential hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77579"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Patients With Advanced Neuroendocrine Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2538">Carcinoid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58975"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249448"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of BAY-59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="40822"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="9298">Thymoglobulin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the safety, efficacy and usefulness of 0.5 M gadobutrol by enhancement effect in patients with diseases of the head and neck, heart, chest, bone/soft tissue or spine</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2490">Spinal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345240"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROSPECT-R</ProtocolAcronym><ProtocolTitle>Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy</ProtocolTitle><Sponsor>The Royal Marsden NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="284305"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROFESS</ProtocolAcronym><ProtocolTitle>Prevention Regimen For Effectively Avoiding Second Strokes</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8146"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29716"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Neomycin on the Pharmacokinetics of Regorafenib</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="162956"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm study to evaluate the added dose efficacy of SH-L-562 in the treatment of patients with known brain tumor or glioma</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342685"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57735"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZBEAM2</ProtocolAcronym><ProtocolTitle>Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma</ProtocolTitle><Sponsor>Lymphoma Study Association</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52267"></Trial><Drug id="3072">etoposide phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GadaCAD 2</ProtocolAcronym><ProtocolTitle>Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="143794"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3294">Metabolic syndrome X</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="24446"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An interventional single site pilot study to determine the prophylactic alteplase in the prevention of line-associated thrombosis and infection in short bowel syndrome</ProtocolTitle><Sponsor>Alnylam Pharmaceuticals Inc, Bayer AG, BioMarin Pharmaceutical Inc, Biogen Inc, Nutricia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="356279"></Trial><Drug id="6893">alteplase</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATMOS</ProtocolAcronym><ProtocolTitle>This Study Tests the Safety of Inhaled BAY-1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="361572"></Trial><Drug id="105762">BAY-1237592</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled study evaluating safety and efficacy sorafenib in combination with capecitabine in patients with advanced metastatic HER-2 negative breast cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59091"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>LEVEQ-3</ProtocolAcronym><ProtocolTitle>Crossover Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="67286"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, single-arm, open-label, non-randomized, multicenter study to evaluate the safety and efficacy of single-agent sorafenib in patients with advanced biliary tract carcinoma</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1515">Biliary tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="63998"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess</ProtocolTitle><Sponsor>KAOHSIUNG VETERANS GENERAL HOSPITAL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2994">Liver abscess</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54535"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of vardenafil when co-administered with cimetidine or ranitidine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52957"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOTIV</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Sequential iv/po Moxifloxacin in Comparison to iv Levofloxacin Plus iv Ceftriaxone Followed by po Levofloxacin, in the Treatment of Patients With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13915"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Pharmacokinetics/Safety Sorafenib + Capecitabine in Advanced Solid Tumors</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="33065"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Oral Contraceptive Pill for Premenstrual Worsening of Depression</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="93">Depression</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184351"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLANTIC</ProtocolAcronym><ProtocolTitle>Randomized, Double-masked, Sham-controlled, Phase IV Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Association for Innovation and Biomedical Research on Light and Image</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="234648"></Trial><Drug id="2622">verteporfin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cardiovascular Safety Study of Magnevist Injection at Two Dose Levels and Two Injection Rates in Normal Subjects</ProtocolTitle><Sponsor>Berlex Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5676"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35202"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label study to evaluate the efficacy of SH-L-562 in patients with primary cancers outside the CNS with brain metastases</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3463">Metastatic CNS cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342679"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alemtuzumab and Pentostatin In T-Cell Neoplasms</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="199">Leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47445"></Trial><Drug id="17015">pentostatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VOYAGER PAD</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235475"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49597"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study of Bevacizumab plus Sorafenib in Metastatic Breast Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44933"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="28035">cabazitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRIDGE</ProtocolAcronym><ProtocolTitle>Iloprost for Bridging to Heart Transplantation in PH</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233298"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Single-center, Non-randomized, Uncontrolled, Open-label, Observational Study To Evaluate The Pharmacokinetics And Safety Of Nifedipine GITS/Candesartan Fixed-Dose Combination In Patients With Hepatic Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="297511"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACROSS-AMI</ProtocolAcronym><ProtocolTitle>A Prospective, Randomized Clinical Trial, the Effect of Long Acting CCBs in Post-Acute Myocardial Infarction Patients</ProtocolTitle><Sponsor>Kumamoto University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132157"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, safety and efficacy study of pemetrexed in combination with carboplatin in patients with platinum-sensitive recurrent ovarian or primary peritoneal cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Eli Lilly &amp; Co, GlaxoSmithKline plc, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85458"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open, randomized trial to compare the effect of Meliane and Femodene on lipid metabolism</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51961"></Trial><Drug id="47516">gestodene + estrogen (oral), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Castrate Resistant Prostate Cancer Bone Metastasis</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186423"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Panther</ProtocolAcronym><ProtocolTitle>Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab in HER2-positive Breast Cancer</ProtocolTitle><Sponsor>All Ireland Cooperative Oncology Research Group, Cancer Trials Ireland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="255521"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo</ProtocolTitle><Sponsor>Bayer AG, Steigerwald Arzneimittelwerk GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="192">Irritable bowel syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154433"></Trial><Drug id="93023">iberogast N (ulcerative colitis), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SURPRISE</ProtocolAcronym><ProtocolTitle>Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux</ProtocolTitle><Sponsor>GWT-TUD GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83592"></Trial><Drug id="4476">fondaparinux sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1705">Endometrioid carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ABCD Trial</ProtocolAcronym><ProtocolTitle>The Effect of Nisoldipine As Compared With Enalapril on Cardiovascular Outcomes In Patients With Non-Insulin-Dependent Diabetes And Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="146882"></Trial><Drug id="44289">enalapril</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Aflibercept for Submacular Hemorrhage</ProtocolTitle><Sponsor>Kim's Eye Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="299946"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab</ProtocolTitle><Sponsor>Vista Klinik</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="217612"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration</ProtocolTitle><Sponsor>Jikei University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159427"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of naproxen on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6131"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I multiple-dose, safety, pharmacokinetic and pharmacodynamic study of BAY-59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6126"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J-ROCKET AF</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4977"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRAIN-AF</ProtocolAcronym><ProtocolTitle>Blinded, Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF</ProtocolTitle><Sponsor>Montreal Heart Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3849">Transient ischemic attack</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224270"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib in Patients With Advanced Myeloid Malignancies</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="287296"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of iv/po Moxifloxacin in Subjects With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21280"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOTIV</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Sequential iv/po Moxifloxacin in Comparison to iv Levofloxacin Plus iv Ceftriaxone Followed by po Levofloxacin, in the Treatment of Patients With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13915"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study for BAY-1251152 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249187"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29716"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29597"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>Hypertension and Atrial Fibrillation treated by Rivaroxaban for the Morning and Night with Synergy with calcium antagonists</ProtocolTitle><Sponsor>Jichi Medical School, Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273125"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72748"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of an Oral Contraceptive in Healthy Females</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31953"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, cross-over study to evaluate the effects of BAY-M-1099 and emiglitate on blood glucose control, insulin requirements and breath hydrogen in patients with insulin dependent diabetes mellitus (IDDM)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56992"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MATCHBOX</ProtocolAcronym><ProtocolTitle>Study of FVIIa Variant BAY-86-6150 (B-0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150246"></Trial><Drug id="52200">BAY-86-6150</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56815">vismodegib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety and Efficacy Study of Different Oral Doses of BAY-94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115003"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetic drug interaction study of talviraline with indinavir and zidovudine</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16972"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III, Randomized, Double-Blind, Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13646"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47753"></Trial><Drug id="3313">fulvestrant</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="28453">degarelix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-escalation Trial of BAY-1187982 in Subjects with Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223770"></Trial><Drug id="90875">BAY-1187982</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative, efficacy study between mesna and argimesna in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55894"></Trial><Drug id="24142">mesna</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO-4D</ProtocolAcronym><ProtocolTitle>Comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)</ProtocolTitle><Sponsor>European Commission against Racism and Intolerance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1565">Aortic valve stenosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265742"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="307713"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2273">Oligodendroglioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the safety, efficacy and tolerability of bendamustine in combination with mitoxantrone and rituximab in patients with symptomatic stage III/IV indolent lymphomas</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49427"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Sorafenib + Protracted Temozolomide in Recurrent GBM</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="24864"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-h Extended Release Tablet From Two Different Manufactuers Under Fed Conditions in Healthy Adult Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="338944"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematological Diseases</ProtocolTitle><Sponsor>NPO Center for Supporting Hematology-Oncology Trials</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3795">Febrile neutropenia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32155"></Trial><Drug id="2736">cefepime</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SH-L-562BB Phase II/III Dose Justification and Gadoteridol-Controlled Comparative Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45767"></Trial><Drug id="3191">gadoteridol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-86-9766 Plus Gemcitabine Phase I Study in Asian</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="104379"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56815">vismodegib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone</ProtocolTitle><Sponsor>Abramson Cancer Center of the University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73243"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGORA</ProtocolAcronym><ProtocolTitle>The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib</ProtocolTitle><Sponsor>Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263264"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Barostor (atorvastatin), tablets, film-coated, 80 mg (Xingfu Laboratorios, SA, Spain) and Lipitor tablets, film-coated, 80 mg (Gedeck GmbH Germany, manufactured by Pfizer Pharmaceuticals, Ireland)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="165856"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="3081">exemestane</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of sorafenib in combination with capecitabine in patients with advanced solid tumors</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83818"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Pharmacokinetics/Safety Sorafenib + Capecitabine in Advanced Solid Tumors</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="33065"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2445">Fibrosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, two-period, multiple-dose, fixed-sequence study to evaluate the effect of linagliptin on the steady-state pharmacokinetics of Microgynon in healthy, premenopausal female subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="347">Wound healing</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65486"></Trial><Drug id="55852">linagliptin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the efficacy of 1.0 M gadobutrol in the diagnosis of patients with evidence of suspected focal liver lesion, patients with COPD or patients with disease of the thoracic aorta</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1606">Aortic disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345215"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Betaferon/Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4401"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Ketoconazole on the Pharmacokinetics of Refametinib</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="151309"></Trial><Drug id="44299">ketoconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPARIOS 1</ProtocolAcronym><ProtocolTitle>BAY-98-7196 Dose-Finding/POC Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215042"></Trial><Drug id="5267">leuprorelin acetate</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="7934">doxorubicin (liposomal, STEALTH), Alza</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Advanced Solid Tumors Selected on Molecular Targets</ProtocolTitle><Sponsor>Southern European New Drug Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Suspended</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71514"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and tolerability of sorafenib in patients with advanced refractory solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52926"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignacies</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46375"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study With Sorafenib and Sirolimus</ProtocolTitle><Sponsor>Radboud University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32826"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the effects of atorvastatin high-dose and atorvastatin/ezetimibe combination therapy</ProtocolTitle><Sponsor>Misaki Naika Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="284962"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ODM-201 Versus Androgen Deprivation Therapy in Hormone Naive Prostate Cancer</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="280153"></Trial><Drug id="7286">goserelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Combination With Enzalutamide</ProtocolTitle><Sponsor>All Ireland Cooperative Oncology Research Group, Cancer Trials Ireland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="209043"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Transdermal Contraceptive Patch - Endometrial Effects Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54513"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>US Ovulation Inhibition Study in Obese Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50521"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS</ProtocolAcronym><ProtocolTitle>BAY-94-8862 Dose Finding Trial in Subjects with Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77024"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="5267">leuprorelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TeLoDe12</ProtocolAcronym><ProtocolTitle>Late-onset hypogonadism (LOH) and depressive mood changes - a double-blind, placebo-controlled study with intramuscular application of testosterone undecanoate</ProtocolTitle><Sponsor>Martin-Luther-Universitaet</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="93">Depression</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="185683"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PLANET</ProtocolAcronym><ProtocolTitle>Aflibercept in Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="183545"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VAULT</ProtocolAcronym><ProtocolTitle>Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Pusan National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="156429"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, two parallel-arm study to compare the efficacy of SH-L-562 versus Omniscan in the diagnosis of patients with evidence of brain lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343152"></Trial><Drug id="3189">gadodiamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to assess the safety and pharmacokinetics of tanomastat, a potential treatment for cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51047"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized study to evaluate efficacy outcomes of liposomal amphotericin B based on revised European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) 2008 definitions of invasive mould disease</ProtocolTitle><Sponsor>University Hospital of Cologne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="124">Fungal infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="81710"></Trial><Drug id="2503">amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of ramatroban in healthy volunteers</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29555"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of ramatroban in healthy volunteers</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29555"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of single-dose cerivastatin in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="33">Atherosclerosis</Indication><HighestDevStatusForInd id="W">Withdrawn</HighestDevStatusForInd><Trial id="55035"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29716"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HOVON 69 T-NHL</ProtocolAcronym><ProtocolTitle>Alemtuzumab, MabCampath With 2-weekly CHOP Chemotherapy For Mature T-cell Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Dutch-Belgian Cooperative Trial Group for Hematology Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="122798"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Campath in Chronic GVHD</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="616">Graft versus host disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47858"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48255"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Karolinska University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="41623"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Continuous Infusion of CAMPATH-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="29820"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HOVON 68 CLL</ProtocolAcronym><ProtocolTitle>A Randomized, Phase III Study In Previously Untreated Patients With Biological High-Risk CLL: Fludarabine + Cyclophosphamide (FC) Versus FC + Low-Dose Alemtuzumab</ProtocolTitle><Sponsor>Rigshospitalet, Denmark</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="153416"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor Plus Breast Cancer</ProtocolTitle><Sponsor>Rutgers University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46977"></Trial><Drug id="2784">letrozole</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib + FOLFIRI Versus Placebo + FOLFIRI as Second-Line Treatment in Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Irish Clinical Oncology Research Group, UNC Lineberger Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74911"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The prognostic value of the Glasgow Prognostic Score (GPS) in metastatic colorectal carcinoma (mCRC) patients receiving conventional cytotoxic therapy</ProtocolTitle><Sponsor>Amgen Inc, Bayer AG, Pfizer Inc, Roche Holding AG, Servier</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="227157"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Controlled Study to Evaluate the Long-Term Effects of Calcium Antagonists on Augmentation Index in Hypertensive Patients with Chronic Kidney Disease</ProtocolTitle><Sponsor>Astellas Pharma Inc, Bayer AG, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Kyowa Hakko Kirin Co Ltd, Pfizer Inc, Saitama Medical University, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90858"></Trial><Drug id="2881">azelnidipine</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multinational, Double-Blind, Randomized, Phase IIb, Cooperative-Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Fondazione Michelangelo</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246017"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65750"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fractionated Docetaxel and Radium-223 in Metastatic Castration-Resistant Prostate Cancer</ProtocolTitle><Sponsor>Tufts Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="359444"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 Mg/DRSP 3 Mg) on Quality of Life</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45040"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of BAY-86-5300 With an Extended Flexible Regimen for Endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="93103"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Oral Contraceptive Pill for Premenstrual Worsening of Depression</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="480">Premenstrual syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="184351"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="76235"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH-T00186D) in Comparison With the Conventional Regimen of YAZ</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45043"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS16 versus COC User Satisfaction and Tolerability Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="290187"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43433"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BENEFIT 15</ProtocolAcronym><ProtocolTitle>Long-term, Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="363303"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AVANTAGE</ProtocolAcronym><ProtocolTitle>Safety Study in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="16438"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CogniMS</ProtocolAcronym><ProtocolTitle>Cognition, Fatigue, Depression and HR-QoL in Early Multiple Sclerosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="148343"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BENEFIT 11</ProtocolAcronym><ProtocolTitle>Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="113918"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized, double-blind, controlled study to evaluate the efficacy and cardiorenal safety of lodixanol versus lopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64659"></Trial><Drug id="3393">iodixanol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="249448"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effect of BAY-M-1099 and BAY-O-1248 on blood glucose in healthy volunteers and in type 2 diabetics</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="56940"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II of Oxaliplatin, Capecitabine and Sorafenib for Advanced Pancreatic and Biliary Carcinoma</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47141"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacokinetics study of tanomastat in combination with paclitaxel and carboplatin, a potential treatment for cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51036"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47449"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pivotal Bioequivalence FDC Nifedipine/Candesartan versus Loose Combination of Single Components, Fed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="77278"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HITT</ProtocolAcronym><ProtocolTitle>High Dose, Absorbed Dose Adjusted 90Y-Ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-Cell Lymphoma</ProtocolTitle><Sponsor>Skne University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48275"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer</ProtocolTitle><Sponsor>Beth Israel Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58127"></Trial><Drug id="5267">leuprorelin acetate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study for Acarbose/Metformin FDC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="98656"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FLAT-SUGAR</ProtocolAcronym><ProtocolTitle>FLuctuATion Reduction With inSULin and Glp-1 Added togetheR</ProtocolTitle><Sponsor>University of Washington</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84715"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EDIT</ProtocolAcronym><ProtocolTitle>Early Diabetes Intervention Trial (EDIT Study)</ProtocolTitle><Sponsor>Bayer AG, Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="151615"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Three-Fold, Crossover, Bioequivalence Study Between Glucobay Oral Disintegerating Tablet (ODT) and Glucobay Standard Tablet</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="79022"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64877"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43543"></Trial><Drug id="6306">aldesleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>High Dose BAY-A-1040-Nifedipine: A Long-Term Combination Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74683"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FOCUS</ProtocolAcronym><ProtocolTitle>Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64319"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect on the early morning and at night home blood pressure of the high-capacity dihydride pyridine-based calcium antagonists in chronic kidney disease patients complicated with diabetes (compared to nifedipine CR and amlodipine)</ProtocolTitle><Sponsor>Saiseikai central Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254463"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Nifedipine-GITS in Patients With Mild-to-moderate Primary Hypertension</ProtocolTitle><Sponsor>Peking University First Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="249630"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Three-Year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-Menopausal Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4995"></Trial><Drug id="6681">raloxifene</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized, double-blind, controlled study to evaluate the efficacy and cardiorenal safety of lodixanol versus lopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64659"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, multicenter study to evaluate the nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62970"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64877"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25586"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIZZ</ProtocolAcronym><ProtocolTitle>A Phase II Study of Fractionated 90Y-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma</ProtocolTitle><Sponsor>Christie Hospital NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83327"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="29510"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of early and delayed imaging with 99mTc-P280 in detection of acute deep vein thrombosis: correlation with contrast venogram</ProtocolTitle><Sponsor>Diatide Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48932"></Trial><Drug id="7908">99mTc-apcitide injection</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The prognostic value of the Glasgow Prognostic Score (GPS) in metastatic colorectal carcinoma (mCRC) patients receiving conventional cytotoxic therapy</ProtocolTitle><Sponsor>Amgen Inc, Bayer AG, Pfizer Inc, Roche Holding AG, Servier</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="227157"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REPLACE</ProtocolAcronym><ProtocolTitle>Riociguat Replacing PDE-5i Therapy Evaluated Against Continued PDE-5i Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271077"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, controlled, cross-over trial of metabolic effects of acarbose or repaglinide when added to a double oral antidiabetic treatment with sulphonylureas and metformin in type 2 diabetic patients</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63005"></Trial><Drug id="8832">glimepiride</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Bayer AG, Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="82297"></Trial><Drug id="8860">fexofenadine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3">Acne</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="21302"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="37885"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea</ProtocolTitle><Sponsor>Clinical Research Center of the Carolinas</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="327838"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Depocyt With Sorafenib in Neoplastic Meningitis</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1814">Neoplastic meningitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="59862"></Trial><Drug id="9049">cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II safety and efficacy trial of vatalanib in patients with recurrent glioblastoma multiforme (GBM)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38132"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="9702">recombinant interferon beta-1a, Merck Serono</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LANDMARK</ProtocolAcronym><ProtocolTitle>Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients</ProtocolTitle><Sponsor>Foundation for Biomedical Research and Innovation, Translational Research Informatics Center, Kobe</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86540"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Chronic Kidney Disease (CKD) Not on Dialysis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65893"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ELAC-Hyper-CKD</ProtocolAcronym><ProtocolTitle>ELAC-Hyper-CKD (Effect of LAnthanum Carbonate on Hyperphosphatemia in Chronic Kidney Disease patients)</ProtocolTitle><Sponsor>Wakayama Medical University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="212068"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety and pharmacokinetics study of nikkomycin Z after oral administration of single doses to healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="124">Fungal infection</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="16772"></Trial><Drug id="10351">nikkomycin Z</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPAN-ORL06</ProtocolAcronym><ProtocolTitle>Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="264936"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Primovist in Chinese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="202">Liver tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48791"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, randomized, double-blind, multicenter, inter-individual comparison study of Gd-EOB-DTPA (SH-L-569) and Gd-BOPTA in MRI with a corresponding blinded reading in patients with known or suspected focal liver lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84885"></Trial><Drug id="11020">gadobenic acid</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the effects of atorvastatin high-dose and atorvastatin/ezetimibe combination therapy</ProtocolTitle><Sponsor>Misaki Naika Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="284962"></Trial><Drug id="11367">ezetimibe</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate the pharmacokinetics of progestogen dienogest in females</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51531"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMMA1</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Gadobutrol 1.0 M (Gadovist) for Breast MRI</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64111"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gadobutrol Magnevist-controlled Body Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63429"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15729"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind study to evaluate the efficacy of Climodien</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49015"></Trial><Drug id="11942">dienogest + estradiol valerate (HRT), Jenapharm</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics (PK) Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45864"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III study to assess efficacy of celecoxib and naproxen in patients with rheumatoid arthritis</ProtocolTitle><Sponsor>Monsanto Co</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="291">Rheumatoid arthritis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19173"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the effect of SH-543 and Mercilon on carbohydrate metabolism  in women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51982"></Trial><Drug id="12164">ethinylestradiol + gestodene (oral), Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="116">Enterobacter infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="485">Bacterial skin infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1394">Bacteroides fragilis infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>mRECT</ProtocolAcronym><ProtocolTitle>Repinotan in Patients With Acute Ischemic Stroke</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="6013"></Trial><Drug id="12980">repinotan</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone</ProtocolTitle><Sponsor>Abramson Cancer Center of the University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="73243"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS-12 Versus ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="79353"></Trial><Drug id="13600">etonogestrel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-KNEE</ProtocolAcronym><ProtocolTitle>An Oral, Direct Factor Xa Inhibitor, BAY-59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6158"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-OD-HIP</ProtocolAcronym><ProtocolTitle>Phase II study of once-daily rivaroxaban (BAY-59-7939), for thromboprophylaxis after total hip replacement</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6144"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-HIP2</ProtocolAcronym><ProtocolTitle>Dose-ranging study of BAY-59-7939 (rivaroxaban) on the prevention of VTE in patients undergoing elective total hip replacement</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4886"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODiXaHip</ProtocolAcronym><ProtocolTitle>A Phase IIa Dose-Escalating Proof-of-Principle Trial</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44864"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, multidose, randomized, double-blind placebo-controlled trial to evaluate the efficacy, tolerability and safety of tanomastat in patients with mild to moderate osteoarthritis (OA) of the knee</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="245">Osteoarthritis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="51056"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bleeding Pattern and User Satisfaction During Second Consecutive Mirena in Contraception and Treatment of Menorrhagia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32167"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, open, randomized, parallel-group study to compare the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) to low dose combined oral contraceptive pills (COC) in patients with idiopathic menorrhagia</ProtocolTitle><Sponsor>Assiut University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2051">Menorrhagia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75856"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss After Treatment With the Levonorgestrel-Releasing Intrauterine System (IUS)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2051">Menorrhagia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45039"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bleeding Pattern and User Satisfaction During Second Consecutive Mirena in Contraception and Treatment of Menorrhagia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2051">Menorrhagia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32167"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="64587"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Granulocyte-Colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59018"></Trial><Drug id="16758">plerixafor</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEYSER</ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="77734"></Trial><Drug id="16957">azelastine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Pharmacokinetic Study of Two Different Strengths of BAY-14-2222</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="89713"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Subjects</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Trial id="241494"></Trial><Drug id="21500">Beriplex P/N</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multiple Dose-Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY-60-4552</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65958"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy, Safety and Reliability of Vardenafil</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31236"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRIVER</ProtocolAcronym><ProtocolTitle>Depression Related Improvement With Vardenafil for Erectile Response</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31233"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PDE5 Inhibitor Use and Non-Arteritic Anterior Ischemic Optic Neuropathy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198958"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1241">Prostate hyperplasia</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="35241"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-Dose Hormone Therapy for Relief of Vasomotor Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2529">Hot flashes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60033"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIEW 2</ProtocolAcronym><ProtocolTitle>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="18499"></Trial><Drug id="22395">ranibizumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 5</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="308273"></Trial><Drug id="23239">ulipristal</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="23624">clofarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="28035">cabazitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, tolerability and pharmacokinetic study of sagopilone in Japanese patients with refractory solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="62548"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of Mass Balance of the Test Drug and Major Metabolites</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="45041"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II safety, tolerability, pharmacokinetics, and efficacy study of an IL-2 antagonist BAY-50-4798, in HIV patients</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="9220"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial Of Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY-43-9006) In Metastatic Melanoma</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="26276"></Trial><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="52354"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalating Study With BAY-43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="64882"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation, crossover study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="52874"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47114"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II of Oxaliplatin, Capecitabine and Sorafenib for Advanced Pancreatic and Biliary Carcinoma</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47141"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Granulocyte-Colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59018"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>University of California San Diego</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="84039"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 Phase II Study for Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28456"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Variance analysis of hepatic functional reserve in TACE and TACE combined with Sorafenib for HCC</ProtocolTitle><Sponsor>The First Affiliated Hospital of Zhengzhou University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="99665"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BASIL</ProtocolAcronym><ProtocolTitle>Assessing BAY-869766 Plus Sorafenib for the Treatment of Liver Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="70433"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46969"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>STORM</ProtocolAcronym><ProtocolTitle>Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="39481"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of BAY-43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28441"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HeiLivCa</ProtocolAcronym><ProtocolTitle>A Prospective, Randomized, Double-Blind, Multicenter, Phase III Clinical Study on Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Plus Placebo in Patients With Hepatocellular Cancer (HCC) Before Liver Transplantation (Ltx) -Heidelberg Liver Cancer Study (Heilivca Study)</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="152756"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="148980"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Safety and Tolerability in Dose-Escalation of Sorafenib in Advanced Renal Cell Cancer</ProtocolTitle><Sponsor>University of Kansas</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69566"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43469"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28459"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-line Therapy by Sorafenib for Lung Metastases Patients in Renal Cell Carcinoma</ProtocolTitle><Sponsor>Kobe University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="135208"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFIRE</ProtocolAcronym><ProtocolTitle>Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study</ProtocolTitle><Sponsor>Japan Cardiovascular Research Foundation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="249714"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement</ProtocolTitle><Sponsor>Ortho-McNeil Janssen Scientific Affairs, LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65667"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-OD-HIP</ProtocolAcronym><ProtocolTitle>Phase II study of once-daily rivaroxaban (BAY-59-7939), for thromboprophylaxis after total hip replacement</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6144"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I safety, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in subjects with extreme body weight</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6130"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXaHIP-OD</ProtocolAcronym><ProtocolTitle>Dose-ranging study of once-daily regimen of BAY-59-7939 in the prevention of VTE in patients undergoing elective total hip replacement</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4885"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>BARIVA</ProtocolAcronym><ProtocolTitle>Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="339268"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients</ProtocolTitle><Sponsor>Kyoto Prefectural University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="301694"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EinsteinChoice</ProtocolAcronym><ProtocolTitle>Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE (Venous Thromboembolism)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="173902"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84431"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MERCURY PE</ProtocolAcronym><ProtocolTitle>A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="243844"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS-TIMI 46</ProtocolAcronym><ProtocolTitle>Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes</ProtocolTitle><Sponsor>Bayer AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5154"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS 2 TIMI 51</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE), Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC, Johnson &amp; Johnson Sdn Bhd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38869"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMINI ACS 1</ProtocolAcronym><ProtocolTitle>A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="216173"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Safety and Effectiveness of Asoprisnil Doses in the Treatment of Women With Endometriosis</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="21374"></Trial><Drug id="34739">asoprisnil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="36669">trastuzumab emtansine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="206309"></Trial><Drug id="37370">azacitidine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="39209">axitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial to evaluate the safety and efficacy of Alpharadin in patients with skeletal metastases from prostate or breast cancer</ProtocolTitle><Sponsor>Algeta ASA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="40423"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REASURE</ProtocolAcronym><ProtocolTitle>Radium-223: evaluation of activity and surrogate response</ProtocolTitle><Sponsor>Cancer Research UK, The Royal Marsden NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239246"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>alpha-RT</ProtocolAcronym><ProtocolTitle>Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastasis</ProtocolTitle><Sponsor>Klinikum der Albert-Ludwigs Universitaet Freiburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="233340"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231217"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="207058"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese BAY-88-8223 Monotherapy, Phase II Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="152518"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARBON</ProtocolAcronym><ProtocolTitle>Capecitabine oral chemotherapy with radium-223 in breast cancer patients with bone metastasis</ProtocolTitle><Sponsor>Sheffield Teaching Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="253603"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="44314">tamoxifen</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Carboplatin/Paclitaxel in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="27986"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Active and Placebo-Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="194098"></Trial><Drug id="44403">lidocaine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation study to evaluate the safety and pharmacokinetics of telatinib in combination with irinotecan and capecitabine in patients with solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="40486"></Trial><Drug id="45497">telatinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="59836"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Compare SH-T00658ID to Ortho Tri-Cyclen Lo (US/Canada)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32271"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Different Concentrations of ZK-245186 in Atopic Dermatitis (AD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="71668"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33473"></Trial><Drug id="46885">aprotinin, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of bendamustine in patients with relapsed or refractory high-grade non-Hodgkin's lymphoma</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49491"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NOVEL</ProtocolAcronym><ProtocolTitle>Nifedipine On Coronary Vascular Function After Drug Eluting Stent Implantation</ProtocolTitle><Sponsor>Tohoku University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210503"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVERENT</ProtocolAcronym><ProtocolTitle>Reducing Blood Pressure Variability in Essential Hypertension With Ramipril Versus Nifedipine GITS Trial</ProtocolTitle><Sponsor>Istituto Auxologico Italiano</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="235002"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSDOY</ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88345"></Trial><Drug id="49721">denosumab</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Cipro Inhale in Patients With Non-Cystic Fibrosis Bronchiectasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="58490"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESPIRE 2</ProtocolAcronym><ProtocolTitle>Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="181044"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MEDICARE</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy</ProtocolTitle><Sponsor>Centre Hospitalier Universitaire De Poitiers Etablissement DHospitalisation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2657">Proliferative diabetic retinopathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="192657"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIVID-Japan</ProtocolAcronym><ProtocolTitle>Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84136"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORESIGHT</ProtocolAcronym><ProtocolTitle>Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept</ProtocolTitle><Sponsor>Konkuk University medical center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="364026"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Morphological-based aflibercept treatment for DME</ProtocolTitle><Sponsor>Tokyo Medical And Dental University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="283793"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIOLET</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="264575"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AQUA</ProtocolAcronym><ProtocolTitle>Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="244661"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Intravitreal Aflibercept Injection</ProtocolTitle><Sponsor>Mie University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="234799"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of the T and E protocol with IVA in combination with retinal photocoagulation in DME patients</ProtocolTitle><Sponsor>Shinshu University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="226572"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PEACE III</ProtocolAcronym><ProtocolTitle>Phase III Radium 223 mCRPC</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210276"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1105">Scleroderma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT-CHILD</ProtocolAcronym><ProtocolTitle>Riociguat in Children With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241682"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESPITE</ProtocolAcronym><ProtocolTitle>Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="163723"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHEST-1</ProtocolAcronym><ProtocolTitle>A Study to Evaluate Efficacy and Safety of Oral BAY-63-2521 in Patients With CTEPH</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47887"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A non-randomized, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY-734506 in patients with advanced solid tumors refractory to standard treatment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="38559"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESORCE</ProtocolAcronym><ProtocolTitle>Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="105823"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOBONE</ProtocolAcronym><ProtocolTitle>A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1772">Osteosarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="224631"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOVAR</ProtocolAcronym><ProtocolTitle>Regorafenib versus Tamoxifen in Patients With Platinum-sensitive Ovarian Carcinoma and Isolated Biological Progression</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="243698"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROSPECT-R</ProtocolAcronym><ProtocolTitle>Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy</ProtocolTitle><Sponsor>The Royal Marsden NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="284305"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PARICCA</ProtocolAcronym><ProtocolTitle>Phase II Study of Perindopril and Regorafenib in mCRC</ProtocolTitle><Sponsor>BC Cancer Agency</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="250589"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers</ProtocolTitle><Sponsor>Sir Mortimer B Davis Jewish General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="155611"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Uncontrolled Study of BAY-73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="38539"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55288">trametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to evaluate the efficacy of florbetaben (18F) in predicting conversion from mild cognitive impairment to Alzheimer's disease (AD) through the imaging of amyloid-beta</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="80648"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the efficacy of PET imaging with BAY-94-9172 in healthy subjects, Alzheimers disease (AD) patients and patients with frontotemporal lobar degeneration (FTLD)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34586"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single Dose-escalation Study in Patients With Chronic Heart Failure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="13183"></Trial><Drug id="59348">nelociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multiple Dose-Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY-60-4552</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="65958"></Trial><Drug id="59348">nelociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="220374"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2975">Ewing sarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="331813"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPAN-ORL06</ProtocolAcronym><ProtocolTitle>Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="264936"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Phase III, Uncontrolled, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY-94-9027 for Prophylaxis and on-Demand Treatment in Children (Age &lt; 12 Years) With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="150845"></Trial><Drug id="65438">damoctocog alfa pegol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE4</ProtocolAcronym><ProtocolTitle>Maintenance Treatment of Anemia Associated with Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa/Beta Treatment Versus BAY-85-3934</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="160484"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Finerenone to Investigate a Pediatric Formulation in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="278261"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-DN Japan</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Different Oral Doses of BAY-94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="158814"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF Japan</ProtocolAcronym><ProtocolTitle>Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="157446"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-DN</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Different Oral Doses of BAY-94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="138995"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 7</ProtocolAcronym><ProtocolTitle>Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="343659"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 8</ProtocolAcronym><ProtocolTitle>A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="333665"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Hysterectomy is Planned</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="319800"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to test the effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adults with high blood pressure whose blood pressure is not well controlled with tablets containing Nifedipine</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="157359"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Compare Pharmacokinetic Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="90267"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>KEIFER SST</ProtocolAcronym><ProtocolTitle>Self-Selection Trial of Naproxen Sodium</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81715"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PARSiFAL</ProtocolAcronym><ProtocolTitle>Multiple-dose Study in Heart Failure of BAY-1067197</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="168943"></Trial><Drug id="75478">neladenoson bialanate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VITALITY HFpEF</ProtocolAcronym><ProtocolTitle>Patient-Reported Outcomes in Vericiguat-Treated Patients With HFpEF</ProtocolTitle><Sponsor>Bayer (Malaysia) Sdn Bhd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="337172"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial of endometriosis therapies, Bayer for the treatment of endometriosis</ProtocolTitle><Sponsor>Bayer HealthCare AG, Evotec SE</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="336662"></Trial><Drug id="81227">endometriosis therapies, Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1276">Female sexual dysfunction</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="100154"></Trial><Drug id="82568">prasterone  (female sexual dysfunction), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Oral BAY-85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="117679"></Trial><Drug id="84161">PHP-303</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A first-in-human, randomized, multicenter, parallel-group, three-arm, open-label, phase I study to assess pharmacokinetics, pharmacodynamics, safety and tolerability of intravaginal ring releasing anastrozole and levonorgestrel in healthy ovulating female subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="282384"></Trial><Drug id="90559">anastrozole + levonorgestrel (intravaginal ring, endometriosis), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPARIOS 1</ProtocolAcronym><ProtocolTitle>BAY-98-7196 Dose-Finding/POC Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="215042"></Trial><Drug id="90559">anastrozole + levonorgestrel (intravaginal ring, endometriosis), Bayer</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Factor VIII Gene Therapy Study in Patients With Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="346470"></Trial><Drug id="91675">DTX-201</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and PK of Multiple-Ascending Doses of Emodepside</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2505">Filariasis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="323780"></Trial><Drug id="92511">emodepside</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial to evaluate the safety and efficacy of BAY-1213790 in the treatment of patients with thrombosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="260413"></Trial><Drug id="94069">BAY-1213790</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Oral BAY-1217389 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="222465"></Trial><Drug id="95532">BAY-1217389</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY-1834845</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="288414"></Trial><Drug id="105371">BAY-1834845</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY-1161116</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1699">Polycystic ovary syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="295572"></Trial><Drug id="106042">BAY-1161116</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY-1830839 in Healthy Male Participants</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="291">Rheumatoid arthritis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="382691"></Trial><Drug id="110323">BAY-1830839</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233483"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74576"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib study to evaluate the safety and efficacy of telatinib administered in combination with docetaxel in patients with solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="40495"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation</ProtocolTitle><Sponsor>Derm Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2010">Hyperpigmentation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62981"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine as Second-line Treatment for Malignant Pleural Mesothelioma (MPM)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246511"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOBONE</ProtocolAcronym><ProtocolTitle>A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2444">Chondrosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224631"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2727">Gliosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246805"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate versus Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="174120"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="53133">dabrafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-73-4506 Probe Substrate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74481"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed-Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-Intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71680"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FDA Phase IV- Commitment- Retinal Function Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55315"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of PI3 (Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY-86-9766) in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="79185"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the efficacy of 1.0 M gadobutrol in the diagnosis of patients with evidence of suspected focal liver lesion, patients with COPD or patients with disease of the thoracic aorta</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345215"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHIARA MIA 2</ProtocolAcronym><ProtocolTitle>A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY-1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="280736"></Trial><Drug id="91352">fulacimstat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnetic Resonance Imaging of the Liver in Children 0 to 2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177578"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="3081">exemestane</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Determine the Maximum Tolerable Dose of BAY-94-9343 in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81044"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RIOPRED</ProtocolAcronym><ProtocolTitle>Riociguat in patients with respiratory disease hypoxia - a proof-of-concept study</ProtocolTitle><Sponsor>Newcastle upon Tyne Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1053">Hypoxia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="256782"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pharmacokinetics, Pharmacodynamics and Safety Study of Single-Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215693"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="203798"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of efficacy and safety of vardenafil in patients with erectile dysfunction and type 1 diabetes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10726"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320618"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer</ProtocolTitle><Sponsor>University of California</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3462">Metastatic liver cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="329900"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2991">Uterine hemorrhage</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44478"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacokinetic study of vatalanib in fed patients with hormone-refractory prostate cancer (HRPC)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38222"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3471">Metastatic brain cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47142"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="629">Hepatobiliary system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, inter-individual, parallel-group comparison study to evaluate the detection of myocardial perfusion defects at rest and after stress compared to SPECT using SH-L-562</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="671">Myocardial disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343148"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Renal Impairment Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="326057"></Trial><Drug id="91352">fulacimstat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-blind, Randomized, Phase II Study of Once Daily Versus Twice Daily PTK-787/ZK-222584 Treatment in Patients With Advanced, Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum - ND</ProtocolTitle><Sponsor>Bayer AG, Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="138984"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, active-controlled, parallel-arm study to compare an improvement in diagnostic ability by the contrast enhancement effect of 0.5 M gadobutrol with 0.5 M gadopentetate dimeglumine in patients with disorders of the liver or pelvis</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345230"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="181148"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rivaroxaban Hypericum Trial</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="365829"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320618"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61539"></Trial><Drug id="44937">amikacin (inhaled, Aeroneb), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS 2 TIMI 51</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE), Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC, Johnson &amp; Johnson Sdn Bhd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38869"></Trial><Drug id="44382">ticlopidine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Angeliq in Thai Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32398"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alpharadin Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton</ProtocolTitle><Sponsor>Algeta ASA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28004"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3240">Medullary thyroid cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="251209"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC</ProtocolTitle><Sponsor>Clinical Research Support Center Kyushu, Kyushu Study Group of Clinical Cancer</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215638"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCKET AF</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer HealthCare AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1077">Embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4937"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Ketoconazole on Regorafenib (BAY-73-4506) Pharmacokinetics</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75641"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99392"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 4</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3442">Metrorrhagia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="325925"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EUCLID</ProtocolAcronym><ProtocolTitle>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99397"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMINI ACS 1</ProtocolAcronym><ProtocolTitle>A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="216173"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35591"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, randomized, placebo-controlled, multiple-dose study to evaluate the safety, pharmacokinetic and efficacy of cerivastatin between young and elderly male patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="246">Osteoporosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55066"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="3311">bicalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NEXUS</ProtocolAcronym><ProtocolTitle>A Phase III, Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28385"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Active and Placebo-Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="517">Common cold</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="194098"></Trial><Drug id="44403">lidocaine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, multicenter, multinational, controlled, double-blind, randomized clinical trial to evaluate the safety and efficacy of treatment with either moxifloxacin or amoxicillin for the treatment of patients with community-acquired pneumonia in Latin America</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73263"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of Sorafenib and Eribulin in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="86865"></Trial><Drug id="28773">eribulin mesylate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1107">Allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="330348"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Roniciclib (BAY-1000394) Drug-drug Interaction (DDI) Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="230830"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEYSER</ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77734"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76265"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost</ProtocolTitle><Sponsor>University of Lund</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5698"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the safety, efficacy and usefulness of 0.5 M gadobutrol by enhancement effect in patients with diseases of the head and neck, heart, chest, bone/soft tissue or spine</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345240"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFIRE</ProtocolAcronym><ProtocolTitle>Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study</ProtocolTitle><Sponsor>Japan Cardiovascular Research Foundation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249714"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HARMONY II</ProtocolAcronym><ProtocolTitle>Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3121">Drug withdrawal syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31744"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3198">Larynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, dosimetric and pharmacokinetic study of the anti fibronectin 131-I-L19-small immunoprotein (SIP), in patients with solid tumors</ProtocolTitle><Sponsor>Philogen SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36556"></Trial><Drug id="43218">131I-radretumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm, comparative study to evaluate the diagnostic accuracy of SH-L-562 in patients with pelvic cancer</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343146"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Finding Study of Gadovist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2920">Spinal cord disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49081"></Trial><Drug id="17382">gadoversetamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="138">Gram positive bacterium infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-blind, Comparative, Randomized Study Of The Effects Of A 23-day Oral Contraceptive Regimen With 20 Microg Ethinyl Estradiol And 75 Microg Gestodene And A 21-day Regimen With 30 Microg Ethinyl Estradiol And 75 Microg Gestodene On Hemostatic Variables, Lipids, And Carbohydrate Metabolism</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="110459"></Trial><Drug id="12164">ethinylestradiol + gestodene (oral), Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="759">Central nervous system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PULSE</ProtocolAcronym><ProtocolTitle>Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis</ProtocolTitle><Sponsor>Bayer AG, Bayer plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="283">Lung disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13572"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Climara Pro in post-menopausal patients with hysterectomies</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="246">Osteoporosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46815"></Trial><Drug id="22274">estradiol + levonorgestrel transdermal combination patch (HRT), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPOSE 2</ProtocolAcronym><ProtocolTitle>A Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose Cinaciguat (25 and 10 microg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1559">Congestive heart failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64124"></Trial><Drug id="29834">cinaciguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPOSE 1</ProtocolAcronym><ProtocolTitle>BAY-58-2667 Dose-Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1559">Congestive heart failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64025"></Trial><Drug id="29834">cinaciguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Vorinostat in Poor-Risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1732">Acute promyelocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50753"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-myeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematological Disorders</ProtocolTitle><Sponsor>Beth Israel Deaconess Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="142">Hematological disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37434"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="287715"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Hormone Naive Biochemical Recurrence of Prostate Cancer</ProtocolTitle><Sponsor>Fox Chase Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47574"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BATTLE-2</ProtocolAcronym><ProtocolTitle>A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72613"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64877"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hepatic Impairment Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="42341"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2453">Astrocytoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47142"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ODM-201 Versus Androgen Deprivation Therapy in Hormone Naive Prostate Cancer</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="280153"></Trial><Drug id="7290">triptorelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PTK-787/ZK-222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib</ProtocolTitle><Sponsor>University of Helsinki</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="24620"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall</ProtocolTitle><Sponsor>University of California Davis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49273"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the safety and efficacy of 100-fold lower dose of cerivastatin with simvastatin in treatment of patients with primary hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55062"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Riliva</ProtocolAcronym><ProtocolTitle>A Phase II Multicenter Trial with Rivaroxaban in The Treatment of Livedoid Vasculopathy Assessing The Pain on A Visual Analog Scale (VAS)</ProtocolTitle><Sponsor>University Hospital Muenster</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130880"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RIVAL-AF</ProtocolAcronym><ProtocolTitle>Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran</ProtocolTitle><Sponsor>Yokohama City University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="219445"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial to Evaluate the Efficacy and Safety of Cipro XR in Treating Female Patients With Lower Urinary Tract Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11951"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS 2 TIMI 51</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE), Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC, Johnson &amp; Johnson Sdn Bhd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38869"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PRIDE</ProtocolAcronym><ProtocolTitle>Primovist Enhanced MRI for the Detection and Evaluation of Focal Liver Lesions</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="202">Liver tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130961"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, two-period, multiple-dose, fixed-sequence study to evaluate the effect of linagliptin on the steady-state pharmacokinetics of Microgynon in healthy, premenopausal female subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65486"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIa, efficacy study of BAY-68-4986 (capadenoson)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5159"></Trial><Drug id="54615">capadenoson</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, randomized, two-period crossover study to assess the safety, tolerability and pharmacokinetics of 17beta-estradiol and to determine the daily delivery rate of 17beta-estradiol from an ultra low dose 17beta-estradiol transdermal system SHP-00577E (3.25 cm2) versus the reference Climara (SHP-00577D) (6.5 cm2) transdermal system in the post-menopausal female subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88823"></Trial><Drug id="45697">estradiol (ultra-low-dose patch, HRT), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VENTURE-AF</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98679"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J-ROCKET AF</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4977"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY59-7939, Japanese phase II in atrial fibrillation trial status</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31727"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RIVAL-AF</ProtocolAcronym><ProtocolTitle>Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran</ProtocolTitle><Sponsor>Yokohama City University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="219445"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REWRAPS</ProtocolAcronym><ProtocolTitle>Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation</ProtocolTitle><Sponsor>Fujita Health University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="165487"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALT GIST</ProtocolAcronym><ProtocolTitle>A Randomized Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumor (GIST)</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group, European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Centre of Singapore</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222463"></Trial><Drug id="11460">imatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="56">Ischemic heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71984"></Trial><Drug id="2428">Adenoscan</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CARILLON study</ProtocolTitle><Sponsor>Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154453"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3462">Metastatic liver cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320087"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II of Oxaliplatin, Capecitabine and Sorafenib for Advanced Pancreatic and Biliary Carcinoma</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47141"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-Dose Hormone Therapy for Relief of Vasomotor Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60033"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III, Randomized, Double-Blind, Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13646"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SH-L-562BB Phase II/III Dose Justification and Gadoteridol-Controlled Comparative Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45767"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Phase I, Dose-Escalation Study With BAY-1143572 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154135"></Trial><Drug id="87787">atuveciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="94">Dermatitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21544"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib, multi-center, open-label, randomized study to evaluate the effect of Angeliq and Activelle on hemostasis in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78382"></Trial><Drug id="10412">estradiol + norethisterone acetate, Novo Nordisk</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="199">Leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10782"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AAABC</ProtocolAcronym><ProtocolTitle>Additional Antibiotics for Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease</ProtocolTitle><Sponsor>Sichuan University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="119465"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84431"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, multicenter, placebo-controlled, phase Ib study to determine the effect of rivaroxaban on the biomarkers of hypercoaguability (F1.2, D-dimer [DD] and thrombin-antithrombin III complex [TAT]) in patients with chronic heart failure (CHF) when given in addition to concurrent CHF therapy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62306"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>LEVEQ-1</ProtocolAcronym><ProtocolTitle>Crossover Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="78">Contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65660"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, single-blind, comparative, parallel-group study to determine the safety and efficacy of moxifloxacin based triple therapy as an alternative second-line therapy in patients suffering from non-ulcer dyspepsia and in whom the initial standard PPI triple therapy had failed to eradicate H pylori infection</ProtocolTitle><Sponsor>AstraZeneca plc, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="149">Helicobacter pylori infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62892"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-Drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1 and OATP1B3 (Uptake Transporters) Probe Substrate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="252336"></Trial><Drug id="12420">rosuvastatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Switching Study From Warfarin to Rivaroxaban</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83871"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45128"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IOPAC study</ProtocolAcronym><ProtocolTitle>Iopamiron Abdominal and Cardiac CT enhancement study</ProtocolTitle><Sponsor>Kumamoto University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="303153"></Trial><Drug id="44295">iopamidol</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>METATEL</ProtocolAcronym><ProtocolTitle>Regulation of inflammatory parameters by telmisartan in hypertensive patients</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2236">Hypertriglyceridemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6339"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety and efficacy study of vatalanib and gemcitabine in patients with advanced pancreatic cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38261"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47096"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Docetaxel Dose-Escalation Trial</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28445"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, single-arm, dose-comparison study to evaluate the brain perfusion imaging efficacy of SH-L-562 in patients with unilateral carotid stenosis or unilateral cerebral infarcts</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1615">Carotid stenosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343149"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 in Previously Untreated Patients With Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47939"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="53133">dabrafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alemtuzumab and Pentostatin In T-Cell Neoplasms</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47445"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I multiple-dose, safety, pharmacokinetic and pharmacodynamic study of BAY-59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6126"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="7286">goserelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE ESUS</ProtocolAcronym><ProtocolTitle>Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1077">Embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="218006"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, 3-day, double-blind, placebo-controlled randomized study to assess the efficacy of ramatroban as an antithrombotic agent in patients with severe stage II limb arteriopathy</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="541">Artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29579"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open, Randomized, Multicenter Comparison Of Efficacy, Cycle Control, And Tolerability Of A 23-day Oral Contraceptive Regimen With 20 Microg Ethinyl Estradiol And 75 Microg Gestodene And A 21-day Regimen With 20 Microg Ethinyl Estradiol And 150 Microg Desogestrel</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="110450"></Trial><Drug id="38812">desogestrel</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS-TIMI 46</ProtocolAcronym><ProtocolTitle>Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes</ProtocolTitle><Sponsor>Bayer AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5154"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2529">Hot flashes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44475"></Trial><Drug id="45697">estradiol (ultra-low-dose patch, HRT), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, single-center, randomized, double-blind, parallel-group, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and systemic exposure of regorafenib eye drops in healthy subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="341798"></Trial><Drug id="95589">regorafenib (ophthalmic, age related macular degeneration), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rogaratinib (BAY-1163877) Human Mass Balance Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="335063"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized-controlled trial to evaluate the efficacy of levonorgestrel intrauterine system (LNG-IUS) in postmenopausal women who had taken at least one year of adjuvant tamoxifen therapy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61600"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Of Drospirenone and Ethinyl Estradiol Versus Placebo in the Treatment of Truncal Acne</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="22799"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma</ProtocolTitle><Sponsor>Swedish Medical Center (Colorado)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44929"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, cross-over study to evaluate the effects of BAY-M-1099 and emiglitate on blood glucose control, insulin requirements and breath hydrogen in patients with insulin dependent diabetes mellitus (IDDM)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56992"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study of BAY-1082439 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98541"></Trial><Drug id="77019">BAY-1082439</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to explore the correlation of 18F-florilglutamic acid uptake with immunohistochemical expression of system xC- and CD44 which stabilizes the xCT subunit of system xC- in patients with cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89209"></Trial><Drug id="66251">florilglutamic acid (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="307713"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NiraRad</ProtocolAcronym><ProtocolTitle>Phase Ib Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290785"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="231217"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46316"></Trial><Drug id="8735">darifenacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99392"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="9298">Thymoglobulin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPARIOS 1</ProtocolAcronym><ProtocolTitle>BAY-98-7196 Dose-Finding/POC Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215042"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation, crossover study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52874"></Trial><Drug id="11603">gefitinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I single dose-escalating, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6120"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMMANDER HF</ProtocolAcronym><ProtocolTitle>A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure</ProtocolTitle><Sponsor>Janssen Pharmaceuticals Inc, Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="143374"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3006">Nasal congestion</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="330348"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 4-week study to evaluate the pharmacokinetics of cerivastatin administered with and without food in morning and evening in healthy male subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55056"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Efficacy of a Non-Hormonal Drug Against Endometriosis Associated Pelvic Pain</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21378"></Trial><Drug id="28194">BX-471</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, randomized, two-way, crossover study to evaluate the effect of dienogest on estradiol valerate pharmacokinetics after single oral administration of estradiol valerate or estradiol valerate + dienogest in healthy postmenopausal volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90916"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate Efficacy and Safety of a New Oral Contraceptive</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72797"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of SH-T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH-D01155E) on Hemostatic Parameters</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72749"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRAP</ProtocolAcronym><ProtocolTitle>A Trinity Antiplatelet Responsiveness (TRAP) study to assess the high on-treatment platelet reactivity on commonly prescribed anti-platelet agents following the transient ischemic attack or ischemic stroke</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Biogen Inc, Merck KGaA, Pfizer Inc, Relitech, Stanley Thomas Johnson Foundation, The European Union</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3849">Transient ischemic attack</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="151241"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMINI ACS 1</ProtocolAcronym><ProtocolTitle>A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="216173"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SAFE CAP</ProtocolAcronym><ProtocolTitle>Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="12405"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Prospective, Non-comparative, Interventional Case series Study to Evaluate the Intraocular Concentrations and Pharmacokinetics of Single Intravitreal Injection of Ranibizumab in Humans</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98593"></Trial><Drug id="22395">ranibizumab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, interventional, efficacy study of one initial injection versus three monthly injections of ranibizumab for macular edema after branch retinal vein occlusion</ProtocolTitle><Sponsor>Bayer AG, Japan Society for the Promotion of Science (JSPS), Novartis Pharma KK</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="298055"></Trial><Drug id="22395">ranibizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPAN-ORL06</ProtocolAcronym><ProtocolTitle>Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="264936"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RELIEF</ProtocolAcronym><ProtocolTitle>Comparison of Sequential iv/po Moxifloxacin With iv Piperacillin/Tazobactam Followed by po Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="790">Diabetic foot ulcer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10316"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple-Dose Study of BAY-1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="291">Rheumatoid arthritis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="335852"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOXIPEDIA</ProtocolAcronym><ProtocolTitle>Moxifloxacin in Pediatric Subjects With Complicated Intra-Abdominal Infection</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="577">Gastrointestinal infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64270"></Trial><Drug id="12543">ertapenem</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg tid</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15475"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase II Study of Sorafenib Plus bicalutamide Versus Placebo Plus Bicalutamide in Castration-Resistant Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer Patients Who Had Orchiectomy or Are Receiving a LHRH Analog</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="139323"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="280698"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3198">Larynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAGELLAN</ProtocolAcronym><ProtocolTitle>Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6337"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CARILLON study</ProtocolTitle><Sponsor>Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154453"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vardenafil ODT (Orally Disintegrating Tablet)-Nifedipine Interaction Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77192"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="106382"></Trial><Drug id="5800">pantoprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="5267">leuprorelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-week trial to evaluate the efficacy of Climara Pro in post-menopausal women with moderate to severe vasomotor symptoms</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46810"></Trial><Drug id="22274">estradiol + levonorgestrel transdermal combination patch (HRT), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study to evaluate the efficacy, safety, pharmacokinetic and pharmacodynamic effect of midazolam, omeprazole and dextromethorphan on sorafenib in metastatic melanoma patients</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52766"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84366"></Trial><Drug id="2773">valsartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21842"></Trial><Drug id="3622">methylprednisolone aceponate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy,Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Quantitative evaluation of brain perfusion MRI with gadobutrol</ProtocolTitle><Sponsor>Hokkaido University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="291038"></Trial><Drug id="11862">gadoterate meglumine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to explore the correlation of 18F-florilglutamic acid uptake with immunohistochemical expression of system xC- and CD44 which stabilizes the xCT subunit of system xC- in patients with cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89209"></Trial><Drug id="66251">florilglutamic acid (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, dosimetric and pharmacokinetic study of the anti fibronectin 131-I-L19-small immunoprotein (SIP), in patients with solid tumors</ProtocolTitle><Sponsor>Philogen SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36556"></Trial><Drug id="43218">131I-radretumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Extension Program for Bay-43-9006</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="26245"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COTSOM</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="217823"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COSMOS</ProtocolAcronym><ProtocolTitle>Copanlisib and Gemcitabine in Relapsed/Refractory PTCL</ProtocolTitle><Sponsor>Bayer Korea Ltd, Chonnam National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="288180"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY12-8039 5 Days Sinusitis versus Placebo</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="509">Respiratory tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8792"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Continuous Dosing of BAY-73-4506 in Patients With Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="66133"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY12-8039 5 Days Sinusitis versus Placebo</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1061">Sinusitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8792"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2273">Oligodendroglioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REMETY</ProtocolAcronym><ProtocolTitle>Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="315441"></Trial><Drug id="7810">trifluridine + tipiracil hydrochloride (oral), Taiho</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation of BAY-1143572 in Subjects With Acute Leukemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1727">Acute leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="220588"></Trial><Drug id="87787">atuveciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99392"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of ISIS-416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis</ProtocolTitle><Sponsor>Ionis Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="321054"></Trial><Drug id="65073">IONIS-FXIRx</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43433"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalating, phase I/II study to evaluate safety, pharmacokinetics and efficacy of sorafenib in combination with gemcitabine in patients with advanced solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53049"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="62282">trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="131">Gastrointestinal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RROPE</ProtocolAcronym><ProtocolTitle>Radium-223 and Radiotherapy in Hormone-Naive Men With Oligometastatic Prostate Cancer to Bone</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="315426"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INHALE 1</ProtocolAcronym><ProtocolTitle>Inhaled Amikacin Solution BAY-41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Covance Asia-Pacific Inc - Philippine Branch</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1815">Bacterial pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="112612"></Trial><Drug id="44937">amikacin (inhaled, Aeroneb), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE4</ProtocolAcronym><ProtocolTitle>Maintenance Treatment of Anemia Associated with Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa/Beta Treatment Versus BAY-85-3934</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160484"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetics and safety study of tanomastat, a potential treatment for cancer, in eldery subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51051"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, 2-week randomized, double-blind, placebo-controlled, crossover study to assess the efficacy of ramatroban in treating bronchial hyperresponsiveness to methacholine in patients with bronchial asthma</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29572"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTERSEPT</ProtocolAcronym><ProtocolTitle>A safety, placebo-controlled study of nerelimomab in septic shock patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="816">Septic shock</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="16759"></Trial><Drug id="2597">nerelimomab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NORASEPT II</ProtocolAcronym><ProtocolTitle>A phase III, multicenter, efficacy study of nerelimomab for the treatment of septic shock</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="816">Septic shock</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="16749"></Trial><Drug id="2597">nerelimomab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>C+CHOP/ESHAP</ProtocolAcronym><ProtocolTitle>The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="58387"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Ottawa Hospital Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31778"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim for HRPC</ProtocolTitle><Sponsor>Veeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32618"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Influence of Peripheral Androgen Conversion at Women Adult Acne</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3">Acne</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="129784"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Endometrial Safety Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72616"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) and L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73463"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effect of BAY-M-1099 and BAY-O-1248 on blood glucose in healthy volunteers and in type 2 diabetics</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56940"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRUST</ProtocolAcronym><ProtocolTitle>A Phase II/III Trial to Evaluate the Efficacy and Safety of BAY-86-6150</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88568"></Trial><Drug id="3089">eptacog alfa (activated)</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase II Trial of Pre-Chemotherapy Leukine Versus Leukine-Dexamethasone in Combination With Gemzar And 5-FU in Patients With Metastatic Renal Cell Carcinoma</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="54629"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47753"></Trial><Drug id="3321">anastrozole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ABOVE</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-Remitting MS</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="16573"></Trial><Drug id="3360">interferon beta-1a, Biogen</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Ospedale Civico, Lugano</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="93703"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BENEFIT Study - Follow-up</ProtocolAcronym><ProtocolTitle>BENEFIT Study (Betaferon/ Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6792"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>PRURITUS-Nimpa</ProtocolAcronym><ProtocolTitle>Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers</ProtocolTitle><Sponsor>Fundacion IMIM</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="109">Eczema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="93255"></Trial><Drug id="3622">methylprednisolone aceponate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to measure the serum cortisol levels in volunteers receiving extensive cutaneous application of methylprednisolone aceponate or mometasone furoate</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="109">Eczema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50602"></Trial><Drug id="3622">methylprednisolone aceponate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESPECT</ProtocolAcronym><ProtocolTitle>Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49433"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed-Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-Intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71680"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation trial of vatalanib in combination with either temozolomide or lomustine in patients with recurrent glioblastoma multiforme (GBM)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38123"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2727">Gliosarcoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="24791"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of the Combination Therapy of DPP-4 Inhibitor Alogliptin and Alfa-Glucosidase Inhibitor on Markers of Inflammation and Oxidative Stress - Comparison Between Acarbose and Voglibose</ProtocolTitle><Sponsor>School of Medicine, Keio University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="124598"></Trial><Drug id="4655">voglibose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZBEAM2</ProtocolAcronym><ProtocolTitle>Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma</ProtocolTitle><Sponsor>Lymphoma Study Association</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52267"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HOVON 77 NHL</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of a Single Dose of 14.8 Mbq/Kg (0.4 Mci/Kg)90y-ibritumomab Tiuxetan (Zevalin) in Elderly Patients with Diffuse Large B-cell Lymphoma and Fdg-pet Positive Partial Remission Following First-line R-CHOP Therapy. A Phase II Clinical Trial</ProtocolTitle><Sponsor>Dutch-Belgian Cooperative Trial Group for Hematology Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="153124"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 24-week, randomized, open-label, multicenter, comparative study to determine the safety and efficacy of dienogest versus leuprolide acetate in patients with endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88731"></Trial><Drug id="5267">leuprorelin acetate</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative, multicenter, open-label study to evaluate the safety and efficacy of acarbose in the treatment of type 2 diabetes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="110730"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="61770"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Double-Blind, Placebo-Controlled, Two-Year Study to Evaluate the Effects of Acarbose Treatment in Type 2 Diabetic Patients Under Dietary Training</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="147262"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on the Mechanism of Glucobay in Chinese Newly diagnosed Type 2 Diabetic Patient</ProtocolTitle><Sponsor>China-Japan Union Hospital of Jilin University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="141006"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5124"></Trial><Drug id="6132">epoprostenol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, open, randomized, controlled, phase III trial to compare the safety and efficacy of fludarabine with conventional combination chemotherapy (CVP) in patients with stages III and IV low grade malignant non-Hodgkins lymphoma</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG, Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74089"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma</ProtocolTitle><Sponsor>Hopital Maisonneuve-Rosemont</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38444"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="29597"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Herceptin and GM-CSF for Metastatic Breast Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44099"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine as Second-line Treatment for Malignant Pleural Mesothelioma (MPM)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="246511"></Trial><Drug id="6408">vinorelbine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186877"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HOVON 77 NHL</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of a Single Dose of 14.8 Mbq/Kg (0.4 Mci/Kg)90y-ibritumomab Tiuxetan (Zevalin) in Elderly Patients with Diffuse Large B-cell Lymphoma and Fdg-pet Positive Partial Remission Following First-line R-CHOP Therapy. A Phase II Clinical Trial</ProtocolTitle><Sponsor>Dutch-Belgian Cooperative Trial Group for Hematology Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="153124"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="53973"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and efficiency of 99mTc-P280 for the detection and localization of acute deep venous thrombosis (DVT)</ProtocolTitle><Sponsor>Diatide Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48957"></Trial><Drug id="7908">99mTc-apcitide injection</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study of Bevacizumab plus Sorafenib in Metastatic Breast Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44933"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Sagopilone in Combination With Carboplatin and Bevacizumab in the First-Line Treatment of Patients With Stage IIIB/IV</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="132432"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assess the Effect of Daily Treatment of Vardenafil 20 mg or Sildenafil 100 mg and Placebo on Sperm Function</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31229"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5124"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetic drug interaction study of talviraline with indinavir and zidovudine</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="16972"></Trial><Drug id="8922">BAY-10-8039</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Influence of Peripheral Androgen Conversion at Women Adult Acne</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3">Acne</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="129784"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating and pharmacokinetic (PK) study of vatalanib in patients with liver metastases from colorectal, breast and other solid tumors</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38143"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating and pharmacokinetic (PK) study of vatalanib in patients with liver metastases from colorectal, breast and other solid tumors</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38143"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical study to evaluate the efficacy of NeoTect compared with F-18 FDG (F-18 fluoro-2-deoxyglucose) for the primary diagnosis and staging of lung cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47703"></Trial><Drug id="9397">99mTc-depreotide</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AVANTAGE</ProtocolAcronym><ProtocolTitle>Safety Study in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="16438"></Trial><Drug id="9702">recombinant interferon beta-1a, Merck Serono</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Gastric Cancer Asian Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28458"></Trial><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FLAT-SUGAR</ProtocolAcronym><ProtocolTitle>FLuctuATion Reduction With inSULin and Glp-1 Added togetheR</ProtocolTitle><Sponsor>University of Washington</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84715"></Trial><Drug id="10252">insulin glargine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>eRADicAte</ProtocolAcronym><ProtocolTitle>Open-Label, Phase II Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration Resistant (Hormone Refractory) Prostate Cancer Subjects With Bone Metastasis</ProtocolTitle><Sponsor>Carolina Research Professionals, LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="179595"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVERCE</ProtocolAcronym><ProtocolTitle>Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="156949"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="485">Bacterial skin infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="158534"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1267">MRSA infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="158534"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II, GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="35413"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, randomized, dose-comparison, single-arm study to evaluate the safety, tolerability and efficacy of SH-L-562 in patients with recurrent herniated disc lesion, primary and secondary bone tumors, or breast lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="342681"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-month, double-blind, randomized, comparartive, multi-center study to evlauate the the efficacy, cycle control and tolerance of two low-dose of SH-543 and Femodene</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51976"></Trial><Drug id="12164">ethinylestradiol + gestodene (oral), Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>US Cycle Control and Blood Pressure Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="57913"></Trial><Drug id="12170">levonorgestrel + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Contrast-enhanced MRI in Children 2 Months to &lt; 2 Years</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="80268"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Contrast-enhanced MRI in Children 2 Months to &lt; 2 Years</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="80268"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III study of gadofosveset for the detection of vascular disease in the pedal arteries</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="8552"></Trial><Drug id="12526">gadofosveset</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, safety and tolerability study of higher dose regimens of metrifonate, in subjects with probable Alzheimer's disease</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8241"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, safety and tolerability study of higher dose regimens of metrifonate, in subjects with probable Alzheimer's disease</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8241"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind and placebo-controlled study of metrifonate, to evaluate safety and efficacy in AD patients</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="15553"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="222">Mycoplasma infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="308">Staphylococcus aureus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study on Yasmin versus Marvelon in Chinese Women Requiring Contraception</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31577"></Trial><Drug id="13599">desogestrel + ethinylestradiol (monophasic), Organon/Merck &amp; Co/Barr</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>WESAIL</ProtocolAcronym><ProtocolTitle>Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users</ProtocolTitle><Sponsor>Columbia University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="221871"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="15130">vinflunine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, open-label, efficacy and safety study of Spheramine in patients with advanced Parkinson's disease</ProtocolTitle><Sponsor>Titan Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="255">Parkinsons disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="7469"></Trial><Drug id="15745">cell therapy (dopamine producers, Parkinsons), Titan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="274717"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib/II Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="245978"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Bay-59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="35291"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, 23-centered, safety and efficacy study of octocog alfa in adults and children with severe hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50113"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33376"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, double-blind, cross-over study to evaluate the pharmacodynamic effect on penile rigidity and tumescence and the pharmacokinetic properties of vardenafil in erectile dysfunction patients</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54286"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-blind, phase III study to evaluate the safety and efficacy of Levitra in the treatment of men with erectile dysfunction resulting from a broad range of causes</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54267"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy, safety and tolerability of vardenafil in patients with diabetes mellitus and erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52802"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ELATED</ProtocolAcronym><ProtocolTitle>Evaluation of Levitra to Advance the Treatment of Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31433"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31432"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy Vardenafil 10 mg versus Tadalafil 10 mg in in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31431"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy and Safety of Flexible-Dose Vardenafil in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31429"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 h Prior to Intercourse</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31209"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LUTECIA</ProtocolAcronym><ProtocolTitle>Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="23385"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EROS</ProtocolAcronym><ProtocolTitle>An Open-Label, Prospective, Multicenter, Single-Arm Study To Investigate Erection Duration Measured By Stopwatch With Flexible Dose Vardenafil Administered For 8 Weeks In Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231102"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-38-9456 - Supportive Trial for Spinal Injury</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="14296"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of efficacy and safety of vardenafil in patients with erectile dysfunction and type 1 diabetes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10726"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vardenafil in Tinnitus</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="998">Tinnitus</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="14231"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalation, phase I study to determine the tolerability and pharmacokinetic properties of vardenafil</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1241">Prostate hyperplasia</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="52933"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vardenafil in Greenlight Laser Surgery of Benign Prostate Hypertrophy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1241">Prostate hyperplasia</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="35414"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2529">Hot flashes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="20573"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 2</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="232028"></Trial><Drug id="23239">ulipristal</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="25606"></Trial><Drug id="24087">entinostat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial Of ZK-EPO (ZK-219477) In Metastatic Melanoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="25194"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label study to evaluate the safety, efficacy and pharmacokinetics of weekly sagopilone in patients with refractory solid tumors</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="61658"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="35085"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="43604"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BATTLE-2</ProtocolAcronym><ProtocolTitle>A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="72613"></Trial><Drug id="28972">selumetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Gastric Cancer Asian Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="28458"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Patients With Advanced Neuroendocrine Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="58975"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II of Oxaliplatin, Capecitabine and Sorafenib for Advanced Pancreatic and Biliary Carcinoma</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47141"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="35683"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Accelerated Community Oncology Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="31715"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAI-skip</ProtocolAcronym><ProtocolTitle>RAI-skip</ProtocolTitle><Sponsor>Tsukuba Clinical Research and Development Organization, University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="230951"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and 5-azacitidine in Acute Leukemia + Myelodysplastic Syndrome</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="72898"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-line Therapy by Sorafenib for Lung Metastases Patients in Renal Cell Carcinoma</ProtocolTitle><Sponsor>Kobe University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="135208"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TACE-2</ProtocolAcronym><ProtocolTitle>Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75852"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of SIR-Spheres Plus Sorafenib as First Line Treatment for Non-Resectable Primary HCC</ProtocolTitle><Sponsor>Singapore Clinical Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="39585"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer</ProtocolTitle><Sponsor>University of California</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="329900"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Asia-Pacific</ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28387"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="146234"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="57816"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="26277"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized phase II study to evaluate the safety and efficacy of two schedules of sorafenib daily and interferon-2a (IFN) in metastatic renal cell carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52530"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EU-ARCCS</ProtocolAcronym><ProtocolTitle>An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY-43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52028"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pre-Operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal</ProtocolTitle><Sponsor>The University Health Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33739"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I single dose-escalating, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6120"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of the effects of BAY 59-7939 (rivaroxaban) on thrombin generation, in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6118"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MARINER</ProtocolAcronym><ProtocolTitle>A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Janssen-Cilag Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="181560"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84431"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD 1</ProtocolAcronym><ProtocolTitle>Rivaroxban (10 mg) Given Once-Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin</ProtocolTitle><Sponsor>Bayer Australia Ltd, Bayer HealthCare AG, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6173"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN CYP</ProtocolAcronym><ProtocolTitle>Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34374"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ISE calf DVT study</ProtocolTitle><Sponsor>Mie University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="304930"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Rivaroxaban</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239537"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN CYP</ProtocolAcronym><ProtocolTitle>Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34374"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients</ProtocolTitle><Sponsor>Kyoto Prefectural University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="301694"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FC Patch Comparator Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="94494"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III study to evaluate the contraceptive reliability of the BAY-86-5016 transdermal patch</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="54294"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EUCLID</ProtocolAcronym><ProtocolTitle>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="99397"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>alpha-RT</ProtocolAcronym><ProtocolTitle>Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastasis</ProtocolTitle><Sponsor>Klinikum der Albert-Ludwigs Universitaet Freiburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="233340"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Standard-Dose Versus High-Dose and Versus Extended Standard-Dose Radium-223 Dichloride in Castration-Resistant Prostate Cancer Metastatic to the Bone</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="165346"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY-88-8223 in Japanese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86065"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Placebo-Controlled, Phase II Study of Bone-Targeted Radium-223 in Symptomatic Hormone-Refractory Prostate Cancer</ProtocolTitle><Sponsor>Algeta ASA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40386"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALSYMPCA</ProtocolAcronym><ProtocolTitle>A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33301"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PEACE III</ProtocolAcronym><ProtocolTitle>Phase III Radium 223 mCRPC</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210276"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Re-Treatment Safety of Radium-223 Dichloride in Castration-Resistant Prostate Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="153754"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIa, open-label, non-randomized trial to study the safety and efficacy of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease</ProtocolTitle><Sponsor>Algeta ASA, Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="204072"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multi-center, double-blind, placebo-controlled study to compare the safety and efficacy of cerivastatin with simvastatin in treatment of patients with primary hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="55059"></Trial><Drug id="44313">simvastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IRIVASC</ProtocolAcronym><ProtocolTitle>Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="174098"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, safety and efficacy study of pemetrexed in combination with carboplatin in patients with platinum-sensitive recurrent ovarian or primary peritoneal cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Eli Lilly &amp; Co, GlaxoSmithKline plc, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85458"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="35085"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY-1000394 When Given Together with Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small-Cell Lung Cancer)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86332"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy of Acarbose, Metformin, Sitagliptin Combination Treatment in DM Patients</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83240"></Trial><Drug id="44499">sitagliptin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>HPA Axis Study in Adults</ProtocolTitle><Sponsor>Bayer AG, Intendis GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="79784"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pearl Index Study With Low-Dose Combined Oral Contraceptive</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32049"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the safety, efficacy and tolerability of bendamustine in combination with mitoxantrone and rituximab in patients with symptomatic stage III/IV indolent lymphomas</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49427"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the efficacy of bendamustine in combination with rituximab in patients with relapsed indolent and mantle-cell non-Hodgkins lymphoma</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49535"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I to evaluate the safety, tolerability and efficacy of bendamustine in combination with thalidomide and prednisolone (BPT) in patients with refractory or relapsed multiple myeloma</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49474"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONCEPT-SCLC</ProtocolAcronym><ProtocolTitle>Roniciclib/Placebo in Combination With Chemotherapy in Small Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="195819"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIREFLeYe</ProtocolAcronym><ProtocolTitle>Aflibercept for Retinopathy of Prematurity  Intravitreal Injection Versus Laser Therapy</ProtocolTitle><Sponsor>Bayer (Malaysia) Sdn Bhd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2478">Retinopathy of prematurity</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="378861"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIBRANT</ProtocolAcronym><ProtocolTitle>Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI, EYLEA, BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84452"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Aflibercept treat and extend for branch retinal vein occlusion</ProtocolTitle><Sponsor>Jikei daisan hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="296361"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RUBY</ProtocolAcronym><ProtocolTitle>Anti-vascular Endothelial Growth Factor Plus Anti-angiopoietin 2 in Fixed Combination Therapy: Evaluation for the Treatment of Diabetic Macular Edema</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="256056"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Modified treat and extend regimen of aflibercept to central retinal vein occlusion with cystoid macular edema</ProtocolTitle><Sponsor>Aoki Eye Clinic, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Jichi Medical University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="277590"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The study of aflibercept with treat and extend regimen for BRVO</ProtocolTitle><Sponsor>Akita City Hospital, Akita University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="270514"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIEW 1 extension</ProtocolAcronym><ProtocolTitle>Open-Label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA; BAY86-5321) in Neovascular ('Wet') Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="59894"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIEW 1</ProtocolAcronym><ProtocolTitle>Vascular Endothelial Growth Factor(VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4787"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Visual and Anatomical Outcomes of Aflibercept in Good Visual Acuity Baseline of Wet Age-Related Macular Degeneration</ProtocolTitle><Sponsor>Jichi Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="154583"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CORE-OCU</ProtocolAcronym><ProtocolTitle>The Combination Therapy With Ra-223 and Enzalutamide</ProtocolTitle><Sponsor>Osaka City University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="314991"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="320087"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOVAR</ProtocolAcronym><ProtocolTitle>Regorafenib versus Tamoxifen in Patients With Platinum-sensitive Ovarian Carcinoma and Isolated Biological Progression</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="243698"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3153">Adenoid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="179772"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALT GIST</ProtocolAcronym><ProtocolTitle>A Randomized Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumor (GIST)</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group, European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Centre of Singapore</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222463"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RESET for GIST</ProtocolTitle><Sponsor>Japanese National Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="219849"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74576"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGORA</ProtocolAcronym><ProtocolTitle>The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib</ProtocolTitle><Sponsor>Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="263264"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54662">ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Refametinib in Combination With Sorafenib in Patients With RAS Mut Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="160758"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to evaluate the influence of PET scan duration on the accuracy of florbetaben (18F) in the diagnosis of Alzheimer's disease (AD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="80659"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the pharmacokinetics and pharmacodynamics of florbetaben (18F) in patients with mild cognitive impairment compared with healthy controls and Alzheimers disease patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="67494"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-94-9027 PK Study Comparing to Another Long Acting Product</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="321971"></Trial><Drug id="60214">efmoroctocog alfa</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-80-6946, Open-label, Phase I Study in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="59742"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COSMOS</ProtocolAcronym><ProtocolTitle>Copanlisib and Gemcitabine in Relapsed/Refractory PTCL</ProtocolTitle><Sponsor>Bayer Korea Ltd, Chonnam National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="288180"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2726">Neuroblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="331813"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to assess the safety and metabolism of BAY-86-4367 in healthy male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="80351"></Trial><Drug id="64471">BAY-86-4367</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of ZK-6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK-6032924 in Healthy Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="62782"></Trial><Drug id="65279">18F-FEDAA-1106</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="62789"></Trial><Drug id="65324">estradiol valerate + levomefolate calcium (contraception), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROTECT-VIII</ProtocolAcronym><ProtocolTitle>A Trial Investigating Safety and Efficacy of Treatment With BAY-94-9027 in Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86650"></Trial><Drug id="65438">damoctocog alfa pegol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Age and Gender Effects on the Pharmacokinetics of BAY-85-3934</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="82053"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Native American Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Group-Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="75664"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE5</ProtocolAcronym><ProtocolTitle>Long-Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa/Beta Treatment Versus BAY-85-3934</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="173914"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Finerenone to Investigate a Pediatric Formulation in Healthy Male Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="278548"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VILLENDO</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="344748"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="213253"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 4</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="325925"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study of IVIG versus IVIG With High Dose Methylprednisolone in Childhood ITP</ProtocolTitle><Sponsor>Hospital for Sick Children</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2259">Immune thrombocytopenic purpura</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="171119"></Trial><Drug id="70137">Gamunex</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="378000"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81714"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Kiefer AUT</ProtocolAcronym><ProtocolTitle>Actual Use Trial of Naproxen Sodium</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81622"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Morpheus II</ProtocolAcronym><ProtocolTitle>Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="181233"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chinese single and multiple dose Phase I study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="271314"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the QT/QTc Interval Prolongation Potential of Vericiguat</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="336967"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>COLIBRI</ProtocolAcronym><ProtocolTitle>A Study to Compare the Menstrual Bleeding Profile Among Jaydess and Copper Intrauterine Device (IUD) Users. (Copper and Levonorgestrel IUD Barcelona Research Initiative)</ProtocolTitle><Sponsor>FUNDACI INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="278450"></Trial><Drug id="82773">levonorgesterol (3-year intrauterine contraceptive system), Bayer Healthcare</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EDIT</ProtocolAcronym><ProtocolTitle>Early Diabetes Intervention Trial (EDIT Study)</ProtocolTitle><Sponsor>Bayer AG, Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="151615"></Trial><Drug id="83247">acarbose + metformin (fixed-dose combination, type 2 diabetes), Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Leopold Kids</ProtocolAcronym><ProtocolTitle>BAY-81-8973 Pediatric Safety and Efficacy Trial</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75370"></Trial><Drug id="94438">octocog alfa (plasma-free, sucrose-formulated), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Leopold II</ProtocolAcronym><ProtocolTitle>A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71921"></Trial><Drug id="94438">octocog alfa (plasma-free, sucrose-formulated), Bayer</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multiple-Escalating Dose Study of BAY-1093884 in Adults With Hemophilia A or B With or Without Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="347281"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multiple-Escalating Dose Study of BAY-1093884 in Adults With Hemophilia A or B With or Without Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="347281"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY-1093884 in Patients With Severe Hemophilia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="334550"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1436032 in Patients With Mutant IDH1 (mIDH1) Advanced Acute Myeloid Leukemia (AML)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="296229"></Trial><Drug id="101614">BAY-1436032</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial of soluble guanylate cyclase activator (adult respiratory distress syndrome), Bayer for the potential treatment of acute respiratory distress syndrome (ARDS)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="8">Respiratory distress syndrome</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="322438"></Trial><Drug id="108138">soluble guanylate cyclase activator (adult respiratory distress syndrome), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Investigate BAY-2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="6833">Chronic myelomonocytic leukemia</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="326222"></Trial><Drug id="109257">BAY-2402234</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of sorafenib for the treatment of patients with relapsed or refractory lymphoma</ProtocolTitle><Sponsor>Bayer AG, Fondazione IRCCS Istituto Nazionale Tumori</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89650"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Treatment Combination for Patients With Unresectable Stage III or IV Melanoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25614"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1705">Endometrioid carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II safety study of vatalanib in patients with myelofibrosis with myeloid metaplasia (MMM)</ProtocolTitle><Sponsor>Bayer AG, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2436">Myelofibrosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38015"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole (ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C] Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="230626"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MONALISA</ProtocolAcronym><ProtocolTitle>A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11557"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-OD-HIP</ProtocolAcronym><ProtocolTitle>Phase II study of once-daily rivaroxaban (BAY-59-7939), for thromboprophylaxis after total hip replacement</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6144"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2749">Hematoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="52967">apixaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="195533"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative 12 Month Study of Menstrually-Signalled Use of a Combined Contraceptive Pill Versus a Combined Contraceptive Vaginal Ring</ProtocolTitle><Sponsor>Family Planning Association New South Wales</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="125349"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I study of PSMA-targeted [227]Th-conjugate in patients with metastatic castration resistant prostate cancer</ProtocolTitle><Sponsor>Bayer AG, Progenics Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="331939"></Trial><Drug id="105999">BAY-2315497</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="131">Gastrointestinal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemia</ProtocolTitle><Sponsor>Nakakinen Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="175">Hyperlipidemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="180271"></Trial><Drug id="11367">ezetimibe</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of tICAM-1-453 to assess tolerability in the treatment of common cold</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="517">Common cold</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="17267"></Trial><Drug id="11174">tICAM-1-453, Bayer/Genetic Therapy</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Multiple-Doses of BAY-63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2466">Interstitial lung disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="17236"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55288">trametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Erlangen Perfusion Stroke</ProtocolAcronym><ProtocolTitle>Comparison of two Gadolinium containing MR contrast media in patients with symptoms of cerebrovascular disease</ProtocolTitle><Sponsor>University of Erlangen-Nurnberg Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="64">Cerebrovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="140582"></Trial><Drug id="11862">gadoterate meglumine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27591"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25522"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, single-arm, open-label, non-randomized, multicenter study to evaluate the safety and efficacy of single-agent sorafenib in patients with advanced biliary tract carcinoma</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="63998"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57816"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESCUE</ProtocolAcronym><ProtocolTitle>Riociguat in Scleroderma Associated Digital Ulcers</ProtocolTitle><Sponsor>University of Michigan</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="372">Ulcer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273025"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>TacroVori</ProtocolAcronym><ProtocolTitle>Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290506"></Trial><Drug id="4510">tacrolimus</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="131058"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, randomized, dose-comparison, single-arm study to evaluate the safety, tolerability and efficacy of SH-L-562 in patients with recurrent herniated disc lesion, primary and secondary bone tumors, or breast lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342681"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study for an Oral Contraceptive Containing Folate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73318"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH-T00186D</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32261"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35591"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of iv/po Moxifloxacin in Subjects With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21280"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3006">Nasal congestion</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="330348"></Trial><Drug id="3159">fluticasone propionate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27592"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of ramatroban in healthy volunteers</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1107">Allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29555"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, efficacy and pharmacokinetics of sorafenib in combination with dacarbazine in patients with advanced metastatic melanoma or solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52790"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of sorafenib in combination with carboplatin and paclitaxel in patients with melanoma</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52773"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-230211 in Postmenopausal Woman With Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="40937"></Trial><Drug id="32396">lonaprisan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5715"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>C+CHOP/ESHAP</ProtocolAcronym><ProtocolTitle>The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58387"></Trial><Drug id="3072">etoposide phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Combination With Enzalutamide</ProtocolTitle><Sponsor>All Ireland Cooperative Oncology Research Group, Cancer Trials Ireland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="209043"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A cross-over, pharmacokinetic study of rolipram in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16890"></Trial><Drug id="4268">rolipram</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Trial in Hormone Withdrawal Associated Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="112">Endocrine disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64988"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Investigate Pharmacokinetics and Safety of BAY-73-4506 in Asian (Japanese) Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59631"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib and Sildenafil for Advanced Solid Tumors</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="231570"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44943"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32724"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of Drospirenone/Estradiol in Postmenopausal Women With Concomitant Disease and Medication Known to Potentiate the Risk of Hyperkalemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78396"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO-4D</ProtocolAcronym><ProtocolTitle>Comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)</ProtocolTitle><Sponsor>European Commission against Racism and Intolerance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1565">Aortic valve stenosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265742"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY-94-8862</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="82461"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO-4D</ProtocolAcronym><ProtocolTitle>Comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)</ProtocolTitle><Sponsor>European Commission against Racism and Intolerance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265742"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Oral BAY-1217389 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222465"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose Escalation and Expansion of Oral BAY-1143269 in Combination With Intravenous Docetaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="228971"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CERDIA</ProtocolAcronym><ProtocolTitle>A Double-Blind, Placebo-Controlled Study on The Effect of Cerivastatin on The Process of Atherosclerosis in Non-Insulin Dependent Diabetes Mellitus (type 2)</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150330"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MISSION</ProtocolAcronym><ProtocolTitle>A Third/Fourth-Line, Placebo-Controlled Trial of Sorafenib in Patients With Predominantly Non-Squamous Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49237"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of lanthanum carbonate on FGF23 in patients with CKD at predialysis stage</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223803"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SH-L-562BB Phase II/III Dose Justification and Gadoteridol-Controlled Comparative Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45767"></Trial><Drug id="3191">gadoteridol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="106382"></Trial><Drug id="5800">pantoprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186877"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-73-4506 Probe Substrate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74481"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, multicenter, dose-escalating study to evaluate the pharmacokinetics, safety and efficacy of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic melanoma</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53035"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and efficacy of L19-IL2 in combination with dacarbazine in chemotherapy-naive stage IV melanoma patients</ProtocolTitle><Sponsor>Eberhard Karls Universitt Tbingen</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="67767"></Trial><Drug id="45599">L19-IL-2 fusion protein, Philogen</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY-1000394 Given in a 3 Days on/4 Days Off Schedule in Subjects with Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="69519"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation study to evaluate the safety and pharmacokinetics of telatinib in combination with irinotecan and capecitabine in patients with solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="40486"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACDC</ProtocolAcronym><ProtocolTitle>Acute Cholecystitis  Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2019">Cholecystitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21958"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRIFT</ProtocolAcronym><ProtocolTitle>Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="311747"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1584">Unstable angina</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CORE-OCU</ProtocolAcronym><ProtocolTitle>The Combination Therapy With Ra-223 and Enzalutamide</ProtocolTitle><Sponsor>Osaka City University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="314991"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PEACE III</ProtocolAcronym><ProtocolTitle>Phase III Radium 223 mCRPC</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210276"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of SH-T00658ID on Libido</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1276">Female sexual dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="116486"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64877"></Trial><Drug id="25182">valganciclovir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="300243"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>OSA-T</ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled trial of testosterone undecanoate in obese men as adjuvant therapy for a weight loss program</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Woolcock Institute of Medical Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3519">Obstructive sleep apnea</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98971"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS II</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 2</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6753"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open, Randomized, Multicenter Comparison Of Efficacy, Cycle Control, And Tolerability Of A 23-day Oral Contraceptive Regimen With 20 Microg Ethinyl Estradiol And 75 Microg Gestodene And A 21-day Regimen With 20 Microg Ethinyl Estradiol And 150 Microg Desogestrel</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="110450"></Trial><Drug id="12164">ethinylestradiol + gestodene (oral), Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Vantictumab (OMP-18R5) in Combination With Nab-paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer</ProtocolTitle><Sponsor>OncoMed Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="163171"></Trial><Drug id="66153">vantictumab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SLOH</ProtocolAcronym><ProtocolTitle>Nebido in Symptomatic Late Onset Hypogonadism (SLOH)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65364"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Prospective, Multicenter, Double-Blind, Randomized  Trial To Compare The Efficacy And Safey Of Moxifloxacin And Clindamycin In The Treatment Of Odontogenic Abscesses And Inflammatory Infiltrates</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2275">Odontogenic tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75743"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, prospective, randomized, double-blind, safety and efficacy study of moxifloxacin, compared to azithromycin in treating adult patients with acute bacterial exacerbations of chronic bronchitis (ABECB)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1488">Chronic bronchitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50271"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1732">Acute promyelocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25586"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized crossover study to compare directly the steady-state pharmacokinetics and anticoagulant effects of rivaroxaban and apixaban in healthy Caucasian male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="326314"></Trial><Drug id="52967">apixaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative, crossover, double-blind, randomized study to evaluate the safety of ciprofloxacin in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="108667"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HARMONY II</ProtocolAcronym><ProtocolTitle>Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3121">Drug withdrawal syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31744"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3460">Metastatic gastrointestinal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89175"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pediatric Risk of Hypothyroidism With Iodinated Contrast Media</ProtocolTitle><Sponsor>GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="182">Hypothyroidism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="350385"></Trial><Drug id="44294">iohexol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GOAL</ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37558"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small-Cell Lung Cancer Progressing on Erlotinib</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46006"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Sagopilone in Combination With Carboplatin and Bevacizumab in the First-Line Treatment of Patients With Stage IIIB/IV</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132432"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2453">Astrocytoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOVAR</ProtocolAcronym><ProtocolTitle>Regorafenib versus Tamoxifen in Patients With Platinum-sensitive Ovarian Carcinoma and Isolated Biological Progression</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243698"></Trial><Drug id="44314">tamoxifen</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of BAY-1436032 in IDH1-mutant Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="258833"></Trial><Drug id="101614">BAY-1436032</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib in Patients With Advanced Myeloid Malignancies</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="287296"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 24-week study to compare the safety and efficacy of cerivastatin with lovastatin in treatment of patients with primary hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55064"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multi-center, double-blind, placebo-controlled study to compare the safety and efficacy of cerivastatin with simvastatin in treatment of patients with primary hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55059"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2938">Thymus neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J-ROCKET AF</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4977"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pilot study to examine the effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3239">Portal hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84949"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro XR) 1000 mg Tablets Given qd For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8689"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>eXtRa</ProtocolAcronym><ProtocolTitle>A Multicenter, Open-Label, Phase IV Study to Evaluate The Safety And Efficacy of Cipro XR for The Treatment of Urinary Tract Infections (UTI) in Adult Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16264"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare The Safety, Efficacy And Tolerability of Cipro XR (Extended Release) And Ciprofloxacin in Non-Pregnant Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15254"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EXTRA</ProtocolAcronym><ProtocolTitle>Cipro XR Excellence in Therapeutic Response and Activity (extra) - Assessing Symptom Relief in Urinary Tract Infections</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="14842"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, single-arm, dose-comparison study to evaluate the brain perfusion imaging efficacy of SH-L-562 in patients with unilateral carotid stenosis or unilateral cerebral infarcts</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="62">Cerebral infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343149"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>Hypertension and Atrial Fibrillation treated by Rivaroxaban for the Morning and Night with Synergy with calcium antagonists</ProtocolTitle><Sponsor>Jichi Medical School, Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273125"></Trial><Drug id="100086">nifedipine once-daily coated core formulation (essential hypertension, angina), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAGELLAN</ProtocolAcronym><ProtocolTitle>Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6337"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29597"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61955"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-center, randomized, double-blind, placebo-controlled, single dose-escalation study to investigate safety, tolerability and pharmacokinetics of BAY-1021189 in Asian (Chinese) healthy male subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="161141"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FRAIL-AF study</ProtocolAcronym><ProtocolTitle>Anticoagulation in frail elderly patients with atrial fibrillation</ProtocolTitle><Sponsor>Julius Center for Health Sciences and Primary Care, Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="315870"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chikushi Anti-coagulation Trial for Xarelto</ProtocolTitle><Sponsor>Fukuoka University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301418"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFIRE</ProtocolAcronym><ProtocolTitle>Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study</ProtocolTitle><Sponsor>Japan Cardiovascular Research Foundation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249714"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of effect of rivaroxaban in patients with non-valvular atrial fibrillation</ProtocolTitle><Sponsor>Yamaguchi University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="221453"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Hot Flushes in Asian Women With Ultra-Low Dose Estradiol Patch</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32856"></Trial><Drug id="45697">estradiol (ultra-low-dose patch, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effects of BAY-M-1099 and emiglitate on metabolic responses to a mixed meal in normal healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56987"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetic study of vardenafil in the healthy males</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52640"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="51388">nilotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REMETY</ProtocolAcronym><ProtocolTitle>Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="315441"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma</ProtocolTitle><Sponsor>Swedish Medical Center (Colorado)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44929"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, two parallel-arm study to compare the efficacy of 0.5 M gadobutrol doses (0.1 versus 0.3 mmol/kg) using pre- and post-contrast images to assess the number of lesions in patients with known or suspected brain metastases</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3471">Metastatic brain cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345242"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SKADI</ProtocolAcronym><ProtocolTitle>Study for Long-Term Treatment of Acne Vulgaris With Skinoren Versus Differin</ProtocolTitle><Sponsor>University of Magdeburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78992"></Trial><Drug id="9411">adapalene</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="244510"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-59-7939 in Atrial Fibrillation Once-Daily (OD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60206"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Subjects</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241494"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPER</ProtocolAcronym><ProtocolTitle>Blood-Sparing During Hip Prosthesis Surgery With Exacyl in Patients Treated With Rivaroxaban</ProtocolTitle><Sponsor>University Hospital, Brest</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="225858"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMMANDER HF</ProtocolAcronym><ProtocolTitle>A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure</ProtocolTitle><Sponsor>Janssen Pharmaceuticals Inc, Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="143374"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind study to evaluate the efficacy of methylprednisolone aceponate (0.1%) versus mometasone furoate with respect to suppression of UVB light-induced erythema, in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50594"></Trial><Drug id="13594">mometasone furoate (nasal), Merck &amp; Co</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROMISE</ProtocolAcronym><ProtocolTitle>Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15274"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY-1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between Two Different Types of Tablets of BAY-1817080 and the Difference Between Oral Dose and Dose in the Vein</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="363220"></Trial><Drug id="102704">BAY-1817080</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MaxSep</ProtocolAcronym><ProtocolTitle>Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem plus Moxifloxacin) in the Treatment of Severe Sepsis and Septic Shock</ProtocolTitle><Sponsor>Kompetenznetz Sepsis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="816">Septic shock</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11415"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-14-2222 Continuous Infusion in Surgeries</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="439">Hemophilia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31149"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="244510"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57735"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib/Cetuximab in Head and Neck Cancer</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="39672"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>WESAIL</ProtocolAcronym><ProtocolTitle>Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users</ProtocolTitle><Sponsor>Columbia University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="119">Epilepsy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="221871"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3081">Abscess</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="63307"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial to evaluate the safety and efficacy of Alpharadin in patients with skeletal metastases from prostate or breast cancer</ProtocolTitle><Sponsor>Algeta ASA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="40423"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1705">Endometrioid carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J-ROCKET AF</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1077">Embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4977"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-Vaginal Ring</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="240273"></Trial><Drug id="44370">clindamycin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320618"></Trial><Drug id="38812">desogestrel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="229314"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Trial in Hormone Withdrawal Associated Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="112">Endocrine disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64988"></Trial><Drug id="13599">desogestrel + ethinylestradiol (monophasic), Organon/Merck &amp; Co/Barr</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative, efficacy study between mesna and argimesna in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55894"></Trial><Drug id="2566">argimesna</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35206"></Trial><Drug id="8050">thalidomide, Celgene</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Doses Of BAY-1902607 In Healthy Males And Proof Of Concept In Chronic Cough Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="82">Cough</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="340496"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2938">Thymus neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21470"></Trial><Drug id="9298">Thymoglobulin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAND</ProtocolAcronym><ProtocolTitle>Radium 223 Following Intermittent ADT</ProtocolTitle><Sponsor>Canadian Urology Research Consortium</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="251104"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57816"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GRIP</ProtocolAcronym><ProtocolTitle>Safety of Gadovist in Renally Impaired Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="42275"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="7934">doxorubicin (liposomal, STEALTH), Alza</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Aromatase Inhibitors (Anastrozole) Associated with Levonorgestrel-releasing Intrauterine Device (Lng-ius) in the Treatment of Endometriosis Moderate/Severe</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130347"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Mahidol University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="39419"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="225976"></Trial><Drug id="43738">pazopanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Treatment Combination for Patients With Unresectable Stage III or IV Melanoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3256">Stage III melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25614"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE ESUS</ProtocolAcronym><ProtocolTitle>Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="218006"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EUCLID</ProtocolAcronym><ProtocolTitle>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99397"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the QT/QTc Interval Prolongation Potential of Vericiguat</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="336967"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY-43-9006) in Chemonaive Patients With Stage IIIB to IV Non-Small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28384"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A controlled, randomized, crossover study to evaluate the safety, bioavailability and pharmacokinetics of cerivastatin in healthy young male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55051"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="148972"></Trial><Drug id="77107">BAY-1125976</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4299">Salivary gland cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, parallel-group, phase I study to evaluate the safety and pharmacokinetics of vilaprisan in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290751"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACROSS-AMI</ProtocolAcronym><ProtocolTitle>A Prospective, Randomized Clinical Trial, the Effect of Long Acting CCBs in Post-Acute Myocardial Infarction Patients</ProtocolTitle><Sponsor>Kumamoto University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132157"></Trial><Drug id="56641">benidipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the histological response, pattern of tumor destruction and clinical outcome with neoadjuvant chemotherapy including bevacizumab or cetuximab in patients with colorectal liver metastases undergoing liver resection</ProtocolTitle><Sponsor>Amgen Inc, Bayer AG, Merck KGaA, Roche Holding AG, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239318"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ITEM</ProtocolAcronym><ProtocolTitle>Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels</ProtocolTitle><Sponsor>Deutsches Wollforschungsinstitut an der Rheinisch-Westfalischen Technischen Hochschule Aachen eV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21038"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CERDIA</ProtocolAcronym><ProtocolTitle>A Double-Blind, Placebo-Controlled Study on The Effect of Cerivastatin on The Process of Atherosclerosis in Non-Insulin Dependent Diabetes Mellitus (type 2)</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="33">Atherosclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150330"></Trial><Drug id="44313">simvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>TacroVori</ProtocolAcronym><ProtocolTitle>Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290506"></Trial><Drug id="54222">tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY-1161116</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1699">Polycystic ovary syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="295572"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating and pharmacokinetic (PK) study of vatalanib in patients with liver metastases from colorectal, breast and other solid tumors</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38143"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BrUOG L301 With Non-Small-Cell Lung Cancer and Bone Metastasis</ProtocolTitle><Sponsor>Brown University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215190"></Trial><Drug id="2765">zoledronic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, first-in-human, multicenter, randomized, double-blind, placebo-controlled, single-dose escalation, safety, tolerability, pharmacodynamic, pharmacokinetic and immunogenicity study of BAY-86-6150 in patients with hemophilia A or B with or without inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="68055"></Trial><Drug id="52200">BAY-86-6150</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea: a Pilot Study</ProtocolTitle><Sponsor>Derm Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="191544"></Trial><Drug id="55053">brimonidine (topical gel, erythema), Galderma</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2975">Ewing sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Finding Study of Gadovist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2920">Spinal cord disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49081"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Treatment Combination for Patients With Unresectable Stage III or IV Melanoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25614"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="385606"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Myocardial Perfusion MRI</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83194"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TOTEM-RRMS</ProtocolAcronym><ProtocolTitle>Testosterone Treatment on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Hopitaux Universitaires de Strasbourg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="376628"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LEPHT</ProtocolAcronym><ProtocolTitle>A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64034"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>RISE-IIP</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187482"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Aflibercept for Submacular Hemorrhage</ProtocolTitle><Sponsor>Kim's Eye Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2522">Ocular hemorrhage</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="299946"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Safety and Exploratory Skin Lesion Measurement of TR-701FA Study</ProtocolTitle><Sponsor>Trius Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2525">Cellulitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84345"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI-3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81893"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the safety, efficacy and usefulness of 0.5 M gadobutrol by enhancement effect in patients with diseases of the head and neck, heart, chest, bone/soft tissue or spine</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="45">Bone disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345240"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Gadobutrol 1.0 M (Gadavist) in Patients for Central Nervous System (CNS) Imaging</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="109914"></Trial><Drug id="3191">gadoteridol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pivotal Bioequivalence FDC Nifedipine/Candesartan versus Loose Combination of Single Components, Fed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77278"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ginseng for Patients on Regorafenib</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243766"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-NOAC</ProtocolAcronym><ProtocolTitle>X-NOAC Study</ProtocolTitle><Sponsor>Dokkyo Medical University, Imari Arita Kyoritsu Hospital, Kameda Medical Center, Saga University, Tokyo Metropolitan Hiroo Hospital, Yokohama Minami Kyosai Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="221456"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Extension Program for Bay-43-9006</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="26245"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>Hypertension and Atrial Fibrillation treated by Rivaroxaban for the Morning and Night with Synergy with calcium antagonists</ProtocolTitle><Sponsor>Jichi Medical School, Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273125"></Trial><Drug id="100086">nifedipine once-daily coated core formulation (essential hypertension, angina), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="179772"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57735"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>RISE-IIP</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187482"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Multiple-Doses of BAY-63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="17236"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MERAK</ProtocolAcronym><ProtocolTitle>A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="484">Skin infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="42277"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57816"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose escalation study to evaluate the safety, pharmacokinetics and efficacy of sorafenib in combination with doxorubicin in patients with solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53041"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of BAY-43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="190805"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein-PE</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6231"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57675"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GRAMS</ProtocolAcronym><ProtocolTitle>Gadobutrol Enhanced MRA of the Renal Arteries</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1620">Renal artery obstruction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76993"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Testosterone, Metformin, or Both, for Hypogonadism in Obese Males</ProtocolTitle><Sponsor>Bayer AG, Fundacion Publica Andaluza para la Investigacion de Malaga en Biomedicina y Salud</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3494">Male hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="236616"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>APOLLO</ProtocolAcronym><ProtocolTitle>Investigation of Eylea for PCV</ProtocolTitle><Sponsor>Kyushu University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="326379"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71984"></Trial><Drug id="2428">Adenoscan</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, prospective, randomized, double-blind, safety and efficacy study of moxifloxacin, compared to azithromycin in treating adult patients with acute bacterial exacerbations of chronic bronchitis (ABECB)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50271"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the tolerability and pharmacodynamics of ramatroban in healthy volunteers</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29553"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, randomized, placebo-controlled, multiple-dose study to evaluate the safety, pharmacokinetic and efficacy of cerivastatin between young and elderly male patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="33">Atherosclerosis</Indication><HighestDevStatusForInd id="W">Withdrawn</HighestDevStatusForInd><Trial id="55066"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SIGHT</ProtocolAcronym><ProtocolTitle>VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="82878"></Trial><Drug id="2622">verteporfin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="25522"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants</ProtocolTitle><Sponsor>The University Health Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="616">Graft versus host disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="30836"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, single-arm, open-label, pilot study to assess the safety and efficacy of the combination of fludarabine, cyclophosphamide and alemtuzumab, in patients with relapsed/refractory B-cell chronic lymphocytic leukemia</ProtocolTitle><Sponsor>Bayer HealthCare AG, Sanofi Genzyme, Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83419"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="2784">letrozole</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO</ProtocolAcronym><ProtocolTitle>Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241242"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation study to evaluate the safety and pharmacokinetics of telatinib in combination with irinotecan and capecitabine in patients with solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40486"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY-73-4506 in Combination With mFOLFOX6 or FOLFIRI</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58597"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>YAZ Post-Authorization, Safety Study (PASS)/Post-Authorization, Efficacy Study (PAES) in China</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="256161"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>YAZ Post-Authorization, Safety Study (PASS)/Post-Authorization, Efficacy Study (PAES) in China</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="256161"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SUSE</ProtocolAcronym><ProtocolTitle>Sorafenib in Urothelium Cancer of Bladder</ProtocolTitle><Sponsor>Association of Urogenital Oncology (AUO)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71022"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NEXUS</ProtocolAcronym><ProtocolTitle>A Phase III, Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28385"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FLORIMS</ProtocolAcronym><ProtocolTitle>Flupirtine as Oral Treatment in Multiple Sclerosis</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186944"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BECOME</ProtocolAcronym><ProtocolTitle>Phase IV, Rater-Blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-Remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-Dose Gadolinium</ProtocolTitle><Sponsor>New Jersey Medical School, University of Medicine and Dentistry of New Jersey</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="13223"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="249448"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, safety and efficacy trial of miglitol in non-insulin dependent diabetic (NIDD) patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19750"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY-73-4506 in Combination With mFOLFOX6 or FOLFIRI</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58597"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="148727"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy Vardenafil 10 mg versus Tadalafil 10 mg in in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31431"></Trial><Drug id="4119">tadalafil</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LUTECIA</ProtocolAcronym><ProtocolTitle>Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="23385"></Trial><Drug id="4119">tadalafil</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN Jr</ProtocolAcronym><ProtocolTitle>Oral Rivaroxaban in Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210054"></Trial><Drug id="4476">fondaparinux sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="24791"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="4563">doxorubicin (liposome formulation), Cephalon</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="35820"></Trial><Drug id="4577">topotecan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GREAN</ProtocolAcronym><ProtocolTitle>Glucose Reduction by Early Acarbose Treatment in Basal Insulin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60087"></Trial><Drug id="4655">voglibose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma</ProtocolTitle><Sponsor>Hopital Maisonneuve-Rosemont</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38444"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG, Biogen Inc, CTI BioPharma Corp, Schering Lusitana Lda</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="43438"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>METATEL</ProtocolAcronym><ProtocolTitle>Regulation of inflammatory parameters by telmisartan in hypertensive patients</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6339"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HIGHCARE-ANDES</ProtocolAcronym><ProtocolTitle>High Altitude Cardiovascular Research in the ANDES</ProtocolTitle><Sponsor>Istituto Auxologico Italiano</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="121584"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>METATEL</ProtocolAcronym><ProtocolTitle>Regulation of inflammatory parameters by telmisartan in hypertensive patients</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1585">Syndrome X</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="6339"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPARIOS 1</ProtocolAcronym><ProtocolTitle>BAY-98-7196 Dose-Finding/POC Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="215042"></Trial><Drug id="5267">leuprorelin acetate</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effects of add-on acarbose on the levels of chronic inflammatory state and gut microbiota in patients with type 2 diabetes mellitus</ProtocolTitle><Sponsor>The Second Affiliated Hospital of Dalian Medical University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="98641"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="320057"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of Acarbose on Incretins Secretion in New Diagnosed T2DM</ProtocolTitle><Sponsor>Guangdong Provincial People's Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="139964"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pivotal, phase II, open-label, multinational, multicenter trial to study the efficacy of fludarabine in relapsed and refractory B-cell chronic lymphocytic leukemia patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="297917"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, placebo-controlled trial to evaluate the efficacy of dofequidar in patients with advanced and recurrent breast cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="36149"></Trial><Drug id="6674">dofequidar</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A two-year, multicenter, randomized, double-blind, active-controlled, noninferiority study to evaluate the safety and efficacy of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62842"></Trial><Drug id="6681">raloxifene</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44334"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NOVEL 1</ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Leukine in the treatment of moderately to severely active Crohns disease</ProtocolTitle><Sponsor>Berlex Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="84">Crohns disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="50786"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BECOME</ProtocolAcronym><ProtocolTitle>Phase IV, Rater-Blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-Remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-Dose Gadolinium</ProtocolTitle><Sponsor>New Jersey Medical School, University of Medicine and Dentistry of New Jersey</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="13223"></Trial><Drug id="8710">glatiramer acetate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacokinetic study of talviraline in healthy volunteers</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="16941"></Trial><Drug id="8922">BAY-10-8039</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="300">Seborrheic dermatitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="21637"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73003"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I efficacy study of bid vatalanib in patients with advanced cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38264"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation trial of vatalanib in combination with either temozolomide or lomustine in patients with recurrent glioblastoma multiforme (GBM)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38123"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, phase III study to evaluate the safety and efficacy of NeoTect for the non-invasive evaluation of solitary pulmonary nodules (SPNs) in patients with lung tumor</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47702"></Trial><Drug id="9397">99mTc-depreotide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS Extension</ProtocolAcronym><ProtocolTitle>An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58388"></Trial><Drug id="9702">recombinant interferon beta-1a, Merck Serono</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Gastric Cancer Asian Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28458"></Trial><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2193">Anal tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PRIDE</ProtocolAcronym><ProtocolTitle>Primovist Enhanced MRI for the Detection and Evaluation of Focal Liver Lesions</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="202">Liver tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="130961"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VISADO</ProtocolAcronym><ProtocolTitle>Visanne Study to Assess Safety in Adolescents</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74067"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of SHT-00660AA in Treatment of Endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73934"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALT GIST</ProtocolAcronym><ProtocolTitle>A Randomized Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumor (GIST)</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group, European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Centre of Singapore</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222463"></Trial><Drug id="11460">imatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III multicenter, single-blind, randomized, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist (single iv injection) in patients with known or suspected renal lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75857"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III multicenter, single-blind, randomized, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist (single iv injection) in patients with known or suspected renal lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75857"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study to Evaluate Gadovist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5286"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="245">Osteoarthritis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="344505"></Trial><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, multi-center study to evlauate the efficacy, cycle control and tolerability of SH-543 in female patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51971"></Trial><Drug id="12164">ethinylestradiol + gestodene (oral), Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="89175"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, crossover, placebo-controlled study to evaluate the safety and efficacy of Climen, a biphasic hormonal replacement therapy in postmenopausal patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73930"></Trial><Drug id="12341">cyproterone acetate + estradiol valerate, Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gadobutrol Magnevist-controlled Body Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63429"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 30-week, multi-center, double-blind, randomized, parallel-group, dose-finding study, of metrifonate in patients with mild-to-moderate Alzheimer's disease (AD)</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8436"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, phase III study to evaluate the efficacy of metrifonate in patients with Alzheimer's disease</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="50610"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the efficacy of moxifloxacin to ceftriaxone plus metronidzaole for the treatment of patients with complicated intraabdominal infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="16401"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="312">Streptococcus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="456">Proteus mirabilis infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1487">Acute bronchitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1815">Bacterial pneumonia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SPEED</ProtocolAcronym><ProtocolTitle>Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2999">Acute sinusitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="21620"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2999">Acute sinusitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>InReTel</ProtocolAcronym><ProtocolTitle>The Influence of Telmisartan on Insulin Resistance and Fatty Liver in Patients Suffer from Hypertension</ProtocolTitle><Sponsor>Klinikum Chemnitz Gmbh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="120057"></Trial><Drug id="13007">torasemide</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SOFIA</ProtocolAcronym><ProtocolTitle>Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer</ProtocolTitle><Sponsor>German Breast Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48473"></Trial><Drug id="13022">epirubicin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32165"></Trial><Drug id="13615">etonogestrel + ethinylestradiol (vaginal ring, contraceptive), Merck &amp; Co</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXaHIP-OD</ProtocolAcronym><ProtocolTitle>Dose-ranging study of once-daily regimen of BAY-59-7939 in the prevention of VTE in patients undergoing elective total hip replacement</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4885"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD 4</ProtocolAcronym><ProtocolTitle>Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY-59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4881"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEINJr</ProtocolAcronym><ProtocolTitle>Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="217784"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS-12 Adolescent Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="80751"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY-1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="234174"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>STEPS</ProtocolAcronym><ProtocolTitle>STEPS Trial  Spheramine Safety and Efficacy Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="255">Parkinsons disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="6311"></Trial><Drug id="15745">cell therapy (dopamine producers, Parkinsons), Titan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Safety and Efficacy of Spheramine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="255">Parkinsons disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="45054"></Trial><Drug id="15745">cell therapy (dopamine producers, Parkinsons), Titan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="85043"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety and pharmacokinetic study of ortataxel every 3 weeks in patients with solid tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="40840"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231217"></Trial><Drug id="17735">sipuleucel-T</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AGENT 2</ProtocolAcronym><ProtocolTitle>A phase IIa, randomized, double-blind, placebo-controlled, safety and efficacy study of Ad5-FGF4 (alferminogene tadenovec) in patients with moderate to severe exertional angina despite antianginal medicine: Angiogenic Gene Therapy Trial</ProtocolTitle><Sponsor>Gene Biotherapeutics Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="5879"></Trial><Drug id="17801">alferminogene tadenovec</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Crossover Study To Evaluate Nasal Symptoms Induced by Platelet Activating Factor, after Nasal Challenge in Both Healthy and Allergic Rhinitis Subjects Pretreated with Rupatadine, Levocetirizine or Placebo</ProtocolTitle><Sponsor>Bayer AG, Chiesi Farmaceutici SpA, GlaxoSmithKline plc, Grupo Uriach, Johnson &amp; Johnson, Laboratorios Dr Esteve SA, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="172862"></Trial><Drug id="18057">levocetirizine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SPINART</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33087"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and pharmacokinetics of vardenafil in the treatment of erectile dysfunction in men with kidney disease</ProtocolTitle><Sponsor>Bayer Corp, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53949"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Investigate the Time to Onset of Action of 10 and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31435"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-Blind 'Preferred' Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31426"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-38-9456, 5/10/20 mg, Versus Placebo in Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31208"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ENDURANCE</ProtocolAcronym><ProtocolTitle>Assessment of Duration of Erection With Vardenafil 10 mg</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31160"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="24446"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-38-9456 - Pivotal Trial for Diabetes Patient</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15407"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VADEOPEN</ProtocolAcronym><ProtocolTitle>Clinical trial, Phase IIIb, Multicenter, Double-blind, to Evaluate the Efficacy of Vardenafil orodispersible versus Placebo in Patients With Erectile Dysfunction More Comorbidity And Impact On Quality Of Life Of Your Sexual Partner</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="129785"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-Independent Prostate Cancer</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="41167"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II trial of BX-471 in patients with multiple sclerosis</ProtocolTitle><Sponsor>Berlex Biosciences</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="30602"></Trial><Drug id="28194">BX-471</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-50-4798 in Patients With HIV Infection</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="13695"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RELIEF</ProtocolAcronym><ProtocolTitle>Comparison of Sequential iv/po Moxifloxacin With iv Piperacillin/Tazobactam Followed by po Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3081">Abscess</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10316"></Trial><Drug id="29446">piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SOFIA</ProtocolAcronym><ProtocolTitle>Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer</ProtocolTitle><Sponsor>German Breast Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="48473"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONKO-006</ProtocolAcronym><ProtocolTitle>Additive Therapy In R1-Resected Pancreatic Cancer With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo Over 12 Months - A Double-blind, Placebo-Controlled, Phase IIb Trial</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="132452"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone</ProtocolTitle><Sponsor>Abramson Cancer Center of the University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73243"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy</ProtocolTitle><Sponsor>National Cancer Center of Korea</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="68019"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="57816"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of sorafenib in patients with acute myeloid leukemia (AML) and activating FLT3-mutations</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="63096"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ORACLE</ProtocolAcronym><ProtocolTitle>Open-Label, Phase II Study of BAY-43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="28455"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Extension From RCC Phase II (11515)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33683"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Tosylate Following a Liver Transplant in Treating Patients with Liver Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88537"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)</ProtocolTitle><Sponsor>Case Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="76585"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients</ProtocolTitle><Sponsor>Columbia University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="61151"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Prediction of Effectiveness of Sorafenib on the Basis of Angiogenesis-Related Cytokines</ProtocolTitle><Sponsor>Okayama University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="250866"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="148987"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="36011"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3240">Medullary thyroid cancer</Indication><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Trial id="182002"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy</ProtocolTitle><Sponsor>Hospital del Mar</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69049"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186912"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AUS1</ProtocolAcronym><ProtocolTitle>An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma (AUS1)</ProtocolTitle><Sponsor>Austin Health</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="145850"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS-TIMI 46</ProtocolAcronym><ProtocolTitle>Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes</ProtocolTitle><Sponsor>Bayer AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5154"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD3</ProtocolAcronym><ProtocolTitle>Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE); A Study of BAY-59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6174"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-HIP2</ProtocolAcronym><ProtocolTitle>Dose-ranging study of BAY-59-7939 (rivaroxaban) on the prevention of VTE in patients undergoing elective total hip replacement</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4886"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO</ProtocolAcronym><ProtocolTitle>Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241242"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239279"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239279"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SELECT-D</ProtocolAcronym><ProtocolTitle>Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism</ProtocolTitle><Sponsor>Warwick University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="140785"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD 1</ProtocolAcronym><ProtocolTitle>Rivaroxban (10 mg) Given Once-Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin</ProtocolTitle><Sponsor>Bayer Australia Ltd, Bayer HealthCare AG, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6173"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J'xactly</ProtocolAcronym><ProtocolTitle>Japanese registry of Rivaroxaban effectiveness and safety for the prevention of recurrence in patients with Deep Vein Thrombosis and Pulmonary Embolism</ProtocolTitle><Sponsor>Nihon University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="280759"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Russia/Ukraine Suppression of Ovarian Activity Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="241046"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="206309"></Trial><Drug id="37370">azacitidine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY88-8223, Dose Finding Study in Pts With HRPC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40322"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="225976"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="207058"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="116253"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="112029"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSDOY</ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88345"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65750"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety and pharmacokinetics study of iv solulin in healthy volunteers</ProtocolTitle><Sponsor>PAION AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1001">Nervous system injury</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="7145"></Trial><Drug id="40733">solulin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, prospective, randomized, double-blind, comparative, multicenter clinical trial to compare	 safety and efficacy of moxifloxacin compared with piperacillin + tazobactam and amoxicillin + clavulanate for the treatment of complicated intra-abdominal infections</ProtocolTitle><Sponsor>Case Western Reserve University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="68863"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INSIGHT</ProtocolAcronym><ProtocolTitle>A comparative, double-blind, randomized study to evaluate the efficacy of nifedipine-GITS, amiloride and hydrochlorothiazide in patients with hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="113421"></Trial><Drug id="44289">enalapril</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clotrimazole Vaginal Tablet Versus Fluconazole for Severe Vulvovaginal Candidiasis</ProtocolTitle><Sponsor>Peking University Shenzhen Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1308">Candida infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="202220"></Trial><Drug id="44292">fluconazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to compare the safety and efficacy of 100-fold lower dose of cerivastatin with simvastatin in treatment of patients with primary hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="55062"></Trial><Drug id="44313">simvastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONCEPT-SCLC</ProtocolAcronym><ProtocolTitle>Roniciclib/Placebo in Combination With Chemotherapy in Small Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="195819"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRAGON</ProtocolAcronym><ProtocolTitle>Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45053"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and efficacy of telatinib in combination with bevacizumab in patients with advanced solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="40492"></Trial><Drug id="45497">telatinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation, safety and pharmacokinetic study of tumor growth inhibitor ZK-304709, administered for 14 days of a 28-day cycle</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="36325"></Trial><Drug id="45637">ZK-304709</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, double-dummy, placebo-controlled, four-way, crossover study to investigate QT/QTc prolonging effects in 12-lead ECG after once daily oral dosing over four days of drug product SHT-00658M (containing 3 mg dienogest and 2 mg estradiol valerate) and a supra-therapeutic dose of 10 mg dienogest in comparison to placebo and to a single-dose of 400 mg moxifloxacin as an open-label positive control in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="345200"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, open-label study to evaluate the pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="116403"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="77700"></Trial><Drug id="46177">mapracorat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33472"></Trial><Drug id="46885">aprotinin, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222484"></Trial><Drug id="49721">denosumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY-79-4980</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="33282"></Trial><Drug id="51391">recombinant Factor VIII (PEGylated liposomal), Bayer/Zilip</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="88">Cystic fibrosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="9240"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Chronic Obstructive Pulmonary Disease (COPD) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single-Dose Inhalations of 50 and 75 mg Ciprofloxacin Inhalation Powder</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="68531"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59782"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESPIRE 1</ProtocolAcronym><ProtocolTitle>Ciprofloxacin Dry Powder for Inhalation in Non-Cystic Fibrosis Bronchiectasis (Non-CF BE)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="104362"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="52967">apixaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The study of aflibercept with treat and extend regimen for BRVO</ProtocolTitle><Sponsor>Akita City Hospital, Akita University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="270514"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The efficacy of Eylea to treat proliferative diabetic retinopathy/preproliferative diabetic retinopathy in patients with diabetic macular edema</ProtocolTitle><Sponsor>Kyorin University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2657">Proliferative diabetic retinopathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="281981"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Aflibercept (Eylea) in the Management of Bevacizumab (Avastin) Resistant Diabetic Macular Edema</ProtocolTitle><Sponsor>Hopital Maisonneuve-Rosemont</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="274291"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective study evaluating aflibercept in patients with recurrent or prolonged diabetic macular edema after vitrectomy</ProtocolTitle><Sponsor>Kyushu University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="219125"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Aflibercept treat and extend for branch retinal vein occlusion</ProtocolTitle><Sponsor>Jikei daisan hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="296361"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The efficacy of intravitreal aflibercept given in a treat and extend regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion</ProtocolTitle><Sponsor>Centre For Eye Research Australia</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="229334"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CLEAR-IT 2</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5043"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BIOIMAGE</ProtocolAcronym><ProtocolTitle>Phase IV Study to Evaluate Genetic Variants of VEGF Pathway as Biomarkers of VEGF Trap-Eye Treatment Efficacy in Subjects With Neovascular Age-Related Macular Degeneration (wAMD)</ProtocolTitle><Sponsor>Bayer AG, The Ocular Microsurgery Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="158784"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Aflibercept (Eylea) as Secondary or Third-Line Treatment for Neovascular Age-Related Macular Degeneration</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="149741"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CORONARIES</ProtocolAcronym><ProtocolTitle>Coronary Vasomotor Response After Riociguat Exposure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="68389"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT PLUS</ProtocolAcronym><ProtocolTitle>Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and other Safety Parameters</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69059"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REPLACE</ProtocolAcronym><ProtocolTitle>Riociguat Replacing PDE-5i Therapy Evaluated Against Continued PDE-5i Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271077"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The drug adempas and its combination with endothelin receptor antagonists or prostanoids in patients with pulmonary arterial hypertension to evaluate its efficacy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="157277"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MR BPA</ProtocolAcronym><ProtocolTitle>MR BPA study</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="244262"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EAS</ProtocolAcronym><ProtocolTitle>Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="108026"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Capadenoson in Angina Pectoris</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="5694"></Trial><Drug id="54615">capadenoson</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIa, efficacy study of BAY-68-4986 (capadenoson)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="5159"></Trial><Drug id="54615">capadenoson</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE II</ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Refractory Advanced Gastro-Esophageal Cancer</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="260950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOVAR</ProtocolAcronym><ProtocolTitle>Regorafenib versus Tamoxifen in Patients With Platinum-sensitive Ovarian Carcinoma and Isolated Biological Progression</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="243698"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="214566"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) who have Progressed after Standard Therapy (Managed Access Program)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="92073"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="89364"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGISTRI</ProtocolAcronym><ProtocolTitle>Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST</ProtocolTitle><Sponsor>Grupo Espanol de Investigacion en Sarcomas</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="249376"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="196950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGO-SARC</ProtocolAcronym><ProtocolTitle>Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma</ProtocolTitle><Sponsor>Centre Oscar Lambret</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="146211"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONCUR</ProtocolAcronym><ProtocolTitle>Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86832"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib + FOLFIRI Versus Placebo + FOLFIRI as Second-Line Treatment in Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Irish Clinical Oncology Research Group, UNC Lineberger Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74911"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAVELLO</ProtocolAcronym><ProtocolTitle>Maintenance Therapy With Regorafenib</ProtocolTitle><Sponsor>University of Campania Luigi Vanvitelli</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231915"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVERCE</ProtocolAcronym><ProtocolTitle>Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="156949"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54662">ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="357065"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of Florbetaben (BAY-94-9172) PET Imaging for Detection/Exclusion of Cerebral Beta-Amyloid Compared to Histopathology</ProtocolTitle><Sponsor>Bayer AG, Life Molecular Imaging</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62250"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study to evaluate the safety, clinical activity and pharmacokinetic profile of L19-TNF-alpha in patients with refractory solid tumors</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="62608"></Trial><Drug id="62330">L19-TNF-alpha</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) Drug-Drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="212225"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCOCO</ProtocolAcronym><ProtocolTitle>Phase I Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="338906"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI ND-C</ProtocolAcronym><ProtocolTitle>A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="320384"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI ND-M</ProtocolAcronym><ProtocolTitle>A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="320383"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE 3</ProtocolAcronym><ProtocolTitle>Long-Term Pre-Dialysis Extension in Europe and Asia Pacific</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="183811"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="213253"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="222235"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="69973">dolutegravir + lamivudine + abacavir (HIV), ViiV</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Long-Term Safety and Efficacy Study of Fixed-Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="109482"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Safety of BAY-1067197 in Stable Heart Failure Patients on Standard Therapy Including Beta-blocker</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="155060"></Trial><Drug id="75478">neladenoson bialanate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SOCRATES-PRESERVED</ProtocolAcronym><ProtocolTitle>Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY-1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="156009"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY-1214784</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1005">Unidentified indication</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="207850"></Trial><Drug id="92188">BAY-1214784</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability Study of Emodepside IR-tablets and Solution</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2505">Filariasis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="323738"></Trial><Drug id="92511">emodepside</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FOXTROT</ProtocolAcronym><ProtocolTitle>Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="312046"></Trial><Drug id="94069">BAY-1213790</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DREAM</ProtocolAcronym><ProtocolTitle>Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="208729"></Trial><Drug id="95589">regorafenib (ophthalmic, age related macular degeneration), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of BAY-1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="296031"></Trial><Drug id="96958">BAY-1193397</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 and 120 mg</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="335">Trypanosoma cruzi infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="320296"></Trial><Drug id="100280">Nifurtimox, Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study for BAY-1251152 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="249187"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A proof-of-concept study to assess safety, tolerability, pharmacokinetics (PK) and antitumor activity of CS-1001 in combination with regorafenib for the potential treatment of multiple cancers including gastric cancer</ProtocolTitle><Sponsor>CStone Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="383949"></Trial><Drug id="103763">CS-1001</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-2328065, Single Dose-Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="328787"></Trial><Drug id="109794">BAY-2328065</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY-85-8050 in Healthy Volunteers and Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59726"></Trial><Drug id="64267">18F-BAY-85-8050</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43433"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?</ProtocolTitle><Sponsor>Bispebjerg Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2520">Insulin resistance</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="105413"></Trial><Drug id="2375">nateglinide</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of SH-T00658ID on Libido</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1276">Female sexual dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="116486"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1750">Primary mediastinal large B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-VERT</ProtocolAcronym><ProtocolTitle>Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Non-valvular Atrial Fibrillation Scheduled for Cardioversion</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90547"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of effect of food, an antacid, and the H2-antagonist ranitidine on the absorption of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6140"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of aspirin on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6132"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of the effects of BAY 59-7939 (rivaroxaban) on thrombin generation, in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6118"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SORAMIC</ProtocolAcronym><ProtocolTitle>Sorafenib and Micro-Therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer</ProtocolTitle><Sponsor>University of Magdeburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88968"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="56">Ischemic heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71984"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FC Patch Low: Metabolism Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58567"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigate Impact of Yasmin Versus Microgynon on Hemostasis Parameters in Healthy Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45042"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2727">Gliosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate versus Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3897">Complicated skin and skin structure infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="174120"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Depocyt With Sorafenib in Neoplastic Meningitis</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1814">Neoplastic meningitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59862"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of BAY-1436032 in IDH1-mutant Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="258833"></Trial><Drug id="101614">BAY-1436032</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FRAIL-AF study</ProtocolAcronym><ProtocolTitle>Anticoagulation in frail elderly patients with atrial fibrillation</ProtocolTitle><Sponsor>Julius Center for Health Sciences and Primary Care, Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="315870"></Trial><Drug id="51255">edoxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Trial of 'Chemo-Switch' Regimen to Treat Advanced Melanoma</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27630"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A feasibility and efficacy study of argimesna in the prevention of hemorragic cystitis in ifosfamide treated patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="403">Cystitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55896"></Trial><Drug id="2566">argimesna</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Autologous and Allogenic Transplantation With Campath-1H for T- Cell Lymphoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54309"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29716"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ODM-201 Versus Androgen Deprivation Therapy in Hormone Naive Prostate Cancer</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="280153"></Trial><Drug id="28453">degarelix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="28453">degarelix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Aflibercept (Eylea) in the Management of Bevacizumab (Avastin) Resistant Diabetic Macular Edema</ProtocolTitle><Sponsor>Hopital Maisonneuve-Rosemont</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274291"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effect of emiglitate and BAY-M-1099 on sucrose metabolism in healthy male subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56910"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rivaroxaban in Bariatric Surgery</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="238">Obesity</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="229033"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability Study in Healthy Subjects Comparing two Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222596"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25522"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Menorrhagia Study in Women With Treatment-resistant Menorrhagia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2051">Menorrhagia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56052"></Trial><Drug id="34739">asoprisnil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine as Second-line Treatment for Malignant Pleural Mesothelioma (MPM)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="704">Pleural disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246511"></Trial><Drug id="6408">vinorelbine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-risk Fever and Neutropenia in Children With Cancer: safety and Efficacy of Oral Antibiotics in an Outpatient Setting</ProtocolTitle><Sponsor>Swiss Pediatric Oncology Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1991">Neutropenia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32141"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GM-CSF as Adjuvant Therapy of Melanoma</ProtocolTitle><Sponsor>Northern California Melanoma Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25932"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-2</ProtocolAcronym><ProtocolTitle>Phase Ib/II Study of Rogaratinib (BAY-1163877) in Combination With Atezolizumab in Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333363"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25611"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56815">vismodegib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="629">Hepatobiliary system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of vardenafil when co-administered with cimetidine or ranitidine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52957"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-73-4506 Probe Substrate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74481"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib Phase I Study in Mainland Chinese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="225318"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="116253"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating and pharmacokinetic (PK) study of vatalanib in patients with liver metastases from colorectal, breast and other solid tumors</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38143"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY-43-9006)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58925"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47096"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="795">Nasopharynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1758">Angioimmunoblastic T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase II Study of Sorafenib Plus bicalutamide Versus Placebo Plus Bicalutamide in Castration-Resistant Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer Patients Who Had Orchiectomy or Are Receiving a LHRH Analog</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="139323"></Trial><Drug id="3311">bicalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intra-patient Dose-Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59427"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or IV Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="39977"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY-43-9006) in Chemonaive Patients With Stage IIIB to IV Non-Small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28384"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase II Study of Sorafenib Plus bicalutamide Versus Placebo Plus Bicalutamide in Castration-Resistant Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer Patients Who Had Orchiectomy or Are Receiving a LHRH Analog</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="139323"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EUCLID</ProtocolAcronym><ProtocolTitle>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99397"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the efficacy and biomarker of sorafenib in advanced-cancer patients</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52922"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY-1000394 Given in a 4-Week on/2-Week Off Schedule in Subjects With Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76429"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55288">trametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Bayer AG, Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="82297"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, open-labelled, single-blind, crossover study of treprostinil in patients with moderate to severe precapillary pulmonary hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6256"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROFESS</ProtocolAcronym><ProtocolTitle>Prevention Regimen For Effectively Avoiding Second Strokes</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8146"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EUCLID</ProtocolAcronym><ProtocolTitle>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="99397"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35206"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARDINAL</ProtocolAcronym><ProtocolTitle>Adalat XL versus Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="20154"></Trial><Drug id="46078">diltiazem hydrocloride (once-daily), Bausch Health/Actavis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="51388">nilotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacodynamic Characterization of Dienogest</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73047"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-NOAC</ProtocolAcronym><ProtocolTitle>X-NOAC Study</ProtocolTitle><Sponsor>Dokkyo Medical University, Imari Arita Kyoritsu Hospital, Kameda Medical Center, Saga University, Tokyo Metropolitan Hiroo Hospital, Yokohama Minami Kyosai Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="221456"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Placebo-Controlled, Randomized, Double-Blind, Multicenter Study to Investigate the Efficacy and Tolerability of BAY-58-2667</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1559">Congestive heart failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5984"></Trial><Drug id="29834">cinaciguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, phase III study to evaluate the safety, efficacy and pharmacokinetics of Nebido in male hypogonadal patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52182"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAESTRAL</ProtocolAcronym><ProtocolTitle>Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1488">Chronic bronchitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13316"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study for Allergy Relief Onset</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="256892"></Trial><Drug id="101632">chlorpheniramine maleate (oral tablet, allergic rhinitis), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetic drug interaction study of talviraline with indinavir and zidovudine</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16972"></Trial><Drug id="5321">indinavir</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY-1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="365058"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, first-in-human, multicenter, randomized, double-blind, placebo-controlled, single-dose escalation, safety, tolerability, pharmacodynamic, pharmacokinetic and immunogenicity study of BAY-86-6150 in patients with hemophilia A or B with or without inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="68055"></Trial><Drug id="52200">BAY-86-6150</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and efficacy of telatinib in combination with bevacizumab in patients with advanced solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="40492"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5124"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An independent, long-term study to evaluate the efficacy of Generx in patients with coronary artery disease</ProtocolTitle><Sponsor>Collateral Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64255"></Trial><Drug id="17801">alferminogene tadenovec</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25586"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX</ProtocolTitle><Sponsor>US Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="227842"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Dacarbazine in Soft Tissue Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44582"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIb to IV Soft Tissue Sarcoma</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="173005"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and efficacy of cerivastatin in treatment of patients with hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55039"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2938">Thymus neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35591"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias</ProtocolTitle><Sponsor>Phramongkutklao College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2643">Autoimmune hemolytic anemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21667"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FRAIL-AF study</ProtocolAcronym><ProtocolTitle>Anticoagulation in frail elderly patients with atrial fibrillation</ProtocolTitle><Sponsor>Julius Center for Health Sciences and Primary Care, Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="315870"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REVERENT</ProtocolAcronym><ProtocolTitle>Reducing Blood Pressure Variability in Essential Hypertension With Ramipril Versus Nifedipine GITS Trial</ProtocolTitle><Sponsor>Istituto Auxologico Italiano</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235002"></Trial><Drug id="4196">ramipril</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter Trial to Compare The Safety And Efficacy of Cipro XR And Cipro in The Treatment of Complicated Urinary Tract Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15249"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DECISION</ProtocolAcronym><ProtocolTitle>Nexavar Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3351">Papillary thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60624"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pivotal Bioequivalence FDC Nifedipine/Candesartan versus Loose Combination of Single Components, Fed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77278"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="67397"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="358374"></Trial><Drug id="105999">BAY-2315497</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-59-7939 in Atrial Fibrillation Once-Daily (OD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60206"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascular calcification, and vascular endothelial dysfunction in patients with atrial fibrillation</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="323638"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54662">ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of oral fludarabine and cyclophosphamide combination therapy in aged patients with B-cell lymphatic leukemia and low grade non Hodgkin lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1729">B-cell acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89882"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, prospective study of comparison of ticagrelor versus thienopyridine loading effect on fractional flow reserve in patients with coronary artery disease</ProtocolTitle><Sponsor>AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, The Medicines Company</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="282951"></Trial><Drug id="19001">prasugrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="62277">emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64877"></Trial><Drug id="4735">valaciclovir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6584"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BrUOG L301 With Non-Small-Cell Lung Cancer and Bone Metastasis</ProtocolTitle><Sponsor>Brown University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215190"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, prospective, randomized, double-blind, comparative, multicenter clinical trial to compare	 safety and efficacy of moxifloxacin compared with piperacillin + tazobactam and amoxicillin + clavulanate for the treatment of complicated intra-abdominal infections</ProtocolTitle><Sponsor>Case Western Reserve University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="68863"></Trial><Drug id="29446">piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-73-4506 Probe Substrate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74481"></Trial><Drug id="8976">rosiglitazone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5715"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Angeliq in Thai Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32398"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74576"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35206"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety and efficacy study of vatalanib and gemcitabine in patients with advanced pancreatic cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38261"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="51388">nilotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GadaCAD 1</ProtocolAcronym><ProtocolTitle>Gadobutrol/Gadavist-Enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="143775"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind study to evaluate the efficacy of methylprednisolone aceponate (0.1%) versus mometasone furoate with respect to atrophogenicity and appearance of telangiectasia, in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50598"></Trial><Drug id="13594">mometasone furoate (nasal), Merck &amp; Co</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55288">trametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Penetration of moxifloxacin (BAY-12-8039) Into the Excretory Pancreatic Secret After Intravenous Application</ProtocolTitle><Sponsor>Albert-Ludwigs-Universitt Freiburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130354"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Staltor tablets, film-coated, 20 mg (EMC SA, Brazil) and Crestor tablets, film-coated, 20 mg ("AstraZeneca UK Limited", UK, produced by AyPiEr Pharmaceuticals Inc., Puerto Rico)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177412"></Trial><Drug id="12420">rosuvastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, active-controlled, parallel-arm study to compare an improvement in diagnostic ability of 0.5 M gadobutrol with 0.5 M gadopentetate dimeglumine by the contrast enhancement effect in patients with CNS disease</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345237"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma</ProtocolTitle><Sponsor>New Mexico Cancer Care Alliance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62695"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study With Sorafenib and Sirolimus</ProtocolTitle><Sponsor>Radboud University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32826"></Trial><Drug id="4200">sirolimus</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Prospective, Multicenter, Double-Blind, Randomized  Trial To Compare The Efficacy And Safey Of Moxifloxacin And Clindamycin In The Treatment Of Odontogenic Abscesses And Inflammatory Infiltrates</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2275">Odontogenic tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75743"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MEMO</ProtocolAcronym><ProtocolTitle>Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-Abdominal Abscesses</ProtocolTitle><Sponsor>Hannover Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="520">Abdominal cavity inflammation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8329"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="199">Leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10782"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2218">Hepatoblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMSAV</ProtocolAcronym><ProtocolTitle>Gadobutrol Enhanced MRA of the Supra-Aortic Vessels</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1615">Carotid stenosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76997"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, non-randomized, single-arm study to evaluate the efficacy of 1.0 M gadobutrol in the diagnosis of patients with unilateral carotid artery stenosis and/or unilateral cerebral infarct by comparing regional cerebral blood to SPECT</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1615">Carotid stenosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345222"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim for HRPC</ProtocolTitle><Sponsor>Veeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32618"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of aspirin on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6132"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Finerenone to Investigate a Pediatric Formulation in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="278261"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, open-label, parallel-group study to evaluate the safety, pharmacokinetics and dialysability of SH-L-562 in patients with renal failure</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2037">Kidney dialysis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342647"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>UNIVERSE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="266753"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2443">Angiosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="172811"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCKET AF</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer HealthCare AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1077">Embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4937"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, prospective study of comparison of ticagrelor versus thienopyridine loading effect on fractional flow reserve in patients with coronary artery disease</ProtocolTitle><Sponsor>AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, The Medicines Company</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="282951"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFIRE</ProtocolAcronym><ProtocolTitle>Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study</ProtocolTitle><Sponsor>Japan Cardiovascular Research Foundation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249714"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ciprofloxacin on Burned Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="52">Skin burns</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36619"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARBON</ProtocolAcronym><ProtocolTitle>Capecitabine oral chemotherapy with radium-223 in breast cancer patients with bone metastasis</ProtocolTitle><Sponsor>Sheffield Teaching Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="253603"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemia</ProtocolTitle><Sponsor>Nakakinen Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="175">Hyperlipidemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="180271"></Trial><Drug id="4155">pravastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="32981">darunavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of BAY-M-1099 and emiglitate on glycemic and hormonal responses in patients with insulin dependent diabetes mellitus (IDDM)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56995"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="62282">trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the safety, efficacy and usefulness of 0.5 M gadobutrol by enhancement effect in patients with diseases of the head and neck, heart, chest, bone/soft tissue or spine</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="769">Head and neck injury</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345240"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib, Letrozole and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I to IV Breast Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="296462"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Granulocyte-Colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59018"></Trial><Drug id="3130">filgrastim</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation of Oral BAY-1161909 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187561"></Trial><Drug id="84711">empesertib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized Study of IVIG versus IVIG With High Dose Methylprednisolone in Childhood ITP</ProtocolTitle><Sponsor>Hospital for Sick Children</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2259">Immune thrombocytopenic purpura</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="171119"></Trial><Drug id="44599">methylprednisolone (Pfizer)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of vardenafil when co-administered with cimetidine or ranitidine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52957"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS II</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 2</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6753"></Trial><Drug id="2752">cetirizine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="194">Sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Phase I, Dose-Escalation Study With BAY-1143572 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154135"></Trial><Drug id="87787">atuveciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HCC</ProtocolAcronym><ProtocolTitle>Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Combined Military Hospital, Pakistan</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46462"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CLEAR-IT 1</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5037"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3460">Metastatic gastrointestinal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89175"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of aspirin on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6132"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I safety, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in subjects with extreme body weight</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6130"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized crossover study to compare directly the steady-state pharmacokinetics and anticoagulant effects of rivaroxaban and apixaban in healthy Caucasian male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="326314"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability of Sorafenib Tablet for Oral Suspension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239386"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study for BAY-1251152 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4299">Salivary gland cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249187"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, open-labelled, single-blind, crossover study of treprostinil in patients with moderate to severe precapillary pulmonary hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6256"></Trial><Drug id="54311">treprostinil (inhaled, sustained-release), United Therapeutics/Aradigm</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>PRE-D</ProtocolAcronym><ProtocolTitle>Effect of dapagliflozin, metformin and physical activity in pre-Diabetes</ProtocolTitle><Sponsor>Steno Diabetes Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254653"></Trial><Drug id="52192">dapagliflozin propanediol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MaxSep</ProtocolAcronym><ProtocolTitle>Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem plus Moxifloxacin) in the Treatment of Severe Sepsis and Septic Shock</ProtocolTitle><Sponsor>Kompetenznetz Sepsis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="816">Septic shock</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11415"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VOYAGER PAD</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1645">Arterial occlusive disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235475"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESPECT</ProtocolAcronym><ProtocolTitle>Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49433"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Ottawa Hospital Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31778"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III clinical trial of IONIS-FXIRx in the treatment of patients with clotting disorders</ProtocolTitle><Sponsor>Ionis Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="75">Blood clotting disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="384560"></Trial><Drug id="65073">IONIS-FXIRx</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>NEST</ProtocolAcronym><ProtocolTitle>Nitrous Oxide for Pain Management During In-office Transcervical Sterilization</ProtocolTitle><Sponsor>University of New Mexico</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="218070"></Trial><Drug id="44362">lorazepam</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicentre, open-label, non-comparative, 20-cycle study of dienogest + estradiol valerate in healthy adult women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65317"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Cycle Control Europe</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62475"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, cross-over study to evaluate the efficacy and tolerability of BAY-M-1099 and BAY-O-1248 in patients with IDDM (insulin dependent diabetes mellitus)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56971"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61458"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of BAY-39-9624 in postmenopausal women, for potential treatment of osteoporosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50339"></Trial><Drug id="32491">BAY-39-9624</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REASON</ProtocolAcronym><ProtocolTitle>Prevention of Sagopilone-Induced Neurotoxicity With Acetyl-L-Carnitine (ALC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="259">Peripheral neuropathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36133"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="181148"></Trial><Drug id="12420">rosuvastatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC</ProtocolTitle><Sponsor>Clinical Research Support Center Kyushu, Kyushu Study Group of Clinical Cancer</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215638"></Trial><Drug id="6104">lansoprazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY-1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="234174"></Trial><Drug id="91354">progesterone (intrauterine system, contraception), Bayer AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1732">Acute promyelocytic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="23624">clofarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-Drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1 and OATP1B3 (Uptake Transporters) Probe Substrate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="252336"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>NEST</ProtocolAcronym><ProtocolTitle>Nitrous Oxide for Pain Management During In-office Transcervical Sterilization</ProtocolTitle><Sponsor>University of New Mexico</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="218070"></Trial><Drug id="45247">hydrocodone bitartrate + paracetamol (oral controlled release, pain), Abbott</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MANTRA Study</ProtocolAcronym><ProtocolTitle>Regorafenib versus placebo as maintenance therapy in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer</ProtocolTitle><Sponsor>Azienda Ospedaliero-Universitaria di Parma</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="257779"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE</ProtocolAcronym><ProtocolTitle>A Randomized, Phase II, Double-Blind Study of Regorafenib or Placebo in Refractory Advanced Esophago-Gastric Cancer (AOGC)</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130456"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind study to evaluate the efficacy of methylprednisolone aceponate (0.1%) versus mometasone furoate with respect to suppression of UVB light-induced erythema, in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50594"></Trial><Drug id="3622">methylprednisolone aceponate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Bordeaux</ProtocolAcronym><ProtocolTitle>To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="244730"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-2</ProtocolAcronym><ProtocolTitle>Phase Ib/II Study of Rogaratinib (BAY-1163877) in Combination With Atezolizumab in Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333363"></Trial><Drug id="72699">atezolizumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A one-year trial to compare the safety of Climara Pro with estradiol alone in post-menopausal women (with intact uteri)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46812"></Trial><Drug id="22274">estradiol + levonorgestrel transdermal combination patch (HRT), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29789"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="795">Nasopharynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="53133">dabrafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARGO</ProtocolAcronym><ProtocolTitle>A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer</ProtocolTitle><Sponsor>NSABP Foundation Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="251813"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, placebo-controlled, double-blind, parallel-group, dose-escalation study to evaluate the tolerability and pharmacokinetics of SH-L-562 in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342490"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="131">Gastrointestinal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hormonal Contraception in Healthy Young Men</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32170"></Trial><Drug id="34820">etonogestrel (implanted) + testosterone undecanoate (depot), Schering/Organon</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>STEP</ProtocolAcronym><ProtocolTitle>Sorafenib Long-Term Extension Program</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45055"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1128">Neuroendocrine tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation</ProtocolTitle><Sponsor>Derm Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62981"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE II</ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Refractory Advanced Gastro-Esophageal Cancer</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="260950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGISTRI</ProtocolAcronym><ProtocolTitle>Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST</ProtocolTitle><Sponsor>Grupo Espanol de Investigacion en Sarcomas</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249376"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RESET for GIST</ProtocolTitle><Sponsor>Japanese National Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="219849"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFLIRAP</ProtocolAcronym><ProtocolTitle>Study, to evaluate the effectiveness of aflibercept in patients with RAP (retinal angiomatous proliferation) lesions</ProtocolTitle><Sponsor>Institut Investigaci Biomdica Bellvitge</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="288">Retinopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="291726"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of BAY-1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="296031"></Trial><Drug id="96958">BAY-1193397</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib for Urothelial Cancer Following Chemotherapy</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="230858"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Determine the Maximum Tolerable Dose of BAY-94-9343 in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81044"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese BAY-88-8223 Monotherapy, Phase II Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="152518"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias</ProtocolTitle><Sponsor>Phramongkutklao College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2259">Immune thrombocytopenic purpura</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21667"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>STARGATE</ProtocolAcronym><ProtocolTitle>Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="69433"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of iv/po Moxifloxacin in Subjects With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21280"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Roniciclib Mass Balance Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224606"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, randomized, double-blind, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist in patients with known or suspected liver lesions and with independent blinded read and assessment of the truth standard</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75861"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, active-controlled, parallel-arm study to compare an improvement in diagnostic ability by the contrast enhancement effect of 0.5 M gadobutrol with 0.5 M gadopentetate dimeglumine in patients with disorders of the liver or pelvis</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345230"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, open-label, dose-escalation, phase I study to evaluate the safety, tolerability, efficacy and pharmacokinetics of sorafenib in combination with dacarbazine in patients with advanced metastatic melanoma or solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52790"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Carboplatin/Paclitaxel in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27986"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Safety, PK and PD of ISIS-416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis</ProtocolTitle><Sponsor>Ionis Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="240736"></Trial><Drug id="65073">IONIS-FXIRx</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="7286">goserelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY-1101042 Tablet Doses in Healthy Male Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="309514"></Trial><Drug id="105761">BAY-1101042</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY-1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="307210"></Trial><Drug id="105761">BAY-1101042</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3542">Hidradenitis suppurativa</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="22544"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35591"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Low-dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-squamous Cell NSCLC</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37834"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect on the early morning and at night home blood pressure of the high-capacity dihydride pyridine-based calcium antagonists in chronic kidney disease patients complicated with diabetes (compared to nifedipine CR and amlodipine)</ProtocolTitle><Sponsor>Saiseikai central Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254463"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>InReTel</ProtocolAcronym><ProtocolTitle>The Influence of Telmisartan on Insulin Resistance and Fatty Liver in Patients Suffer from Hypertension</ProtocolTitle><Sponsor>Klinikum Chemnitz Gmbh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="120057"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, 4-day, randomized, double-blind, placebo-controlled study to evaluate the effect of ramatroban on the bronchoconstriction caused by exercise or PGD2 inhalation in patients with mild asthma</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29563"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, placebo-controlled study to evaluate the efficacy of three doses of ramatroban in atopic asthmatics</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29560"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, 6-week, open-label study to evaluate the efficacy of bromerguride in schizophrenic patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="299">Schizophrenia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="55729"></Trial><Drug id="2686">bromerguride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS II</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 2</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6753"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CRC005</ProtocolAcronym><ProtocolTitle>Study of Subcutaneous Campath-1H in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) and Residual Disease After Chemotherapy</ProtocolTitle><Sponsor>Chronic Lymphocytic Leukemia Research Consortium</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="37713"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multinational, Double-Blind, Randomized, Phase IIb, Cooperative-Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Fondazione Michelangelo</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246017"></Trial><Drug id="2784">letrozole</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I pharmacokinetic and pharmacodynamic study of oral cicaprost in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56015"></Trial><Drug id="2813">cicaprost</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study of the safety and pharmacokinetics of vatalanib and 5-FU/leucovorin/irinotecan (IFL) in patients with treatment-naive metastatic colorectal cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38139"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NEXIRI</ProtocolAcronym><ProtocolTitle>Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation</ProtocolTitle><Sponsor>Institut Regional Du Cancer De Montpellier</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60844"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="344881"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of BAY-86-5300 With a Flexible Extended Regimen for Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="144835"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, placebo-controlled study to evaluate the safety and efficacy of Yasmin in treating premenstrual dysphoric disorder (PMDD) in women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="480">Premenstrual syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46800"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="146650"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, placebo-controlled, double-blind, randomized study to evaluate the safety and efficacy of emiglitate in patients with non-insulin dependent diabetes mellitus (NIDDM) being treated with sulfonylureas</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56999"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1107">Allergic rhinitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="330348"></Trial><Drug id="3159">fluticasone propionate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BAGPAC</ProtocolAcronym><ProtocolTitle>Combination With Gemcitabine in Advanced Pancreatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72717"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>KinSEP</ProtocolAcronym><ProtocolTitle>Rehabilitation Study in MS Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="180218"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>NEST</ProtocolAcronym><ProtocolTitle>Nitrous Oxide for Pain Management During In-office Transcervical Sterilization</ProtocolTitle><Sponsor>University of New Mexico</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="218070"></Trial><Drug id="3422">ketorolac</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONFIRM-2</ProtocolAcronym><ProtocolTitle>Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Novartis AG, Queen Mary Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="37552"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Oral BAY-1217389 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222465"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, controlled, cross-over trial of metabolic effects of acarbose or repaglinide when added to a double oral antidiabetic treatment with sulphonylureas and metformin in type 2 diabetic patients</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63005"></Trial><Drug id="4212">repaglinide</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2727">Gliosarcoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246805"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIZZ</ProtocolAcronym><ProtocolTitle>A Phase II Study of Fractionated 90Y-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma</ProtocolTitle><Sponsor>Christie Hospital NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83327"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, placebo-controlled, crossover trial to evaluate the effects of BAY-X-7195 on leukotriene D4-induced bronchoconstriction in normal volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="30871"></Trial><Drug id="5541">BAY-X-7195</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, placebo-controlled study to evaluate the pharmacokinetics, safety and tolerability of BAY-X-7195 in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="30837"></Trial><Drug id="5541">BAY-X-7195</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MARCH</ProtocolAcronym><ProtocolTitle>A Post-market, Open-label, Randomized, Parallel, Controlled Trial To Evaluate Mechanism of Glucobay in Chinese, Newly diagnosed, Type 2 Diabetic Patients</ProtocolTitle><Sponsor>China-Japan Friendship Hospital, Chinese Diabetes Society</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="97563"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, controlled, cross-over trial of metabolic effects of acarbose or repaglinide when added to a double oral antidiabetic treatment with sulphonylureas and metformin in type 2 diabetic patients</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63005"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GREAN</ProtocolAcronym><ProtocolTitle>Glucose Reduction by Early Acarbose Treatment in Basal Insulin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60087"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on the Mechanism of Glucobay in Chinese Newly diagnosed Type 2 Diabetic Patient</ProtocolTitle><Sponsor>China-Japan Union Hospital of Jilin University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="141006"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MARCH</ProtocolAcronym><ProtocolTitle>A Post-market, Open-label, Randomized, Parallel, Controlled Trial To Evaluate Mechanism of Glucobay in Chinese, Newly diagnosed, Type 2 Diabetic Patients</ProtocolTitle><Sponsor>China-Japan Friendship Hospital, Chinese Diabetes Society</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="97563"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A post-marketing, case-control study to assess the effect of acarbose on incretins (GLP-1 and GIP) secretion pattern in newly diagnosed type 2 diabetes mellitus (T2DM)</ProtocolTitle><Sponsor>Bayer AG, Guangdong Provincial People's Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="97447"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exercise and Acarbose in Type 2 Diabetes</ProtocolTitle><Sponsor>Karolinska Institutet</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72469"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44334"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="29597"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Fludarabine, Cytoxan and FCCAM (Alemtuzumab) in Untreated B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47855"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43543"></Trial><Drug id="6306">aldesleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARDINAL</ProtocolAcronym><ProtocolTitle>Adalat XL versus Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="20154"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Ospedale Civico, Lugano</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="93703"></Trial><Drug id="6692">natalizumab</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the efficacy of bendamustine in combination with rituximab in patients with relapsed indolent and mantle-cell non-Hodgkins lymphoma</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49535"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186877"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43497"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, multicenter, extension study to evaluate the safety and efficacy of sargramostim in patients who had participated in previous trials of Leukine for the treatment of Crohns disease</ProtocolTitle><Sponsor>Berlex Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="84">Crohns disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="50790"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="186877"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="7310">ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE 2</ProtocolAcronym><ProtocolTitle>Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY-85-3934</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="165213"></Trial><Drug id="7413">darbepoetin alfa</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REMETY</ProtocolAcronym><ProtocolTitle>Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="315441"></Trial><Drug id="7810">trifluridine + tipiracil hydrochloride (oral), Taiho</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Crossover Study To Evaluate Nasal Symptoms Induced by Platelet Activating Factor, after Nasal Challenge in Both Healthy and Allergic Rhinitis Subjects Pretreated with Rupatadine, Levocetirizine or Placebo</ProtocolTitle><Sponsor>Bayer AG, Chiesi Farmaceutici SpA, GlaxoSmithKline plc, Grupo Uriach, Johnson &amp; Johnson, Laboratorios Dr Esteve SA, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="172862"></Trial><Drug id="8228">rupatadine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BEYOND</ProtocolAcronym><ProtocolTitle>Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="78962"></Trial><Drug id="8710">glatiramer acetate</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONFIRMED</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, cross-over design study to compare the efficacy and safety of vardenafil to that of sildenafil when used on demand in a population of men with erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54419"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea: a Pilot Study</ProtocolTitle><Sponsor>Derm Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="191544"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Drug-Drug Interaction Study of 1250 mg Vatalanib Administered Under Fasting and Fed Conditions With a Proton-Pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="37559"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II trial of vatalanib in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38018"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open Study of BAY-77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84312"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GREAN</ProtocolAcronym><ProtocolTitle>Glucose Reduction by Early Acarbose Treatment in Basal Insulin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60087"></Trial><Drug id="10252">insulin glargine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ezetimibe and omega-3-acid ethyl esters study</ProtocolTitle><Sponsor>Kurume University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="281454"></Trial><Drug id="11367">ezetimibe</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="35202"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety, efficacy, and pharmacodynamic properties of SH-U-555-A for magnetic resonance (MR) imaging of the liver in patients with hepatic lesions</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="18451"></Trial><Drug id="11665">ferucarbotran (small superparamagnetic), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the tolerability and efficacy of resovist for imaging hepatic tumors in patients with no more than five known focal solid liver lesions</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="18445"></Trial><Drug id="11665">ferucarbotran (small superparamagnetic), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Gadobutrol 1.0 M (Gadavist) in Patients for Central Nervous System (CNS) Imaging</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="109914"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the quality of contrast-enhanced segments and confidence in diagnosis in MRA studies using SH-L-562 of body and peripheral arteries in patients with suspected or known arterial vascular disease</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="343147"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="28057"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="25522"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II of Oxaliplatin, Capecitabine and Sorafenib for Advanced Pancreatic and Biliary Carcinoma</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47141"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III multicenter, single-blind, randomized, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist (single iv injection) in patients with known or suspected renal lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75857"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MALT</ProtocolAcronym><ProtocolTitle>A multi-center, randomized, double-blinded, placebo-controlled, safety and efficacy study of metrifonate in patients with mild-to-moderate Alzheimer's disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8443"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>The Metrifonate Study Group.</ProtocolAcronym><ProtocolTitle>A double-blinded, randomized, placebo-controlled, parallel-group, safety and tolerability study of metrifonate in patients with probable mild-to-moderate Alzheimer's disease</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8296"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, multicenter, 26-week, double-blind, parallel-group, safety and efficacy study of metrifonate, in patients with probable Alzheimer's disease of mild-to-moderate severity</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8288"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 2 dosage regimens of qd metrifonate, in patients with probable Alzheimer's disease (AD)</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8221"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="120">Escherichia coli infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="145">Haemophilus influenzae infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="10685"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RELIEF</ProtocolAcronym><ProtocolTitle>Comparison of Sequential iv/po Moxifloxacin With iv Piperacillin/Tazobactam Followed by po Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="485">Bacterial skin infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10316"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1075">Haemophilus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1410">Clostridiaceae infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, double-blind, multicenter study to evaluate the safety and efficacy of moxifloxacin when compared with cefuroxime axetil in the treatment of acute sinusitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2999">Acute sinusitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="30288"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3082">Abdominal abscess</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Patients With Advanced Neuroendocrine Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1128">Neuroendocrine tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58975"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="96066"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="91099"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>HR-QoL and Sexuality in Mirena Inserted Contraception Users</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32201"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47575"></Trial><Drug id="15541">ixabepilone</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Leopold I</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human Factor VIII for Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62562"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 10-week, open-label, multicenter, phase III study to evaluate the safety and efficacy of Levitra in the treatment of men of diverse ethnic origin with erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54258"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A placebo-controlled, single-dose, multicenter, phase III study to evaluate the safety and efficacy of vardenafil in the treatment of ercetile dysfunction in men with stable ischemic coronary artery disease (CAD) who were not currently on nitrate medication</ProtocolTitle><Sponsor>Bayer Corp, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53940"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of vardenafil in men who had experienced erectile dysfunction (ED) for more than 6 months</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52787"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, placebo-controlled, phase II trial to evalaute the safety and efficacy of  vardenafil in men with mild to severe erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52772"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REALISE</ProtocolAcronym><ProtocolTitle>Levitra - Real Life Safety and Efficacy of Levitra</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31238"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31237"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the efficacy of entinostat in melanoma patients</ProtocolTitle><Sponsor>Mitsui Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="36731"></Trial><Drug id="24087">entinostat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="25483"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of ZK-219477 in Patients With Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="25305"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RELIEF</ProtocolAcronym><ProtocolTitle>Comparison of Sequential iv/po Moxifloxacin With iv Piperacillin/Tazobactam Followed by po Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="790">Diabetic foot ulcer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10316"></Trial><Drug id="29446">piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib/Cetuximab in Head and Neck Cancer</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="39672"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="51091"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Vorinostat in Poor-Risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="50753"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="206309"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacodynamic study to evaluate the efficacy of sorafenib in patients with renal cell carcinoma (RCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52522"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SORAMIC</ProtocolAcronym><ProtocolTitle>Sorafenib and Micro-Therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer</ProtocolTitle><Sponsor>University of Magdeburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88968"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma</ProtocolTitle><Sponsor>New Mexico Cancer Care Alliance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62695"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SEARCH</ProtocolAcronym><ProtocolTitle>Nexavar-Tarceva Combination Therapy for First-Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="55235"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer</ProtocolTitle><Sponsor>Beth Israel Deaconess Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="39373"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Phase Ib, Dose Escalation Study Of  OMP-54F28 In Combination With Sorafenib  In Patients With First-Line Locally Advanced or Metastatic Hepatocellular cancer</ProtocolTitle><Sponsor>Bayer AG, OncoMed Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="174083"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Refametinib in Combination With Sorafenib in Patients With RAS Mut Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="160758"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II study of sorafenib with TS-1 for advanced hepatocellular carcinoma</ProtocolTitle><Sponsor>Bayer AG, Chiba University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="118704"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas</ProtocolTitle><Sponsor>New York University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2453">Astrocytoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="76662"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="35683"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3769">Anaplastic thyroid cancer</Indication><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Trial id="182002"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to assess the safety, efficacy, pharmacokinetics and immunological parameters of sorafenib in combination with interferon alfa-2a in Japanese patients with unresectable or metastatic renal cell carcinoma (RCC)</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88509"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dosing and Effectiveness Study of Sorafenib and RAD-001 in the Treatment of Patients With Advanced Kidney Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43636"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 Phase II Study for Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28456"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Dose-Escalation in Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28451"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="225976"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="485">Bacterial skin infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="158534"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="106382"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAGELLAN</ProtocolAcronym><ProtocolTitle>Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6337"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of effect of food, an antacid, and the H2-antagonist ranitidine on the absorption of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6140"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONKO-011</ProtocolAcronym><ProtocolTitle>Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="243750"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN-DVT</ProtocolAcronym><ProtocolTitle>Oral Direct Factor-Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism: Einstein-DVT Evaluation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="7140"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein-PE</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6231"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-59-7939 in Atrial Fibrillation Once-Daily (OD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60206"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study</ProtocolTitle><Sponsor>Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="135932"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HoT-PE</ProtocolAcronym><ProtocolTitle>Home Treatment of Patients with Low-Risk Pulmonary Embolism with Rivaroxaban</ProtocolTitle><Sponsor>Mainz University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246874"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and 5-azacitidine in Acute Leukemia + Myelodysplastic Syndrome</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72898"></Trial><Drug id="37370">azacitidine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib/II Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="245978"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY-88-8223 in Japanese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86065"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65750"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NiraRad</ProtocolAcronym><ProtocolTitle>Phase Ib Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="290785"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REASURE</ProtocolAcronym><ProtocolTitle>Radium-223: evaluation of activity and surrogate response</ProtocolTitle><Sponsor>Cancer Research UK, The Royal Marsden NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239246"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BrUOG L301 With Non-Small-Cell Lung Cancer and Bone Metastasis</ProtocolTitle><Sponsor>Brown University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="215190"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="212684"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PEACE III</ProtocolAcronym><ProtocolTitle>Phase III Radium 223 mCRPC</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210276"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Castrate Resistant Prostate Cancer Bone Metastasis</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186423"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY88-8223, Dose Finding Study in Pts With HRPC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40322"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Does Response Study in HRPC Patients</ProtocolTitle><Sponsor>Algeta ASA, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33388"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222237"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Castrate Resistant Prostate Cancer Bone Metastasis</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186423"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="116253"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety and pharmacokinetics study of iv solulin in healthy volunteers</ProtocolTitle><Sponsor>PAION AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="7145"></Trial><Drug id="40733">solulin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An investigator-led, randomized, controlled, clinical trial comparing iopamidol 250 to ioversol 320 in patients with hepatic disease</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG, Bracco SpA, Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Trial id="248577"></Trial><Drug id="44295">iopamidol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 24-week study to compare the safety and efficacy of cerivastatin with lovastatin in treatment of patients with primary hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="W">Withdrawn</HighestDevStatusForInd><Trial id="55064"></Trial><Drug id="44300">lovastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, single-blind, comparative, parallel-group study to determine the safety and efficacy of moxifloxacin based triple therapy as an alternative second-line therapy in patients suffering from non-ulcer dyspepsia and in whom the initial standard PPI triple therapy had failed to eradicate H pylori infection</ProtocolTitle><Sponsor>AstraZeneca plc, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="149">Helicobacter pylori infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62892"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84431"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib study to evaluate the safety and efficacy of telatinib administered in combination with docetaxel in patients with solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="40495"></Trial><Drug id="45497">telatinib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ovulation inhibition of two four-phasic oral contraceptive regimens</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38182"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of a Four-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2051">Menorrhagia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="89117"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Aprotinin US Special Access Protocol</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="20604"></Trial><Drug id="46885">aprotinin, Bayer</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, controlled, cross-over trial of metabolic effects of acarbose or repaglinide when added to a double oral antidiabetic treatment with sulphonylureas and metformin in type 2 diabetic patients</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63005"></Trial><Drug id="46890">glibenclamide</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalation, phase I/II study to evaluate the safety and efficacy of bendamustine in refractory or relapsed chronic lymphocytic leukemia (CLL) patients</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49489"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study comparing protection from bleeding in BAY-79-4980 and BAY-14-2222</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="41428"></Trial><Drug id="51391">recombinant Factor VIII (PEGylated liposomal), Bayer/Zilip</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD; GOLD II to III)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="64396"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="63507"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CLARITY Version 1.0</ProtocolAcronym><ProtocolTitle>Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy</ProtocolTitle><Sponsor>Moorfields Eye Hospital, Moorfields Eye Hospital Nhs Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="576">Diabetic retinopathy</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="203743"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Modified treat and extend regimen of aflibercept to branch retinal vein occlusion with cystoid macular edema</ProtocolTitle><Sponsor>Aoki Eye Clinic, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Jichi Medical University Hospital, Okubo Eye Clinic, Saito Eye Clinic, Takahashi Eye Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="277534"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CENTERA</ProtocolAcronym><ProtocolTitle>Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="263357"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of an anti-VEGF drug on proliferative diabetic retinopathy</ProtocolTitle><Sponsor>Tokyo Women's Medical College</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2657">Proliferative diabetic retinopathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="300404"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of an anti-VEGF drug on proliferative diabetic retinopathy</ProtocolTitle><Sponsor>Tokyo Women's Medical College</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="300404"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIBRANT</ProtocolAcronym><ProtocolTitle>Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI, EYLEA, BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84452"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ONYX</ProtocolAcronym><ProtocolTitle>Anti-angiopoeitin 2 Plus Anti-Vascular Endothelial Growth Factor as a Therapy for Neovascular Age Related Macular Degeneration: Evaluation of a Fixed Combination Intravitreal Injection</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="256118"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Efficacy of Aflibercept in Neovascular Age-Related Macular Degeneration (wAMD) With Non-Responder of Ranibizumab</ProtocolTitle><Sponsor>Nagoya City University Graduate School of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="137924"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODENZA</ProtocolAcronym><ProtocolTitle>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</ProtocolTitle><Sponsor>Cancer Campus, Grand Paris, Institut Gustave Roussy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="316586"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="88">Cystic fibrosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="478">Raynauds disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RISE-SSc</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1105">Scleroderma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="215200"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Multiple-Doses of BAY-63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="17236"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="214566"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, non-randomized, single-agent clinical trial to evaluate the safety, tolerability, antitumor activity and pharmacokinetic profile of BAY-73-4506 for the treatment of patients with non-small-cell lung cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="67675"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="214566"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMA</ProtocolAcronym><ProtocolTitle>Regorafenib in Relapsed Glioblastoma</ProtocolTitle><Sponsor>Istituto Oncologico Veneto Irccs</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="274491"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONCUR</ProtocolAcronym><ProtocolTitle>Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86832"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY-73-4506 in Combination With mFOLFOX6 or FOLFIRI</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58597"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REMETY</ProtocolAcronym><ProtocolTitle>Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="315441"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy</ProtocolTitle><Sponsor>Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="240453"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SMART</ProtocolAcronym><ProtocolTitle>A Phase IV Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="215486"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PREVIUM</ProtocolAcronym><ProtocolTitle>Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab</ProtocolTitle><Sponsor>Grupo de Tratamiento de los Tumores Digestivos</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="199975"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="165927"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COAST</ProtocolAcronym><ProtocolTitle>Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-Blind, Placebo-Controlled, Phase III Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="154339"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer</ProtocolTitle><Sponsor>University of California</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="329900"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="357065"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BASIL</ProtocolAcronym><ProtocolTitle>Assessing BAY-869766 Plus Sorafenib for the Treatment of Liver Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="70433"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BATTLE-2</ProtocolAcronym><ProtocolTitle>A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="72613"></Trial><Drug id="60210">MK-2206</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NiraRad</ProtocolAcronym><ProtocolTitle>Phase Ib Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="290785"></Trial><Drug id="61287">niraparib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="230538"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-2</ProtocolAcronym><ProtocolTitle>Phase III Copanlisib in Rituximab-refractory iNHL</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222628"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-2</ProtocolAcronym><ProtocolTitle>Phase III Copanlisib in Rituximab-refractory iNHL</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="222628"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI-3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="81893"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59836"></Trial><Drug id="64238">estradiol valerate + dienogest + levomefolic acid (contraception), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROTECT KIDS</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-94-9027 in Previously Treated Male Children With Hemophilia A</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="105926"></Trial><Drug id="65438">damoctocog alfa pegol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-man Dose-escalation Study of BAY-2010112 in Patients With Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="97491"></Trial><Drug id="68967">pasotuxizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE 2</ProtocolAcronym><ProtocolTitle>Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY-85-3934</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="165213"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="280698"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY-1002670</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="117154"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARASENS</ProtocolAcronym><ProtocolTitle>ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="263277"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>ARIADME</ProtocolAcronym><ProtocolTitle>Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects</ProtocolTitle><Sponsor>Orion Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="227379"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="170154"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="233483"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>VERNE</ProtocolAcronym><ProtocolTitle>Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81719"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VICTORIA</ProtocolAcronym><ProtocolTitle>A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF)</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="268385"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SOCRATES-REDUCED</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety, and Efficacy Study of Four Dose Regimens of BAY-1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="156010"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VISOR</ProtocolAcronym><ProtocolTitle>Vericiguat Drug-drug Interaction Study With Isosorbide Mononitrate in Stable Coronary Artery Disease Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="309646"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, randomized, open-label study to evaluate the safety and efficacy of levonorgesterol for the prevention of pregnancy in women</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="104380"></Trial><Drug id="82773">levonorgesterol (3-year intrauterine contraceptive system), Bayer Healthcare</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1128">Neuroendocrine tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY-1905254</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="353074"></Trial><Drug id="86786">BAY-1905254</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-2</ProtocolAcronym><ProtocolTitle>Phase Ib/II Study of Rogaratinib (BAY-1163877) in Combination With Atezolizumab in Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="333363"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-Vaginal Ring</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="240273"></Trial><Drug id="90559">anastrozole + levonorgestrel (intravaginal ring, endometriosis), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RUBY</ProtocolAcronym><ProtocolTitle>Anti-vascular Endothelial Growth Factor Plus Anti-angiopoietin 2 in Fixed Combination Therapy: Evaluation for the Treatment of Diabetic Macular Edema</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="256056"></Trial><Drug id="93467">nesvacumab + aflibercept (AMD, DME), Regeneron/ Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1213790 Pharmacokinetic Study</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="382040"></Trial><Drug id="94069">BAY-1213790</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY-1093884 in Patients With Severe Hemophilia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="334550"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of BAY-1436032 in IDH1-mutant Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="258833"></Trial><Drug id="101614">BAY-1436032</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate BAY-1817080 for the treatment of persistent chronic cough</ProtocolTitle><Sponsor>Evotec SE</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="82">Cough</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="372132"></Trial><Drug id="102704">BAY-1817080</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Doses Of BAY-1902607 In Healthy Males And Proof Of Concept In Chronic Cough Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="82">Cough</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="340496"></Trial><Drug id="106990">BAY-1902607</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Investigate BAY-2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="326222"></Trial><Drug id="109257">BAY-2402234</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-OD-HIP</ProtocolAcronym><ProtocolTitle>Phase II study of once-daily rivaroxaban (BAY-59-7939), for thromboprophylaxis after total hip replacement</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6144"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence of Single-Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="240641"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-PLORER</ProtocolAcronym><ProtocolTitle>Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81253"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I safety, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in subjects with extreme body weight</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6130"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I multiple-dose, safety, pharmacokinetic and pharmacodynamic study of BAY-59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6126"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRACK</ProtocolAcronym><ProtocolTitle>Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease</ProtocolTitle><Sponsor>George Institute, Australia</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="383053"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290198"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Placebo-Controlled, Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="432">Dyspepsia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="152434"></Trial><Drug id="13016">famotidine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A two part, phase II, safety, tolerability and pharmacokinetic study of BAY-63-2521 in patients with pulmonary artery hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2466">Interstitial lung disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5157"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of SH-T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH-D01155E) on Hemostatic Parameters</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72749"></Trial><Drug id="12170">levonorgestrel + ethinylestradiol, Schering AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="148727"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC</ProtocolTitle><Sponsor>Clinical Research Support Center Kyushu, Kyushu Study Group of Clinical Cancer</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="829">Fatigue</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215638"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="87879"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, multicenter, dose-escalating study to evaluate the pharmacokinetics, safety and efficacy of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic melanoma</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53035"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of sorafenib in combination with carboplatin and paclitaxel in patients with melanoma</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52773"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-73-4506 Probe Substrate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74481"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A proof-of-concept study to assess safety, tolerability, pharmacokinetics (PK) and antitumor activity of CS-1001 in combination with regorafenib for the potential treatment of multiple cancers including gastric cancer</ProtocolTitle><Sponsor>CStone Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="383949"></Trial><Drug id="103763">CS-1001</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>RISE-IIP</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="708">Pulmonary fibrosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187482"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer</ProtocolTitle><Sponsor>The University Health Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31409"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Estradiol + Drospirenone Versus Estradiol + MPA on Endothelial Function</ProtocolTitle><Sponsor>Brigham &amp; Women's Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="67739"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD 1</ProtocolAcronym><ProtocolTitle>Rivaroxban (10 mg) Given Once-Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin</ProtocolTitle><Sponsor>Bayer Australia Ltd, Bayer HealthCare AG, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6173"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="307713"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of Regorafenib (BAY-73-4506) in Cancer Subjects With Severe Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130631"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study of BAY-1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222235"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASCEND</ProtocolAcronym><ProtocolTitle>A Study of Cardiovascular Events in Diabetes</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187516"></Trial><Drug id="9544">doconexent ethyl ester + icosapent ethyl ester</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2193">Anal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="623">Head and neck tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib, multi-center, open-label, randomized study to evaluate the effect of Angeliq and Activelle on hemostasis in healthy postmenopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78382"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222237"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Determine the Maximum Tolerable Dose of BAY-94-9343 in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81044"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion</ProtocolTitle><Sponsor>Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="304367"></Trial><Drug id="101262">LOXO-195</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="229314"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Aromatase Inhibitors (Anastrozole) Associated with Levonorgestrel-releasing Intrauterine Device (Lng-ius) in the Treatment of Endometriosis Moderate/Severe</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130347"></Trial><Drug id="3321">anastrozole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BATTLE-2</ProtocolAcronym><ProtocolTitle>A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72613"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 in Previously Untreated Patients With Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47939"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Prospective, Multicenter, Double-Blind, Randomized  Trial To Compare The Efficacy And Safey Of Moxifloxacin And Clindamycin In The Treatment Of Odontogenic Abscesses And Inflammatory Infiltrates</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2275">Odontogenic tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75743"></Trial><Drug id="44370">clindamycin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter Trial to Compare The Safety And Efficacy of Cipro XR And Cipro in The Treatment of Complicated Urinary Tract Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15249"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY-1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="365058"></Trial><Drug id="106990">BAY-1902607</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGO-SARC</ProtocolAcronym><ProtocolTitle>Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma</ProtocolTitle><Sponsor>Centre Oscar Lambret</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2447">Liposarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="146211"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1000394 for MCL-1, MYC and CCNE1-Amplified Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="251115"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese BAY-1000394 Monotherapy, Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="170130"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="51388">nilotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AIR  II</ProtocolAcronym><ProtocolTitle>Aerosolized randomized iloprost study, long-term safety, tolerability, and clinical effects of iloprost inhalation in patients with primary or secondary pulmonary hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6178"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRAIN-AF</ProtocolAcronym><ProtocolTitle>Blinded, Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF</ProtocolTitle><Sponsor>Montreal Heart Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="353">Cognitive disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224270"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Erlangen Perfusion Stroke</ProtocolAcronym><ProtocolTitle>Comparison of two Gadolinium containing MR contrast media in patients with symptoms of cerebrovascular disease</ProtocolTitle><Sponsor>University of Erlangen-Nurnberg Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="64">Cerebrovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="140582"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Copanlisib on Metformin PK and PD</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="351877"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="63597"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320618"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3467">Metastatic renal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARASENS</ProtocolAcronym><ProtocolTitle>ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263277"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF Japan</ProtocolAcronym><ProtocolTitle>Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="157446"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PULSE</ProtocolAcronym><ProtocolTitle>Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis</ProtocolTitle><Sponsor>Bayer AG, Bayer plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1488">Chronic bronchitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13572"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of The Effects of Testosterone in Frail Elderly Men</ProtocolTitle><Sponsor>Central Manchester Healthcare NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2639">Testosterone deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54907"></Trial><Drug id="17837">testosterone gel, Solvay/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-Man, Dose-Escalation Study of BAY-1179470 in Patients With Advanced, Refractory Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="141560"></Trial><Drug id="85887">BAY-1179470</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naive Patients With Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46031"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY-1817080</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="264484"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-blind, Randomized, Multicenter Comparison Of Efficacy, Cycle Control, And Tolerability Of A 23-day Versus A 21-day Low-dose Oral Contraceptive Regimen Containing 20 Microg Ethinyl Estradiol And 75 Microg Gestodene</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="110423"></Trial><Drug id="47516">gestodene + estrogen (oral), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY59-7939 Japanese in Atrial Fibrillation (Second)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60207"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study on Anticoagulant Therapy in Catheter Ablation for Atrial Fibrillation - Rivaroxaban versus Warfarin : A Comparative Study</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="183113"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IRIVASC</ProtocolAcronym><ProtocolTitle>Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="174098"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HOVON 74 ALL</ProtocolAcronym><ProtocolTitle>Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse: A randomized, phase II study</ProtocolTitle><Sponsor>Stichting Hemato-Oncologie voor Volwassenen Nederland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="120280"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Drug-Drug Interaction Study of 1250 mg Vatalanib Administered Under Fasting and Fed Conditions With a Proton-Pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37559"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, multicenter, placebo-controlled, double-blind, parallel-group study to compare the safety and efficacy of three different dosing regimens of cerivastatin in treatment of patients with hypercholesterolemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55054"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multi-center, randomized, double-blind, group-comparison study to evaluate the efficacy and safety of cerivastatin in patients with hypercholesterolemia in Japan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55042"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II, GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35413"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2938">Thymus neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, prospective, randomized, double-blind, safety and efficacy study of moxifloxacin, compared to azithromycin in treating adult patients with acute bacterial exacerbations of chronic bronchitis (ABECB)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1488">Chronic bronchitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50271"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-escalation Trial of BAY-1187982 in Subjects with Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223770"></Trial><Drug id="90875">BAY-1187982</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EXPRESS</ProtocolAcronym><ProtocolTitle>A Phase IV Study of Cipro XR in Uncomplicated UTI</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11158"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Phase I, Dose-Escalation Study With BAY-1143572 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154135"></Trial><Drug id="87787">atuveciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PARICCA</ProtocolAcronym><ProtocolTitle>Phase II Study of Perindopril and Regorafenib in mCRC</ProtocolTitle><Sponsor>BC Cancer Agency</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="250589"></Trial><Drug id="17745">perindopril</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 21-day Irritancy Test of Azelaic Acid Pre-foam Formulation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="80571"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, pilot study to evaluate the safety and efficacy of bendamustine as salvage treatment in patients with advanced breast cancer</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49478"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, single-arm study to evaluate the efficacy of 1.0 M gadobutrol in the diagnosis of patients with evidence of suspected focal liver lesion, patients with COPD or patients with disease of the thoracic aorta</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="202">Liver tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345215"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm study to evaluate the efficacy of gadobutrol in the treatment of hospitalized patients with tumor in the liver, pelvis, or bone and soft tissue</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="202">Liver tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343144"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective study of rivaroxaban in the prevention of PICC related thrombosis in cancer patients</ProtocolTitle><Sponsor>Sun Yat-Sen University, Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="295134"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="3364">peginterferon alfa-2b</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRAIN-AF</ProtocolAcronym><ProtocolTitle>Blinded, Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF</ProtocolTitle><Sponsor>Montreal Heart Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224270"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="62282">trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>JACRE-WEx</ProtocolAcronym><ProtocolTitle>Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry  - Warfarin cohort Extension</ProtocolTitle><Sponsor>Reimeikyou</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="341596"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Research for the Adheerence and QOL for Oral Anti-coagulants(OAC) in Patients With Atrial Fibrillation</ProtocolTitle><Sponsor>KKR Takamatsu Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="168764"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effect of emiglitate and BAY-M-1099 on sucrose metabolism in healthy male subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56910"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84366"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastasis (BCBM)</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="97850"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47142"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>University of Colorado at Denver and Health Sciences Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46036"></Trial><Drug id="17625">vorinostat (oral), Merck &amp; Co</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="20573"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of vasomotor symptoms in Korean post-menopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="20516"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343780"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RE-ARRANGE</ProtocolAcronym><ProtocolTitle>Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC</ProtocolTitle><Sponsor>Grupo de Tratamiento de los Tumores Digestivos</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265924"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers</ProtocolTitle><Sponsor>Sir Mortimer B Davis Jewish General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="155611"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGARD</ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="131104"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONKO-006</ProtocolAcronym><ProtocolTitle>Additive Therapy In R1-Resected Pancreatic Cancer With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo Over 12 Months - A Double-blind, Placebo-Controlled, Phase IIb Trial</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132452"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ultravist: Safety and Efficacy in Computed Tomography of Head and Body</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1005">Unidentified indication</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45044"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="793">Mouth tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="7286">goserelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability and Food Effect Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83142"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NOVEL</ProtocolAcronym><ProtocolTitle>Nifedipine On Coronary Vascular Function After Drug Eluting Stent Implantation</ProtocolTitle><Sponsor>Tohoku University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210503"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="999">Renal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28318"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II of Oxaliplatin, Capecitabine and Sorafenib for Advanced Pancreatic and Biliary Carcinoma</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47141"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III multicenter, single-blind, randomized, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist (single iv injection) in patients with known or suspected renal lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75857"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacokinetics study of tanomastat in combination with paclitaxel and carboplatin, a potential treatment for cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51036"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of Sorafenib and Eribulin in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="86865"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BAGPAC</ProtocolAcronym><ProtocolTitle>Combination With Gemcitabine in Advanced Pancreatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="72717"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY-43-9006) in Chemonaive Patients With Stage IIIB to IV Non-Small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28384"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56815">vismodegib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of effect of food, an antacid, and the H2-antagonist ranitidine on the absorption of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6140"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, randomized, two-period crossover study to assess the safety, tolerability and pharmacokinetics of 17beta-estradiol and to determine the daily delivery rate of 17beta-estradiol from an ultra low dose 17beta-estradiol transdermal system SHP-00577E (3.25 cm2) versus the reference Climara (SHP-00577D) (6.5 cm2) transdermal system in the post-menopausal female subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88823"></Trial><Drug id="12356">estradiol (transdermal, menopausal symptoms), Theramex</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Corp, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="234876"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-TRA</ProtocolAcronym><ProtocolTitle>Exploring the Efficacy of Once-daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Non-valvular Atrial Fibrillation or Atrial Flutter</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124203"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47575"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor Plus Breast Cancer</ProtocolTitle><Sponsor>Rutgers University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46977"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fractionated Docetaxel and Radium-223 in Metastatic Castration-Resistant Prostate Cancer</ProtocolTitle><Sponsor>Tufts Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="359444"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARASENS</ProtocolAcronym><ProtocolTitle>ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263277"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>High-Dose BAY-A1040 CR: A Long-Term Extension Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77456"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DISTINCT</ProtocolAcronym><ProtocolTitle>Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75238"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, comparative, open, randomized study to evaluate the efficacy of tanomastat versus gemcitabine in the treatment of patients with advanced or metastatic pancreatic adenocarcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51025"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to assess the safety and pharmacokinetics of [18F]DPA-714 in healthy male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="80350"></Trial><Drug id="62600">BAY-85-8102</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of The Effects of Testosterone in Frail Elderly Men</ProtocolTitle><Sponsor>Central Manchester Healthcare NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54907"></Trial><Drug id="17837">testosterone gel, Solvay/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, two-period crossover, concentration comparison study to evaluate the white and gray matter and brain lesions based on the ratio of decreases in peak signal, contrast enhancement effect, and improvement using SH-L-562 in diagnosis in patients with brain processes such as prior infarct or surgery</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1630">Brain infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343151"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for Six Treatment Cycles in Women With Moderate Acne</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21606"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4582"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="344881"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the histological response, pattern of tumor destruction and clinical outcome with neoadjuvant chemotherapy including bevacizumab or cetuximab in patients with colorectal liver metastases undergoing liver resection</ProtocolTitle><Sponsor>Amgen Inc, Bayer AG, Merck KGaA, Roche Holding AG, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239318"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LDS</ProtocolAcronym><ProtocolTitle>Lipids in Diabetes Study</ProtocolTitle><Sponsor>Bayer plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="119376"></Trial><Drug id="16986">fenofibrate (micronized), Fournier/Abbott</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ONYX</ProtocolAcronym><ProtocolTitle>Anti-angiopoeitin 2 Plus Anti-Vascular Endothelial Growth Factor as a Therapy for Neovascular Age Related Macular Degeneration: Evaluation of a Fixed Combination Intravitreal Injection</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="256118"></Trial><Drug id="93467">nesvacumab + aflibercept (AMD, DME), Regeneron/ Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status</ProtocolTitle><Sponsor>Medica Scientia Innovation Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="283222"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212684"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein Jr</ProtocolAcronym><ProtocolTitle>Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3644">Arterial thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241991"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY-87-2243 in Patients With Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74781"></Trial><Drug id="70197">BAY-87-2243</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="577">Gastrointestinal infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Phase III Trial of Leukine Versus Neupogen in Patients Receiving Cisplatin &amp; Gemcitabine for Urothelial Cancer</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44754"></Trial><Drug id="3130">filgrastim</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase II Trial of Pre-Chemotherapy Leukine Versus Leukine-Dexamethasone in Combination With Gemzar And 5-FU in Patients With Metastatic Renal Cell Carcinoma</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54629"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29597"></Trial><Drug id="9829">Busulfex</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="3081">exemestane</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27591"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of effect of food, an antacid, and the H2-antagonist ranitidine on the absorption of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6140"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>OCEAN</ProtocolAcronym><ProtocolTitle>Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198570"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Prospective, Multicenter, Double-Blind, Randomized  Trial To Compare The Efficacy And Safey Of Moxifloxacin And Clindamycin In The Treatment Of Odontogenic Abscesses And Inflammatory Infiltrates</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2275">Odontogenic tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75743"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine as Second-line Treatment for Malignant Pleural Mesothelioma (MPM)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="704">Pleural disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246511"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial of BAY-1251152 for Advanced Blood Cancers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="258786"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="304890"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21470"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOTIV</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Sequential iv/po Moxifloxacin in Comparison to iv Levofloxacin Plus iv Ceftriaxone Followed by po Levofloxacin, in the Treatment of Patients With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="13915"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A proof-of-concept study to assess safety, tolerability, pharmacokinetics (PK) and antitumor activity of CS-1001 in combination with regorafenib for the potential treatment of multiple cancers including gastric cancer</ProtocolTitle><Sponsor>CStone Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="383949"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARAMIS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Orion Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="206573"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnevist (SH L 451A) Intra-Individual Dose Comparison Study in Magnetic Resonance Angiography</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="541">Artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9672"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="629">Hepatobiliary system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="793">Mouth tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of oral fludarabine and cyclophosphamide combination therapy in aged patients with B-cell lymphatic leukemia and low grade non Hodgkin lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1729">B-cell acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89882"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-2</ProtocolAcronym><ProtocolTitle>Phase III Copanlisib in Rituximab-refractory iNHL</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222628"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Benin tablets 5 mg (Xingfu Laboratorios, SA, Spain) and Nebilet 5 mg tablets (Berlin-Chemie AG / Menarini Group, Germany)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="164603"></Trial><Drug id="3686">nebivolol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib/Cetuximab in Head and Neck Cancer</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="39672"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY-1830839 in Healthy Male Participants</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="291">Rheumatoid arthritis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="382691"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DILATE-1</ProtocolAcronym><ProtocolTitle>A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="68726"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety and efficacy study of nelarabine in patients with indolent leukemia</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, GlaxoSmithKline Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="199">Leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64381"></Trial><Drug id="14643">nelarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRAIN-AF</ProtocolAcronym><ProtocolTitle>Blinded, Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF</ProtocolTitle><Sponsor>Montreal Heart Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="90">Dementia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224270"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnevist Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4994"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246805"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="148727"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADVISE</ProtocolAcronym><ProtocolTitle>Low-Dose Nifedipine-Valsartan Combination Compared to Up-Titrated Valsartan Monotherapy in Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61043"></Trial><Drug id="2773">valsartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the effects of atorvastatin high-dose and atorvastatin/ezetimibe combination therapy</ProtocolTitle><Sponsor>Misaki Naika Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="284962"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Double-blind, Randomized, Reference-controlled, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Advantan Ointment Once Daily With Protopic 0.03% Ointment Twice Daily Over Maximum 3 Weeks in 250 Children and Adolescents With Atopic Dermatitis</ProtocolTitle><Sponsor>Bayer AG, Schering AG, Schering-Plough AB</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="117316"></Trial><Drug id="3622">methylprednisolone aceponate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pediatric Risk of Hypothyroidism With Iodinated Contrast Media</ProtocolTitle><Sponsor>GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="182">Hypothyroidism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="350385"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI-3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81893"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS II</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 2</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6753"></Trial><Drug id="44258">aciclovir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DECISION</ProtocolAcronym><ProtocolTitle>Nexavar Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60624"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE II</ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Refractory Advanced Gastro-Esophageal Cancer</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="260950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALT GIST</ProtocolAcronym><ProtocolTitle>A Randomized Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumor (GIST)</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group, European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Centre of Singapore</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222463"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21470"></Trial><Drug id="3669">mycophenolate mofetil</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating and pharmacokinetic (PK) study of vatalanib in patients with liver metastases from colorectal, breast and other solid tumors</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="202">Liver tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38143"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SMS</ProtocolAcronym><ProtocolTitle>Sorafenib in Previously Treated Malignant Mesothelioma</ProtocolTitle><Sponsor>King's College London</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36471"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, carbapenem-controlled, efficacy study of ciprofloxacin in patients with biliary tract infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2237">Biliary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62123"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2218">Hepatoblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost</ProtocolTitle><Sponsor>University of Lund</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2563">Neonatal respiratory distress syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5698"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Ketoconazole on Regorafenib (BAY-73-4506) Pharmacokinetics</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75641"></Trial><Drug id="44299">ketoconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacokinetic study of regorafenib and its metabolites (N-oxide [M-2] and demethylated N-oxide [M-5]) in colon cancer patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="767">Colon tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="66265"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase II Study of Sorafenib Plus bicalutamide Versus Placebo Plus Bicalutamide in Castration-Resistant Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer Patients Who Had Orchiectomy or Are Receiving a LHRH Analog</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="139323"></Trial><Drug id="3311">bicalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese BAY-88-8223 Monotherapy, Phase II Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="152518"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN-DVT</ProtocolAcronym><ProtocolTitle>Oral Direct Factor-Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism: Einstein-DVT Evaluation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="7140"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD 1</ProtocolAcronym><ProtocolTitle>Rivaroxban (10 mg) Given Once-Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin</ProtocolTitle><Sponsor>Bayer Australia Ltd, Bayer HealthCare AG, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6173"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="220374"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FC Patch Low: Metabolism Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58567"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, parallel-group, dose-comparison study to evaluate the efficacy of SH-L-562 in the treatment of patients with stenosis</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1620">Renal artery obstruction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342858"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety and Efficacy Study of Different Oral Doses of BAY-94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115003"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastasis</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="245669"></Trial><Drug id="3311">bicalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Determination of Safety, Efficacy, and Pharmacokinetics of 'Regorafenib' Combined with Pemetrexed and Cisplatin in Patients with Nonsquamous Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="69431"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLANTIC</ProtocolAcronym><ProtocolTitle>Randomized, Double-masked, Sham-controlled, Phase IV Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Association for Innovation and Biomedical Research on Light and Image</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="234648"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Evaluation of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Yokohama City University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="138709"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pharmacokinetics study of tanomastat in combination with paclitaxel and carboplatin, a potential treatment for cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51036"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to assess the safety and pharmacokinetics of tanomastat in conjunction with 5-FU and folinic acid (FA), a potential treatment for cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51028"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the effects of atorvastatin high-dose and atorvastatin/ezetimibe combination therapy</ProtocolTitle><Sponsor>Misaki Naika Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="284962"></Trial><Drug id="11367">ezetimibe</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, four-arm, parallel-group, placebo-controlled, single-blind study to assess the safety and efficacy of norethisterone enanthate (NET-EN) plus testosterone undecanoate (TU) for male contraception</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90987"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCOCO</ProtocolAcronym><ProtocolTitle>Phase I Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="338906"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma</ProtocolTitle><Sponsor>Peking University Cancer Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3467">Metastatic renal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="103912"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="7290">triptorelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ramatroban in asthmatic subjects</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29558"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6616"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS Extension</ProtocolAcronym><ProtocolTitle>An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58388"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Subcutaneous Alemtuzumab (CAMPATH, MabCampath) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Genzyme Europe B.V., Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43510"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25586"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FOCUS</ProtocolAcronym><ProtocolTitle>Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64319"></Trial><Drug id="2773">valsartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I pharmaockinetic study of two different formulations of cicaprost (iv and oral) in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56021"></Trial><Drug id="2813">cicaprost</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multinational, Double-Blind, Randomized, Phase IIb, Cooperative-Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Fondazione Michelangelo</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246017"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 Mg/DRSP 3 Mg) on Quality of Life</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3">Acne</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45040"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 Mg/DRSP 3 Mg) on Quality of Life</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="480">Premenstrual syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45040"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS-12 versus Combined Oral Contraceptive (COC) User Satisfaction Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72841"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-month, open-label study to evaluate the safety and efficacy of Yasmin as an oral contraceptive in women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46823"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study on Yasmin versus Marvelon in Chinese Women Requiring Contraception</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31577"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of Kogenate for surgical procedures or in-hospital treatment of serious hemorrhage</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="439">Hemophilia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51458"></Trial><Drug id="3091">octocog alfa, Genentech/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BEYOND Follow-up</ProtocolAcronym><ProtocolTitle>Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG, Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6800"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="3364">peginterferon alfa-2b</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Determination of Safety, Efficacy, and Pharmacokinetics of 'Regorafenib' Combined with Pemetrexed and Cisplatin in Patients with Nonsquamous Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69431"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of miglitol and glibenclamide in non insulin-dependent diabetic (NIDD) patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19798"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of miglitol on pharmacokinetics and pharmacodynamics of glyburide in a randomized, double-blind, placebo-controlled crossover study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19759"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preoperative Trial of Sorafenib in Combination with Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69878"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SOFIA</ProtocolAcronym><ProtocolTitle>Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer</ProtocolTitle><Sponsor>German Breast Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48473"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II trial of vatalanib in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38018"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2567">Anaplastic astrocytoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Porsche</ProtocolAcronym><ProtocolTitle>Comparative Safety and Efficacy Study of New Bifonazole Spray versus Terbinafine Solution versus Placebo</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2429">Tinea pedis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="190338"></Trial><Drug id="4533">terbinafine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study for Evaluation of Efficacy and Safety of SHL-749 to Indolent B-Cell Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25584"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TALENT</ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control</ProtocolTitle><Sponsor>Bayer AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58507"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ITEM</ProtocolAcronym><ProtocolTitle>Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels</ProtocolTitle><Sponsor>Deutsches Wollforschungsinstitut an der Rheinisch-Westfalischen Technischen Hochschule Aachen eV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="21038"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>InReTel</ProtocolAcronym><ProtocolTitle>The Influence of Telmisartan on Insulin Resistance and Fatty Liver in Patients Suffer from Hypertension</ProtocolTitle><Sponsor>Klinikum Chemnitz Gmbh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="120057"></Trial><Drug id="5051">telmisartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, placebo-controlled, crossover trial to evaluate the effects of BAY-X-7195 on leukotriene D4-induced bronchoconstriction in normal volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="30872"></Trial><Drug id="5541">BAY-X-7195</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="320057"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, parallel control study to investigate the efficacy and safety of isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) and acarbose combination therapy in elderly diabetic patients, evaluate whether acarbose in insulin-treated patients can reduce glycemic variability and shorten injection-meal interval</ProtocolTitle><Sponsor>Chinese PLA General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="92231"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GREAN</ProtocolAcronym><ProtocolTitle>Glucose Reduction by Early Acarbose Treatment in Basal Insulin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60087"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of Add-On Acarbose on the Levels of Chronic Inflammatory State and Gut Microbiota in Patients With Type 2 Diabetes Mellitus</ProtocolTitle><Sponsor>The Second Affiliated Hospital of Dalian Medical University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="127972"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IBUKI</ProtocolAcronym><ProtocolTitle>Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="82268"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5124"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53973"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="29510"></Trial><Drug id="6306">aldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="27592"></Trial><Drug id="6306">aldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INSIGHT</ProtocolAcronym><ProtocolTitle>A comparative, double-blind, randomized study to evaluate the efficacy of nifedipine-GITS, amiloride and hydrochlorothiazide in patients with hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="113421"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pilot study to evaluate the safety and efficacy of Leukine in patients with Crohns disease</ProtocolTitle><Sponsor>Berlex Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="84">Crohns disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="50789"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="44334"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6616"></Trial><Drug id="8710">glatiramer acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-Inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-Inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47898"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38773"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I pharmacokinetics study of bid vatalanib in patients with advanced solid tumor</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38266"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CASTA-DIVA</ProtocolAcronym><ProtocolTitle>Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="258814"></Trial><Drug id="9291">dalteparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONKO-011</ProtocolAcronym><ProtocolTitle>Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="243750"></Trial><Drug id="9291">dalteparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical study to evaluate the efficacy of NeoTect in patients with solitary pulmonary nodules (SPNs) seen on chest X-ray and significant risk factors for lung cancer</ProtocolTitle><Sponsor>Diatide Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47713"></Trial><Drug id="9397">99mTc-depreotide</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS II</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 2</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6753"></Trial><Drug id="9702">recombinant interferon beta-1a, Merck Serono</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6616"></Trial><Drug id="9702">recombinant interferon beta-1a, Merck Serono</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III, Double-blind Comparative Study of BAY-77-1931 (Lanthanum Carbonate) With Calcium Carbonate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84182"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Study in Chronic Kidney Disease (Extension From Study 14817)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69441"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-77-1931 Long-Term Extension From Phase II Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="39832"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LAVALIER</ProtocolAcronym><ProtocolTitle>Lanthanum versus Calcium Carbonate for Vascular Abnormalities in Patients with CKD and Hyperphosphatemia</ProtocolTitle><Sponsor>Osaka University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="210182"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6616"></Trial><Drug id="10154">fingolimod</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS Extension</ProtocolAcronym><ProtocolTitle>An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58388"></Trial><Drug id="10154">fingolimod</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to compare the efficacy of static and dynamic magnetic resonance (MR) imaging using the superparamagnetic iron oxide SH-U-555-A (Resovist) versus standard dose of gadolinium (Gd)-DTPA in patients with focal liver lesions</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="18465"></Trial><Drug id="11665">ferucarbotran (small superparamagnetic), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SH-L-562BB Phase II/III Dose Justification and Gadoteridol-Controlled Comparative Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45767"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>06-882 A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer</ProtocolTitle><Sponsor>New York University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45857"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="29716"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESILIENCE</ProtocolAcronym><ProtocolTitle>Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71942"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARBON</ProtocolAcronym><ProtocolTitle>Capecitabine oral chemotherapy with radium-223 in breast cancer patients with bone metastasis</ProtocolTitle><Sponsor>Sheffield Teaching Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="253603"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison Study of Vasovist Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="170328"></Trial><Drug id="12526">gadofosveset</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label extension trial to evaluate the relationship between peripheral and central cholinesterase inhibition in Alzheimer's disease patients, after chronic treatment with metrifonate</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8455"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blinded, placebo-controlled, pharmacokinetic and pharmacodynamic study to evaluate the recovery rate of CSF acetylcholinesterase activity in Alzheimer's disease patients treated with metrifonate</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8447"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="196950"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and efficacy of moxifloxacin in comparision with cephalexin in patients being treated for uncomplicated skin and soft tissue infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="16244"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1393">Bacteroides infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1397">Yersinia pestis infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1455">Moraxella catarrhalis infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAIDEN</ProtocolAcronym><ProtocolTitle>Uncomplicated Pelvic Inflammatory Disease; Treatment With Moxifloxacin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="22547"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FLAT-SUGAR</ProtocolAcronym><ProtocolTitle>FLuctuATion Reduction With inSULin and Glp-1 Added togetheR</ProtocolTitle><Sponsor>University of Washington</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84715"></Trial><Drug id="13572">exenatide</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD3</ProtocolAcronym><ProtocolTitle>Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE); A Study of BAY-59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6174"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONKO-011</ProtocolAcronym><ProtocolTitle>Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients</ProtocolTitle><Sponsor>AIO-Studien-gGmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="243750"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative, double-blind, placebo-controlled, randomized study to evaluate pharmacokinetics, safety, and tolerability of BAY-12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="245">Osteoarthritis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="110828"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to assess the safety of tanomastat in colorectal and breast cancer patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="51041"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Finding Study for the Ultralow-Dose Levonorgestrel Intrauterine Contraceptive System (LCS)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86265"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mirena Efficiency and Tolerability During the First Year of Use</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32258"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MET</ProtocolAcronym><ProtocolTitle>Mirena Extension Trial</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="281448"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="26282"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of BAY-59-8862 in Patients With Advanced Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="32475"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Upfront Combination Pulmonary Arterial Hypertension Therapy</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="367069"></Trial><Drug id="18425">ambrisentan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-14-2222 Prophylaxis and Joint Function Improvement (Adults)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31144"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prophylaxis Versus on Demand Treatment for Children With Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="116275"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized, double-blind study to evaluate the effect of glycemic control (control of blood glucose levels) on the safety and efficacy of vardenafil in the treatment of men with diabetes and erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54254"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and pharmacokinetics of vardenafil when taken concomitantly with alcohol</ProtocolTitle><Sponsor>Bayer Corp, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53952"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multi-center, randomized, double-blind, placebo-controlled, fixed-dose, prospective study to evaluate the safety and efficacy  of vardenafil on erectile function in men who had undergone either unilateral or bilateral nerve-sparing radical retropubic prostatectomy 6 months to five years prior to screening</ProtocolTitle><Sponsor>Bayer Corp, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53927"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalation, phase I study to determine the tolerability and pharmacokinetic properties of vardenafil</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52933"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REINVENT</ProtocolAcronym><ProtocolTitle>Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil versus Vardenafil PRN versus Placebo in Men Immediately After Nerve-Sparing Prostatectomy for Improving ED</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31309"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assess the Effect of Daily Treatment of Vardenafil 20 mg or Sildenafil 100 mg and Placebo on Sperm Function</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31229"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assess Efficacy of Vardenafil 10 mg in Erectile Dysfunction Within Intake of 6 h</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31162"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="14302"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of vardenafil in healthy male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1241">Prostate hyperplasia</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="52939"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DREAM</ProtocolAcronym><ProtocolTitle>Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="208729"></Trial><Drug id="22395">ranibizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I trial to evaluate the efficacy and safety of pitrakinra in asthma patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="24852"></Trial><Drug id="22438">pitrakinra (inhaled dry powder, asthma), Aerovance</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I safety study of KN-38-7271 in healthy volunteers</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="5164"></Trial><Drug id="22439">KN-38-7271</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="23624">clofarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Efficacy of a Non-Hormonal Drug Against Endometriosis Associated Pelvic Pain</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="21378"></Trial><Drug id="28194">BX-471</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Low-dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-squamous Cell NSCLC</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="37834"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="85043"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML</ProtocolTitle><Sponsor>University Hospital Muenster</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="40918"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SORMAIN</ProtocolAcronym><ProtocolTitle>Study, to investigate, if Sorafinib can prevent a relapse in AML patients after stem cell transplantation</ProtocolTitle><Sponsor>Philipps-Universitat Marburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="138496"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I extension study to evaluate the safety, efficacy and pharmacokinetics of sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62848"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study to evaluate the efficacy, safety, pharmacokinetic and pharmacodynamic effect of midazolam, omeprazole and dextromethorphan on sorafenib in metastatic melanoma patients</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="52766"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Treatment Combination for Patients With Unresectable Stage III or IV Melanoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="25614"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43553"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="41364"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-PLORER</ProtocolAcronym><ProtocolTitle>Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="81253"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMMANDER HF</ProtocolAcronym><ProtocolTitle>A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure</ProtocolTitle><Sponsor>Janssen Pharmaceuticals Inc, Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="143374"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="106382"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-KNEE</ProtocolAcronym><ProtocolTitle>An Oral, Direct Factor Xa Inhibitor, BAY-59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6158"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD2</ProtocolAcronym><ProtocolTitle>Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-Blind, Randomized Study of BAY-59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4877"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PRONOMOS</ProtocolAcronym><ProtocolTitle>Prophylaxis in Non-Major Orthopedic Surgery</ProtocolTitle><Sponsor>Bayer HealthCare AG, Centre Hospitalier Universitaire de Saint Etienne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="226110"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEINJr</ProtocolAcronym><ProtocolTitle>Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="217784"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J'xactly</ProtocolAcronym><ProtocolTitle>Japanese registry of Rivaroxaban effectiveness and safety for the prevention of recurrence in patients with Deep Vein Thrombosis and Pulmonary Embolism</ProtocolTitle><Sponsor>Nihon University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="280759"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Myocardial perfusion and MR angiography of chest with SH-U-555-C</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="5789"></Trial><Drug id="34939">ferucarbotran (ultra-small superparamagnetic), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, prospective study of comparison of ticagrelor versus thienopyridine loading effect on fractional flow reserve in patients with coronary artery disease</ProtocolTitle><Sponsor>AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, The Medicines Company</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="282951"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and 5-azacitidine in Acute Leukemia + Myelodysplastic Syndrome</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72898"></Trial><Drug id="37370">azacitidine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSDOY</ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88345"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="385606"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK in Patients With HRPC And Skeletal Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33298"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222484"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="116253"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="344881"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NiraRad</ProtocolAcronym><ProtocolTitle>Phase Ib Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="290785"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>eRADicAte</ProtocolAcronym><ProtocolTitle>Open-Label, Phase II Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration Resistant (Hormone Refractory) Prostate Cancer Subjects With Bone Metastasis</ProtocolTitle><Sponsor>Carolina Research Professionals, LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="179595"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Standard-Dose Versus High-Dose and Versus Extended Standard-Dose Radium-223 Dichloride in Castration-Resistant Prostate Cancer Metastatic to the Bone</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="165346"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="222484"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="225976"></Trial><Drug id="43738">pazopanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blinded study investigating the safety and efficacy of daily low-dose oral fluconazole versus weekly fluconazole in the treatment of chronic vulvovaginal candidiasis</ProtocolTitle><Sponsor>Royal North Shore Hospital, University of Sydney</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1308">Candida infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="226473"></Trial><Drug id="44292">fluconazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PECASO</ProtocolAcronym><ProtocolTitle>Study in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib</ProtocolTitle><Sponsor>Eli Lilly &amp; Co, University Hospital Muenster</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47958"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MONALISA</ProtocolAcronym><ProtocolTitle>A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11557"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>SOPHI</ProtocolAcronym><ProtocolTitle>Study of Pain Control With Hormonal IUS Insertion</ProtocolTitle><Sponsor>Childrens Hospital of Philadelphia</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="220967"></Trial><Drug id="44403">lidocaine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II clinical trial of EP-2104R for the detection of blood clots</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="5567"></Trial><Drug id="44480">EP-2104R</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety anti-tumor activity of telatinib in patients with solid tumors</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="40499"></Trial><Drug id="45497">telatinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33462"></Trial><Drug id="46885">aprotinin, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of miglitol on pharmacokinetics and pharmacodynamics of glyburide in a randomized, double-blind, placebo-controlled crossover study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19759"></Trial><Drug id="46890">glibenclamide</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label phase II study to evaluate the safety and efficacy of bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49486"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63597"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="50038">tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY-1000394 When Given Together with Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small-Cell Lung Cancer)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="86332"></Trial><Drug id="51089">roniciclib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multi-center, patient-blinded study of BAY-79-4980 in patients with severe hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="41430"></Trial><Drug id="51391">recombinant Factor VIII (PEGylated liposomal), Bayer/Zilip</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LIPLONG</ProtocolAcronym><ProtocolTitle>BAY-79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="31251"></Trial><Drug id="51391">recombinant Factor VIII (PEGylated liposomal), Bayer/Zilip</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cipro Inhaler for Cystic Fibrosis Children Ages 6 to 12 Years</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1457">Pseudomonas infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56957"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="52967">apixaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VEGA</ProtocolAcronym><ProtocolTitle>Japanese Phase III Study of Aflibercept in Neovascular Glaucoma Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="134">Glaucoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="225195"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO</ProtocolAcronym><ProtocolTitle>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="61912"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPERNICUS</ProtocolAcronym><ProtocolTitle>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58987"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TADI study</ProtocolAcronym><ProtocolTitle>Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (Eylea) as a Second Line Treatment for Diabetic Macular Edema</ProtocolTitle><Sponsor>Hadassah Medical Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248830"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIVID EAST</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="108267"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AMOUR</ProtocolAcronym><ProtocolTitle>Aflibercept for Macular Edema With Underlying Retinitis Pigmentosa (AMOUR) Study</ProtocolTitle><Sponsor>Moorfields Eye Hospital, Moorfields Eye Hospital Nhs Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="251579"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of omacianine fluorescent dye for detection of breast cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="34704"></Trial><Drug id="54014">omacianine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT-1</ProtocolAcronym><ProtocolTitle>A Study to Evaluate Efficacy and Safety of Oral BAY-63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38966"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RIALTO</ProtocolAcronym><ProtocolTitle>A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="259969"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOTION</ProtocolAcronym><ProtocolTitle>Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="204681"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="9768"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="7624"></Trial><Drug id="54615">capadenoson</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A proof-of-concept study to assess safety, tolerability, pharmacokinetics (PK) and antitumor activity of CS-1001 in combination with regorafenib for the potential treatment of multiple cancers including gastric cancer</ProtocolTitle><Sponsor>CStone Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="383949"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE II</ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Refractory Advanced Gastro-Esophageal Cancer</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="260950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE II</ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Refractory Advanced Gastro-Esophageal Cancer</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="260950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DAST</ProtocolAcronym><ProtocolTitle>Safety Study of BAY-73-4506 in Patients With Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="61463"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CORRECT</ProtocolAcronym><ProtocolTitle>Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65608"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="343780"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="148987"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="148980"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese BAY-86-9766 Monotherapy Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="69055"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="56815">vismodegib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase IIb trial to assess the use of florbetaben (18F) as a PET imaging agent for the diagnosis of Alzhiemer's disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="80649"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Measuring Brain Amyloid Plaque Load in Older Adults Using BAY-94-9172</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71473"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the efficacy of BAY-94-9172 in humans</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34633"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-283197 for treatment of vasomotor symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2529">Hot flashes</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="20522"></Trial><Drug id="58468">ZK-283197</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46969"></Trial><Drug id="59664">doxorubicin (drug eluting bead, hepatocellular carcinoma), Biocompatibles</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-2</ProtocolAcronym><ProtocolTitle>Phase III Copanlisib in Rituximab-refractory iNHL</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="222628"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Chinese PK Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="336232"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY-94-9027 Following Single- and Multiple-Dose Administration</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69615"></Trial><Drug id="65438">damoctocog alfa pegol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-94-9027 PK Study Comparing to Another Long Acting Product</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="321971"></Trial><Drug id="65438">damoctocog alfa pegol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combined Single/Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="76288"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, randomized, single-blind, placebo-controlled, group-comparison, dose-escalation study to examine the pharmacokinetics, safety, tolerability and effect on erythropoietin levels of single oral doses of molidustat in healthy male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="349235"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI PD</ProtocolAcronym><ProtocolTitle>A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="327793"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI HD-C</ProtocolAcronym><ProtocolTitle>A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="320385"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="320705"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIDELIO-DKD</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Finerenone in Patients With Type 2 Diabetes Mellitus and Diabetic Kidney Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited, Bayer Philippines Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="239571"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole (ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C] Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="230626"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of Vilaprisan in Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="327209"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 3</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer (Malaysia) Sdn Bhd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="325833"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pivotal Bioequivalence FDC Nifedipine/Candesartan versus Loose Combination of Single Components, Fed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="77278"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed-Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-Intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="71680"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MORPHEUS</ProtocolAcronym><ProtocolTitle>Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="179248"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PANACHE</ProtocolAcronym><ProtocolTitle>A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="295237"></Trial><Drug id="75478">neladenoson bialanate</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PANTHEON</ProtocolAcronym><ProtocolTitle>A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="282173"></Trial><Drug id="75478">neladenoson bialanate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion</ProtocolTitle><Sponsor>Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="285546"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY-1905254</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="353074"></Trial><Drug id="86786">BAY-1905254</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ascending-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY-1128688 After Multiple Oral Administrations in Healthy Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="228474"></Trial><Drug id="92237">BAY-1128688</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Leopold I</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human Factor VIII for Hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62562"></Trial><Drug id="94438">octocog alfa (plasma-free, sucrose-formulated), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single Escalating Dose and Multiple Dose Study of BAY-1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="242381"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="385629"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHICO</ProtocolAcronym><ProtocolTitle>Prospective Study of a Pediatric Nifurtimox Formulation for Chaga's Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="335">Trypanosoma cruzi infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="248126"></Trial><Drug id="100280">Nifurtimox, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AVANTI</ProtocolAcronym><ProtocolTitle>A Trial to Study BAY-1753011 in Patients With Congestive Heart Failure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="375864"></Trial><Drug id="102383">BAY-1753011</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1003803 Single and Multiple Dose-Escalation, Safety, Tolerability and Pharmacokinetics Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="281">Psoriasis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="275993"></Trial><Drug id="103866">BAY-1003803</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>SOPHI</ProtocolAcronym><ProtocolTitle>Study of Pain Control With Hormonal IUS Insertion</ProtocolTitle><Sponsor>Childrens Hospital of Philadelphia</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="220967"></Trial><Drug id="82773">levonorgesterol (3-year intrauterine contraceptive system), Bayer Healthcare</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44943"></Trial><Drug id="11862">gadoterate meglumine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2567">Anaplastic astrocytoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Keifer</ProtocolAcronym><ProtocolTitle>Fast and Fed Pharmacokinetic (PK) Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="196676"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pediatric Risk of Hypothyroidism With Iodinated Contrast Media</ProtocolTitle><Sponsor>GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="182">Hypothyroidism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="350385"></Trial><Drug id="3393">iodixanol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone</ProtocolTitle><Sponsor>SELARL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="96177"></Trial><Drug id="17837">testosterone gel, Solvay/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine as Second-line Treatment for Malignant Pleural Mesothelioma (MPM)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246511"></Trial><Drug id="6408">vinorelbine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADEPT</ProtocolAcronym><ProtocolTitle>Blood Pressure Control of Nifedipine GITS 60 mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="226625"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Cycle Control Europe</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62475"></Trial><Drug id="12170">levonorgestrel + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, randomized comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables</ProtocolTitle><Sponsor>Schering AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115125"></Trial><Drug id="12170">levonorgestrel + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alemtuzumab and Pentostatin In T-Cell Neoplasms</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47445"></Trial><Drug id="17015">pentostatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>eRADicAte</ProtocolAcronym><ProtocolTitle>Open-Label, Phase II Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration Resistant (Hormone Refractory) Prostate Cancer Subjects With Bone Metastasis</ProtocolTitle><Sponsor>Carolina Research Professionals, LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="179595"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARDINAL</ProtocolAcronym><ProtocolTitle>Adalat XL versus Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="20154"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence of rivaroxaban granules for oral suspension and rivaroxaban tablets</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="318585"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY-43-9006)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58925"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, parallel-group, controlled, US trial to compare the safety, efficacy, and bioequivalence of Beyaz and Yaz in healthy women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71262"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial Of Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY-43-9006) In Metastatic Melanoma</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="26276"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>TacroVori</ProtocolAcronym><ProtocolTitle>Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290506"></Trial><Drug id="8714">voriconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MaxSep</ProtocolAcronym><ProtocolTitle>Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem plus Moxifloxacin) in the Treatment of Severe Sepsis and Septic Shock</ProtocolTitle><Sponsor>Kompetenznetz Sepsis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="114">Sepsis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11415"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, randomized, double-blind, two parallel-arm study to evaluate the efficacy of SH-L-562 in the diagnosis of patients with CNS (brain) tumors</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="759">Central nervous system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343150"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm, within dose comparison with dose-escalation study to evaluate the efficacy of gadobutrol in hospitalized patients with known CNS lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="759">Central nervous system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343145"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-myeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematological Disorders</ProtocolTitle><Sponsor>Beth Israel Deaconess Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="142">Hematological disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37434"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ophthalmological Examinations After Infusion of ZK-200775</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61262"></Trial><Drug id="10539">fanapanel, Schering AG/Novo Nordisk</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of YAZ for dysmenorrhea</ProtocolTitle><Sponsor>Saitama Medical University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="214349"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, randomized, double-blind, two parallel-arm study to evaluate the efficacy of SH-L-562 in the diagnosis of patients with CNS (brain) tumors</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="759">Central nervous system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343150"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetic study of rolipram in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16895"></Trial><Drug id="4268">rolipram</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors</ProtocolTitle><Sponsor>Cancer Centre of Monoclonal Therapy, LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="228572"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Phase III Trial of Leukine Versus Neupogen in Patients Receiving Cisplatin &amp; Gemcitabine for Urothelial Cancer</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44754"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGORA</ProtocolAcronym><ProtocolTitle>The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib</ProtocolTitle><Sponsor>Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263264"></Trial><Drug id="16026">esomeprazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Long-Term Follow-Up Program</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="218250"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation of Oral BAY-1161909 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187561"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, safety and efficacy study of pemetrexed in combination with carboplatin in patients with platinum-sensitive recurrent ovarian or primary peritoneal cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Eli Lilly &amp; Co, GlaxoSmithKline plc, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85458"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 8</ProtocolAcronym><ProtocolTitle>A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3442">Metrorrhagia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333665"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43433"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, randomized, cross-over study to evaluate the effect of food and time of administration on the pharmacokinetic/pharmacodynamic profile of metrifonate, in healthy Caucasian volunteers</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8228"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BIRUMM-01</ProtocolAcronym><ProtocolTitle>Breast Interventional Radiology Using MRI in Mie (BIRUMM-01)</ProtocolTitle><Sponsor>Mie University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="135593"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to explore the correlation of 18F-florilglutamic acid uptake with immunohistochemical expression of system xC- and CD44 which stabilizes the xCT subunit of system xC- in patients with cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89209"></Trial><Drug id="66251">florilglutamic acid (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BATTLE</ProtocolAcronym><ProtocolTitle>BATTLE Program: Sorafenib in Patients With NSCLC</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48125"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small-Cell Lung Cancer Progressing on Erlotinib</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46006"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28783"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Acarbose-Adiponectin Study</ProtocolAcronym><ProtocolTitle>Investigation of the Effects of Postprandial Glucose Reduction by Acarbose on Insulin Sensitivity and Cardiovascular Markers in the Subjects With Different Stages of Glucose Tolerance</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3294">Metabolic syndrome X</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="120791"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1902607: Single-Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="305044"></Trial><Drug id="106990">BAY-1902607</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MBD-CRF</ProtocolAcronym><ProtocolTitle>MBD-CRF study</ProtocolTitle><Sponsor>Tokyo Women's Medical College</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="192747"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Chinese PK Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="336232"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I dose escalating study to evaluate the pharmacokinetics of sorafenib in patients with locally advanced or metastatic cancer</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52951"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38773"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32724"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, randomized, double-blind, two parallel-arm study to evaluate the efficacy of SH-L-562 in the diagnosis of patients with CNS (brain) tumors</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343150"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Gly-CS</ProtocolAcronym><ProtocolTitle>Pathophysiology of Cheyne-Stokes Respiration: Lowering of the Pulmonary Capillary Wedge Pressure as a Causal Therapeutic Option</ProtocolTitle><Sponsor>Ruhr Universitat Bochum</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3223">Cheynes Stokes breathing</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="139258"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Russian Kogenate Pediatric Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31152"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of bendamustine in combination with rituximab in the treatment of patients with advanced low-grade and mantle cell lymphomas with unfavorable prognosis</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49436"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate the efficacy of progestogen dienogest on pituitary and ovarian function in healthy fertile females</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51527"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety and efficacy study of nelarabine in patients with indolent leukemia</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, GlaxoSmithKline Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="199">Leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64381"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="15130">vinflunine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, double-blind, dose-escalation study to assess the safety and pharmacokinetics of BAY-85-8501 in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210870"></Trial><Drug id="84161">PHP-303</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47096"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate the efficacy and tolerability of progestogen dienogest in fertile female volunteers</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51497"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPOSE EARLY</ProtocolAcronym><ProtocolTitle>A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150, 100 and 50 microg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1559">Congestive heart failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64014"></Trial><Drug id="29834">cinaciguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, prospective, one-arm study to evaluate the safety and eficacy of Nebido in hypogonadal patient</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52188"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Proof of Concept Study to Investigate the Impact of BAY-58-2667 Given Intravenously in Patients With Acute Decompensated Chronic Congestive Heart Failure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1559">Congestive heart failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="140202"></Trial><Drug id="29834">cinaciguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer</ProtocolTitle><Sponsor>Beth Israel Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58127"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY-1905254</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="353074"></Trial><Drug id="86786">BAY-1905254</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?</ProtocolTitle><Sponsor>Bispebjerg Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1821">Hyperglycemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="105413"></Trial><Drug id="2375">nateglinide</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MEMO</ProtocolAcronym><ProtocolTitle>Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-Abdominal Abscesses</ProtocolTitle><Sponsor>Hannover Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="520">Abdominal cavity inflammation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8329"></Trial><Drug id="29446">piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-VERT</ProtocolAcronym><ProtocolTitle>Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Non-valvular Atrial Fibrillation Scheduled for Cardioversion</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90547"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-59-7939 in Atrial Fibrillation Once-Daily (OD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60206"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>J-ROCKET AF</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4977"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effects of changing from warfarin to rivaroxaban on bone mineral metabolism, vascular calcification, and vascular endothelial dysfunction in patients with atrial fibrillation</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="323638"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2453">Astrocytoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Multiple-Doses of BAY-63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1036">Sarcoidosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="17236"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2938">Thymus neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="273">Myeloproliferative disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT-CHILD</ProtocolAcronym><ProtocolTitle>Riociguat in Children With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3661">Idiopathic pulmonary arterial hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241682"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-month, prospective, open-label, multicenter, long-term study to evaluate the safety and efficacy of sildenafil in the treatment of patients with Eisenmenger syndrome</ProtocolTitle><Sponsor>Tongji University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2087">Eisenmenger syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="82873"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6584"></Trial><Drug id="8013">nimodipine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI-3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81893"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY-1093884 in Patients With Severe Hemophilia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3905">Congenital hemophilia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="334550"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EMERON</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="14917"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>High Dose BAY-A-1040-Nifedipine: a Dose-Comparative Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="74350"></Trial><Drug id="100086">nifedipine once-daily coated core formulation (essential hypertension, angina), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAI-skip</ProtocolAcronym><ProtocolTitle>RAI-skip</ProtocolTitle><Sponsor>Tsukuba Clinical Research and Development Organization, University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3351">Papillary thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="230951"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4299">Salivary gland cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, prospective, non-randomized, drug-intervention, self-controlled study to demonstrate the evidence of reduced thrombin generation at the trough plasma rivaroxaban concentration (by factor Xa inhibition) in anticoagulation therapy-naive patients with nonvalvular atrial fibrillation</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="332066"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CVI ARO 2</ProtocolAcronym><ProtocolTitle>R-mark</ProtocolTitle><Sponsor>Cardiovascular Institute Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="275595"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II clinical trial of EP-2104R for the detection of blood clots</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5567"></Trial><Drug id="44480">EP-2104R</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Compare Omeprazole Administered as Zegerid Powder and as Prilosec Capsule in Healthy Participants (P08050 AM1)(CL2010-12)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="432">Dyspepsia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="182323"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Advanced Pancreatic Cancer Patients</ProtocolTitle><Sponsor>Atrium Health</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="176745"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of two contrast agents for magnetic resonance imaging in patients with liver cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169693"></Trial><Drug id="11862">gadoterate meglumine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, non-randomized, single-arm, dose-comparative, intra-individual controlled study to evaluate the efficacy of 1.0 M gadobutrol in patients with evidence of brain or spine lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2490">Spinal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345208"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY-79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64023"></Trial><Drug id="64356">BAY-79-4620</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of iv/po Moxifloxacin in Subjects With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21280"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalating, phase I/II study to evaluate safety, pharmacokinetics and efficacy of sorafenib in combination with gemcitabine in patients with advanced solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53049"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Agent Regorafenib in Refractory Advanced Biliary Cancers</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3461">Metastatic hepatobiliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="182248"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4299">Salivary gland cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPAN-ORL06</ProtocolAcronym><ProtocolTitle>Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3198">Larynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="264936"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-DVT</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor BAY-59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44583"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN Jr</ProtocolAcronym><ProtocolTitle>Oral Rivaroxaban in Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210054"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>LEVEQ-2</ProtocolAcronym><ProtocolTitle>Crossover Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="78">Contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="67214"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="97">Diabetes mellitus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21470"></Trial><Drug id="4510">tacrolimus</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38773"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOVAR</ProtocolAcronym><ProtocolTitle>Regorafenib versus Tamoxifen in Patients With Platinum-sensitive Ovarian Carcinoma and Isolated Biological Progression</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243698"></Trial><Drug id="44314">tamoxifen</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGO-SARC</ProtocolAcronym><ProtocolTitle>Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma</ProtocolTitle><Sponsor>Centre Oscar Lambret</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2446">Leiomyosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="146211"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="51388">nilotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY-1817080</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="264484"></Trial><Drug id="102704">BAY-1817080</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, carbapenem-controlled, efficacy study of ciprofloxacin in patients with biliary tract infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2237">Biliary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62123"></Trial><Drug id="44406">imipenem + cilastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-escalation Study of Lupartumab Amadotin (BAY-1129980)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186238"></Trial><Drug id="90898">lupartumab amadotin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Oral BAY-1217389 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222465"></Trial><Drug id="95532">BAY-1217389</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SAFE CAP</ProtocolAcronym><ProtocolTitle>Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="12405"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alemtuzumab and Pentostatin In T-Cell Neoplasms</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="199">Leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47445"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARDINAL</ProtocolAcronym><ProtocolTitle>Adalat XL versus Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="20154"></Trial><Drug id="24189">irbesartan + hydrochlorothiazide (oral, hypertension), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CERDIA</ProtocolAcronym><ProtocolTitle>A Double-Blind, Placebo-Controlled Study on The Effect of Cerivastatin on The Process of Atherosclerosis in Non-Insulin Dependent Diabetes Mellitus (type 2)</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150330"></Trial><Drug id="44313">simvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-escalation Trial of BAY-1187982 in Subjects with Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223770"></Trial><Drug id="90875">BAY-1187982</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of naproxen on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6131"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I single dose-escalating, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6120"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety and Efficacy Study of Different Oral Doses of BAY-94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115003"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RELIEF</ProtocolAcronym><ProtocolTitle>Comparison of Sequential iv/po Moxifloxacin With iv Piperacillin/Tazobactam Followed by po Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3081">Abscess</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10316"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastasis (BCBM)</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="97850"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESILIENCE</ProtocolAcronym><ProtocolTitle>Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71942"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Second Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="247966"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multinational, Double-Blind, Randomized, Phase IIb, Cooperative-Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Fondazione Michelangelo</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="246017"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MADONNA</ProtocolAcronym><ProtocolTitle>Randomized, Double-Blind, Phase II Study of Docetaxel + Sorafenib (Nexavar) Versus Docetaxel + Placebo in First-Line Treatment of Patients With HER2-Negative, Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, University Hospital Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="142525"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY-1905254</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="353074"></Trial><Drug id="86786">BAY-1905254</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Hot Flushes in Asian Women With Ultra-Low Dose Estradiol Patch</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2529">Hot flashes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32856"></Trial><Drug id="45697">estradiol (ultra-low-dose patch, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Finding Study of Gadovist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="556">Brain disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49081"></Trial><Drug id="17382">gadoversetamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, two-period, multiple-dose, fixed-sequence study to evaluate the effect of linagliptin on the steady-state pharmacokinetics of Microgynon in healthy, premenopausal female subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="347">Wound healing</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65486"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1273">Barretts esophagus</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47137"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation of Oral BAY-1161909 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187561"></Trial><Drug id="84711">empesertib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Testogel in Men With Partial Androgen Deficiency of Aging Males (PADAM)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34054"></Trial><Drug id="17837">testosterone gel, Solvay/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57816"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GA YAZ ACNE in China Phase III</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44811"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY 43-9006 / 13266 / MISSION</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="755">Lung tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="157812"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open-Label, Non-randomized, Sequential-Design</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="297157"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36139"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Effects of Two Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89865"></Trial><Drug id="21500">Beriplex P/N</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Standard-Dose Versus High-Dose and Versus Extended Standard-Dose Radium-223 Dichloride in Castration-Resistant Prostate Cancer Metastatic to the Bone</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="165346"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, two parallel-arm study to compare an improvement in diagnostic ability of 0.5 M gadobutrol doses (0.05 versus 0.1 mmol/kg) by contrast enhancement in patients with known or suspected renal disorder</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345246"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MOXIPEDIA</ProtocolAcronym><ProtocolTitle>Moxifloxacin in Pediatric Subjects With Complicated Intra-Abdominal Infection</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="577">Gastrointestinal infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64270"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27591"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLANTIC</ProtocolAcronym><ProtocolTitle>Randomized, Double-masked, Sham-controlled, Phase IV Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Association for Innovation and Biomedical Research on Light and Image</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="234648"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of the effects of BAY 59-7939 (rivaroxaban) on thrombin generation, in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6118"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fat Distribution in Healthy Early Post-menopausal Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46525"></Trial><Drug id="11942">dienogest + estradiol valerate (HRT), Jenapharm</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness and Safety Study of Tace Plus Oral Sorafenib for Unresectable HCC</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="39412"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSDOY</ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88345"></Trial><Drug id="49721">denosumab</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS 2 TIMI 51</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE), Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC, Johnson &amp; Johnson Sdn Bhd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38869"></Trial><Drug id="16026">esomeprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Phase I, Dose-Escalation Study With BAY-1143572 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154135"></Trial><Drug id="87787">atuveciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="478">Raynauds disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-2</ProtocolAcronym><ProtocolTitle>Phase Ib/II Study of Rogaratinib (BAY-1163877) in Combination With Atezolizumab in Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333363"></Trial><Drug id="72699">atezolizumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VOLCANIC-CTA</ProtocolAcronym><ProtocolTitle>Voltage-based Contrast Media Adaptation in Coronary Computed Tomography Angiography</ProtocolTitle><Sponsor>Bayer AG, Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="300914"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HeiLivCa</ProtocolAcronym><ProtocolTitle>A Prospective, Randomized, Double-Blind, Multicenter, Phase III Clinical Study on Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Plus Placebo in Patients With Hepatocellular Cancer (HCC) Before Liver Transplantation (Ltx) -Heidelberg Liver Cancer Study (Heilivca Study)</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="152756"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRIDGE</ProtocolAcronym><ProtocolTitle>Iloprost for Bridging to Heart Transplantation in PH</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2982">Heart transplantation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233298"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-blind, placebo-controlled trial of effects of miglitol on hyperglycemia in insulin dependent diabetics</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="19796"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-Vaginal Ring</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="240273"></Trial><Drug id="44370">clindamycin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A two part, phase II, safety, tolerability and pharmacokinetic study of BAY-63-2521 in patients with pulmonary artery hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5157"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, multicenter, multinational, controlled, double-blind, randomized clinical trial to evaluate the safety and efficacy of treatment with either moxifloxacin or amoxicillin for the treatment of patients with community-acquired pneumonia in Latin America</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73263"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="63307"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of iv/po Moxifloxacin in Subjects With Community-Acquired Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="360">Pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21280"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3668">Metastatic lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOBONE</ProtocolAcronym><ProtocolTitle>A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2975">Ewing sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224631"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Treatment Combination for Patients With Unresectable Stage III or IV Melanoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3256">Stage III melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25614"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Tolerability of 7-Day Multiple Dose Tedizolid Phosphate in Japanese Healthy Male Subjects for Nosocomial  Pneumonia and Skin and Soft Tissue Infection</ProtocolTitle><Sponsor>Bayer Yakuhin Research Center Kyoto, Kyoto University Graduate School of Medicine, Medical Co LTA Sumida Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="173688"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Clinical Study to Assess the Safety and Tolerability of Single Dose Tedizolid Phosphate in Japanese Healthy Subjects for Nosocomial Pneumonia (and Skin and Soft Tissue Infection)</ProtocolTitle><Sponsor>Bayer Yakuhin Research Center Kyoto, Kyoto University Graduate School of Medicine, Medical Co LTA Sumida Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="173582"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HEARTWORK</ProtocolAcronym><ProtocolTitle>Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64050"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)</ProtocolTitle><Sponsor>Accelerated Community Oncology Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48633"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide</ProtocolTitle><Sponsor>Translational Research In Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="283839"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of oral fludarabine and cyclophosphamide combination therapy in aged patients with B-cell lymphatic leukemia and low grade non Hodgkin lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89882"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="356333"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="229314"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="170154"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25722"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind study to evaluate the efficacy of methylprednisolone aceponate (0.1%) versus mometasone furoate with respect to atrophogenicity and appearance of telangiectasia, in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50598"></Trial><Drug id="3622">methylprednisolone aceponate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, multicenter study to evaluate the safety and efficacy of transdermally administered estradiol/levonorgestrel preparation in hormone therapy over 24 months (26 cycles) in post-menopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81239"></Trial><Drug id="22274">estradiol + levonorgestrel transdermal combination patch (HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61594"></Trial><Drug id="6104">lansoprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnevist Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches</ProtocolTitle><Sponsor>Berlex Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4665"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, placebo-controlled, double-blind, four-period crossover, dose-escalation study to evaluate the safety, pharmacokinetics and metabolism of SH-L-562 in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342426"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-86-9766 Plus Gemcitabine Phase I Study in Asian</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="104379"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1105">Scleroderma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124761"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1755">Anaplastic large cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="88">Cystic fibrosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIb to IV Soft Tissue Sarcoma</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="173005"></Trial><Drug id="13022">epirubicin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64193"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="53133">dabrafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RIOPRED</ProtocolAcronym><ProtocolTitle>Riociguat in patients with respiratory disease hypoxia - a proof-of-concept study</ProtocolTitle><Sponsor>Newcastle upon Tyne Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="256782"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose escalating study to evaluate the maximum-tolerated dose, toxicity, efficacy, pharmacokinetics and pharmacodynamics of sorafenib in patients with refractory solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52941"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of sorafenib in patients with refractory solid cancers</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52915"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="7286">goserelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the effect of ramatroban on allergen-induced nasal swelling in patients with perennial allergic rhinitis</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3201">Perennial allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29575"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN Jr</ProtocolAcronym><ProtocolTitle>Oral Rivaroxaban in Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210054"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-2</ProtocolAcronym><ProtocolTitle>Phase III Copanlisib in Rituximab-refractory iNHL</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222628"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EU/LA Pearl Index Study - Transdermal Contraceptive Patch</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57615"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32914"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalating, double-blind study of talviraline in HIV-infected patients</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="159">HIV-1 infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16936"></Trial><Drug id="8922">BAY-10-8039</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY-85-3934 in Subjects With Chronic Kidney Disease (CKD)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90928"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGORA</ProtocolAcronym><ProtocolTitle>The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib</ProtocolTitle><Sponsor>Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263264"></Trial><Drug id="16026">esomeprazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47753"></Trial><Drug id="11603">gefitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="220374"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NARRAS</ProtocolAcronym><ProtocolTitle>Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness</ProtocolTitle><Sponsor>People's Hospital Peking University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="276457"></Trial><Drug id="2500">amlodipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 7-day, placebo-controlled, crossover trial to evaluate the effect of ramatroban in patients with Dacron aortic grafts</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29588"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CERDIA</ProtocolAcronym><ProtocolTitle>A Double-Blind, Placebo-Controlled Study on The Effect of Cerivastatin on The Process of Atherosclerosis in Non-Insulin Dependent Diabetes Mellitus (type 2)</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="33">Atherosclerosis</Indication><HighestDevStatusForInd id="W">Withdrawn</HighestDevStatusForInd><Trial id="150330"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, randomized, placebo-controlled, multiple-dose study to evaluate the safety, pharmacokinetic and efficacy of cerivastatin between young and elderly male patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="175">Hyperlipidemia</Indication><HighestDevStatusForInd id="W">Withdrawn</HighestDevStatusForInd><Trial id="55066"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants</ProtocolTitle><Sponsor>The University Health Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="46">Bone marrow transplantation</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="30836"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64877"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CLL8</ProtocolAcronym><ProtocolTitle>A Randomized, Phase III Study to Assess Alemtuzumab Consolidation Therapy in Patients With Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Previous Therapy</ProtocolTitle><Sponsor>Bayer AG, Leeds Teaching Hospitals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="121538"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BrUOG L301 With Non-Small-Cell Lung Cancer and Bone Metastasis</ProtocolTitle><Sponsor>Brown University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="215190"></Trial><Drug id="2765">zoledronic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multinational, Double-Blind, Randomized, Phase IIb, Cooperative-Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Fondazione Michelangelo</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246017"></Trial><Drug id="2784">letrozole</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the effects of atorvastatin high-dose and atorvastatin/ezetimibe combination therapy</ProtocolTitle><Sponsor>Misaki Naika Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="174">Hypercholesterolemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="284962"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I pharmaockinetic study of two different formulations of cicaprost (iv and oral) in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56021"></Trial><Drug id="2813">cicaprost</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation study to evaluate the safety, efficacy and pharmacokinetics of sorafenib in combination with docetaxel and prednisone for the treatment of chemo-naive patients with metastatic castration-resistant prostate cancer</ProtocolTitle><Sponsor>Bayer AG, Clinique Universitaires Saint-Luc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="91174"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARASENS</ProtocolAcronym><ProtocolTitle>ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="263277"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled study to evaluate the tolerability and efficacy of 3-mg drospirenone/20-microg ethinyl estradiol for the treatment of moderate acne vulgaris in healthy female volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3">Acne</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65013"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51271"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral hormonal contraceptives BAY 86-5300 for the treatment of female dysmenorrhea efficacy and safety</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="240097"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>YAZ Premenstrual Dysphric Disorder (PMDD) in China</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="480">Premenstrual syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="41381"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) and L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73186"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV study to evaluate the safety and efficacy of Yasmin for contraception</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46838"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 Mg/DRSP 3 Mg) on Quality of Life</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45040"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>YAZ, Oral Contaceptive Registration in China</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="40742"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONCEPT-SCLC</ProtocolAcronym><ProtocolTitle>Roniciclib/Placebo in Combination With Chemotherapy in Small Cell Lung Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="195819"></Trial><Drug id="3072">etoposide phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="629">Hepatobiliary system tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248938"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Vantictumab (OMP-18R5) in Combination With Nab-paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer</ProtocolTitle><Sponsor>OncoMed Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="163171"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="3321">anastrozole</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BEYOND</ProtocolAcronym><ProtocolTitle>Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="78962"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BEYOND</ProtocolAcronym><ProtocolTitle>Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron to Treat Relapsing-Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6933"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250 microg in Patients of Chinese Origin With Multiple Sclerosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6860"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BEYOND</ProtocolAcronym><ProtocolTitle>BEYOND Pilot Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54024"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, multicenter study to evaluate the nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, GE Healthcare</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="62970"></Trial><Drug id="3393">iodixanol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONFIRM 1</ProtocolAcronym><ProtocolTitle>Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="37551"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The prognostic value of the Glasgow Prognostic Score (GPS) in metastatic colorectal carcinoma (mCRC) patients receiving conventional cytotoxic therapy</ProtocolTitle><Sponsor>Amgen Inc, Bayer AG, Pfizer Inc, Roche Holding AG, Servier</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="227157"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="148727"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEINJunior</ProtocolAcronym><ProtocolTitle>Oral Rivaroxaban in Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="91371"></Trial><Drug id="4476">fondaparinux sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Sorafenib + Protracted Temozolomide in Recurrent GBM</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="24864"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2727">Gliosarcoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Yt90 Zevalin and Combination Chemotherapy (Z-CHOP) in Treating Patients With Stage II, III, or IV Diffuse Large B-Cell Lymphoma</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="48264"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>STEP-DM</ProtocolAcronym><ProtocolTitle>The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes</ProtocolTitle><Sponsor>Medstar Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="214483"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study for Acarbose/Metformin FDC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="98656"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EDIT</ProtocolAcronym><ProtocolTitle>Early Diabetes Intervention Trial (EDIT Study)</ProtocolTitle><Sponsor>Bayer AG, Merck KGaA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="151615"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of the Combination Therapy of DPP-4 Inhibitor Alogliptin and Alfa-Glucosidase Inhibitor on Markers of Inflammation and Oxidative Stress - Comparison Between Acarbose and Voglibose</ProtocolTitle><Sponsor>School of Medicine, Keio University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="124598"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative, multicenter, open-label study to evaluate the safety and efficacy of acarbose in the treatment of type 2 diabetes</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="110730"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double blind, randomized, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="109706"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Fox versus I-Neb</ProtocolAcronym><ProtocolTitle>Comparative PK PD Study in PAH Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="167107"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fludara (Oral) Phase II Study for Indolent Lymphoma</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG, Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44483"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of oral fludarabine and cyclophosphamide combination therapy in aged patients with B-cell lymphatic leukemia and low grade non Hodgkin lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="89882"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and efficacy of fludarabine and paclitaxel in patients with non-Hodgkins lymphoma</ProtocolTitle><Sponsor>Jacobi Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73461"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CFAR Study in Patients With Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50839"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REASON</ProtocolAcronym><ProtocolTitle>Prevention of Sagopilone-Induced Neurotoxicity With Acetyl-L-Carnitine (ALC)</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="259">Peripheral neuropathy</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="36133"></Trial><Drug id="6206">acetyl-L-carnitine hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TALENT</ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control</ProtocolTitle><Sponsor>Bayer AG, Bayer SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58507"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48093"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nifedipine (Adalat CR, BAY-A1040) High Dose PK/PD Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32324"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VOLCANIC-CTA</ProtocolAcronym><ProtocolTitle>Voltage-based Contrast Media Adaptation in Coronary Computed Tomography Angiography</ProtocolTitle><Sponsor>Bayer AG, Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="300914"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="6692">natalizumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZBEAM2</ProtocolAcronym><ProtocolTitle>Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma</ProtocolTitle><Sponsor>Lymphoma Study Association</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52267"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186877"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="58867"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53973"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CFAR Study in Patients With Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50839"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32379"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63597"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG, Biogen Inc, CTI BioPharma Corp, Schering Lusitana Lda</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43438"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to investigate the efficacy of sargramostim in patients with Crohn's disease</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="84">Crohns disease</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="19307"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="58867"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI ND-M</ProtocolAcronym><ProtocolTitle>A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="320383"></Trial><Drug id="7413">darbepoetin alfa</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIALOGUE 3</ProtocolAcronym><ProtocolTitle>Long-Term Pre-Dialysis Extension in Europe and Asia Pacific</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="183811"></Trial><Drug id="7413">darbepoetin alfa</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 in Previously Untreated Patients With Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47939"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PDE5 Inhibitor Use and Non-Arteritic Anterior Ischemic Optic Neuropathy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198958"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, dose-escalating trial to evaluate the safety and tolerability of talviraline in HIV-infected patients</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="16930"></Trial><Drug id="8922">BAY-10-8039</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination Gel and Vascular ND in Mild to Moderate Rosacea</ProtocolTitle><Sponsor>Wake Forest University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88856"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploration of Safety and Efficacy of Azelaic Acid 15% Foam Twice a Day in Rosacea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="37887"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of vatalanib using MRI as a surrogate marker for efficacy in solid tumor patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38268"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study of the safety and pharmacokinetics of vatalanib and 5-FU/leucovorin/irinotecan (IFL) in patients with treatment-naive metastatic colorectal cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38139"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SELECT-D</ProtocolAcronym><ProtocolTitle>Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism</ProtocolTitle><Sponsor>Warwick University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="140785"></Trial><Drug id="9291">dalteparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, parallel-group study to assess the effect of lanthanum carbonate compared to calcium carbonate on serum phosphate in patients with hyperphosphatemia undergoing hemodialysis</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52935"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Treatment on BAY-77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="30133"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="10154">fingolimod</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing No or Only Mild Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="169389"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety and pharmacokinetics study of nikkomycin Z after oral administration of single doses to healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1109">Dermatomycosis</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="16772"></Trial><Drug id="10351">nikkomycin Z</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of BAY-86-5300 With an Extended Flexible Regimen for Endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="93103"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of SHT-00660AA in Treatment of Endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="57106"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate the efficacy of progestogen dienogest in women with endometriosis</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51529"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis</ProtocolTitle><Sponsor>Rennes University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83167"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMMA 2</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Gadobutrol 1.0 M (Gadovist) for Breast Magnetic Resonance Imaging (MRI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65718"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Gadobutrol 1.0 M in Japanese Subjects for CNS Imaging</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90055"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III multicenter, single-blind, randomized, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist (single iv injection) in patients with known or suspected renal lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="75857"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, non-randomized, single-arm, dose-comparative, intra-individual controlled study to evaluate the efficacy of 1.0 M gadobutrol in patients with evidence of brain or spine lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="345208"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm study to evaluate the added dose efficacy of SH-L-562 in the treatment of patients with known brain tumor or glioma</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="342685"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45855"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="330912"></Trial><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1102">Atopic dermatitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="165898"></Trial><Drug id="12083">pimecrolimus</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="245">Osteoarthritis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="344505"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>STARGATE</ProtocolAcronym><ProtocolTitle>Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation</ProtocolTitle><Sponsor>Asan Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69433"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71984"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REMoxTB</ProtocolAcronym><ProtocolTitle>Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="49258"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="758">Multidrug resistant infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1482">Enterococcus faecalis infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, prospective, randomized, double-blind, safety and efficacy study of moxifloxacin, compared to azithromycin in treating adult patients with acute bacterial exacerbations of chronic bronchitis (ABECB)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1484">Bacterial respiratory tract infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50271"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MONALISA</ProtocolAcronym><ProtocolTitle>A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11557"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Patients With Advanced Neuroendocrine Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="58975"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dosing and Effectiveness Study of Sorafenib and RAD-001 in the Treatment of Patients With Advanced Kidney Cancer</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43636"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A placebo-controlled, phase I/II trial to evaluate the tolerability and efficacy of PapViRx vacccine, a potential treatment for precancerous cervical dysplasia</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, MediGene AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="396">Papillomavirus infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="41913"></Trial><Drug id="13441">PapViRx</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FINESSE-HF</ProtocolAcronym><ProtocolTitle>Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensation</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="253339"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS16 versus COC User Satisfaction and Tolerability Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="290187"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VINSOR</ProtocolAcronym><ProtocolTitle>Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract</ProtocolTitle><Sponsor>Karolinska University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="129696"></Trial><Drug id="15130">vinflunine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I safety study of weekly ortataxel in patients with advanced solid tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="40839"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="85043"></Trial><Drug id="17625">vorinostat (oral), Merck &amp; Co</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY-94-9027 Following Single- and Multiple-Dose Administration</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69615"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study comparing protection from bleeding in BAY-79-4980 and BAY-14-2222</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="41428"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Comparative, Open-Label Treatment With Double-Blind, Placebo-Controlled Periods Within Treatment Study to Evaluate the Efficacy and Safety of a Once-a-Week Prophylaxis Treatment With BAY-79-4980 Compared to Once-a-Week Prophylaxis Treatment and to on-Demand Treatment With rFVIII-FS Reconstituted With Water for Injection in Previously Treated Patients With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="134515"></Trial><Drug id="18690">octocog alfa (sucrose-formulated), Bayer/Aventis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, phase III study to evalaute the safety and efficacy of vardenafil in the treatment of erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54320"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the safety and pharmacokinetics of vardenafil in the treatment of erectile dysfunction in men with high blood pressure who were taking nifedipine</ProtocolTitle><Sponsor>Bayer Corp, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53946"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A large phase II study to compare the safety and efficacy of vardenafil in the treatment of erectile dysfuntion in older and younger men</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53900"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, double-blind, cross-over study to evaluate the safety, efficacy and pharmacokinetics of vardenafil in male volunteers with mild to moderate with erectile dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52646"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31496"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31437"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31436"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31430"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31428"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PROVEN</ProtocolAcronym><ProtocolTitle>Placebo-Controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31427"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>POTENT II</ProtocolAcronym><ProtocolTitle>Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31425"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PARTNER II</ProtocolAcronym><ProtocolTitle>Levitra (Vardenafil, BAY-38-9456) Partner Satisfaction Study II</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31304"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIS</ProtocolAcronym><ProtocolTitle>A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patient With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31295"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FINDER</ProtocolAcronym><ProtocolTitle>A Randomized Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31163"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LEMDE</ProtocolAcronym><ProtocolTitle>Assess Efficacy in Subjects With Traumatic Spinal Cord Injury</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="14297"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Assess If 10 mg Vardenafil (BAY-389456) Taken bid For 6 Weeks Has An Effect On Bladder Function</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2376">Overactive bladder</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="41177"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIEW 1</ProtocolAcronym><ProtocolTitle>Vascular Endothelial Growth Factor(VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4787"></Trial><Drug id="22395">ranibizumab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="23624">clofarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of afeletecan in patients with non-small cell lung cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="49163"></Trial><Drug id="27970">afeletecan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer</ProtocolTitle><Sponsor>West german study group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="282745"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Veeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45720"></Trial><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Vantictumab (OMP-18R5) in Combination With Nab-paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer</ProtocolTitle><Sponsor>OncoMed Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="163171"></Trial><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Gastric Cancer Asian Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="127">Stomach tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="28458"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>06-882 A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer</ProtocolTitle><Sponsor>New York University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="45857"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="35820"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PECASO</ProtocolAcronym><ProtocolTitle>Study in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib</ProtocolTitle><Sponsor>Eli Lilly &amp; Co, University Hospital Muenster</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="47958"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SORAML</ProtocolAcronym><ProtocolTitle>Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia &lt; 60 Years of Age</ProtocolTitle><Sponsor>Technische Universitat Dresden</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="54207"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Vorinostat in Poor-Risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="50753"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-arm, expanded access, phase III study to evaluate the safety and efficacy of sorafenib in patients with non-clear cell renal cell carcinoma with prior bevacizumab treatment</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53055"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients Undergoing Surgery for Stage II, III, or IV Kidney Cancer</ProtocolTitle><Sponsor>UNC Lineberger Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44847"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SORCE</ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer</ProtocolTitle><Sponsor>Medical Research Council, University of Sydney</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28818"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28378"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Estimate Safety and Efficacy of Sorafenib (BAY-43-9006) in the Treatment of Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28022"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study on Safety and Efficacy of Sorafenib as Maintenance Chemotherapy After Percutaneous Isolated Hepatic Perfusion Chemotherapy (PIHP) for Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Kobe University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="137021"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="64587"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3504">Aggressive fibromatosis</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="174102"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)</ProtocolTitle><Sponsor>Accelerated Community Oncology Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45550"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEINJunior</ProtocolAcronym><ProtocolTitle>Oral Rivaroxaban in Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="91371"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of aspirin on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6132"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of naproxen on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6131"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-daily oral direct factor Xa inhibitor BAY-59-7939 (rivaroxaban) in patients with acute symptomatic deep-vein thrombosis</ProtocolTitle><Sponsor>Bayer Corp, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4884"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD 4</ProtocolAcronym><ProtocolTitle>Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY-59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4881"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODiXaHip</ProtocolAcronym><ProtocolTitle>A Phase IIa Dose-Escalating Proof-of-Principle Trial</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44864"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Rivaroxaban</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239537"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84321"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein VTE III and Einstein Extension</ProtocolAcronym><ProtocolTitle>The effect of oral rivaroxaban in treating and in the long term prevention in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism</ProtocolTitle><Sponsor>Bayer Australia Ltd, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="267386"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84321"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAYQ-3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="14968"></Trial><Drug id="32696">ciprofloxacin (sustained, oral), Sun/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>US Cycle Control and Blood Pressure Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="57913"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="39209">axitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="274717"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Does Response Study in HRPC Patients</ProtocolTitle><Sponsor>Algeta ASA, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33388"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARBON</ProtocolAcronym><ProtocolTitle>Capecitabine oral chemotherapy with radium-223 in breast cancer patients with bone metastasis</ProtocolTitle><Sponsor>Sheffield Teaching Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="253603"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="229314"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing No or Only Mild Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="169389"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK in Patients With HRPC And Skeletal Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33298"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Combination With Enzalutamide</ProtocolTitle><Sponsor>All Ireland Cooperative Oncology Research Group, Cancer Trials Ireland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="209043"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing No or Only Mild Symptoms</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="169389"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="116253"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="212684"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="225976"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, dosimetric and pharmacokinetic study of the anti fibronectin 131-I-L19-small immunoprotein (SIP), in patients with solid tumors</ProtocolTitle><Sponsor>Philogen SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="36556"></Trial><Drug id="43218">131I-radretumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-daily oral direct factor Xa inhibitor BAY-59-7939 (rivaroxaban) in patients with acute symptomatic deep-vein thrombosis</ProtocolTitle><Sponsor>Bayer Corp, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4884"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84321"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47449"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, dose-escalation study of tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="88">Cystic fibrosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="179750"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin Following Inhalation of Ciprofloxacin Dry Powder for Inhalation Administered to Pediatric Patients With Cystic Fibrosis Aged 12 to 17 Years</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="88">Cystic fibrosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="117764"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ-3939 in Patients With Bacterial Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1815">Bacterial pneumonia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85918"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, non-randomized, continuous dose study to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of telatinib in patients with colorectal cancer</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="40467"></Trial><Drug id="45497">telatinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, dose-escalating, safety and pharmacokinetic study of L19-IL-2 fusion protein in patients with recurrent/refractory solid tumors</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="39984"></Trial><Drug id="45599">L19-IL-2 fusion protein, Philogen</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Three-Year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-Menopausal Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4995"></Trial><Drug id="45697">estradiol (ultra-low-dose patch, HRT), Bayer Schering</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33474"></Trial><Drug id="46885">aprotinin, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of miglitol and glibenclamide in non insulin-dependent diabetic (NIDD) patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19798"></Trial><Drug id="46890">glibenclamide</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, safety and efficacy trial of miglitol in non-insulin dependent diabetic (NIDD) patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19750"></Trial><Drug id="46890">glibenclamide</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198792"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of bendamustine in patients with pre-treated low-grade non-Hodgkin's lymphoma (NHL)</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49507"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, multicenter, randomized, active control study to evaluate the safety and efficacy of bendamustine + prednisone versus melphalan + prednisone in the treatment of previously untreated patients with multiple myeloma (MM)</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49469"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="84366"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="85148"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FRAIL-AF study</ProtocolAcronym><ProtocolTitle>Anticoagulation in frail elderly patients with atrial fibrillation</ProtocolTitle><Sponsor>Julius Center for Health Sciences and Primary Care, Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="315870"></Trial><Drug id="52967">apixaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SIGHT</ProtocolAcronym><ProtocolTitle>VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="82878"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Focal macular ERG with wAMD after IVA</ProtocolTitle><Sponsor>Dokkyo Medical University, Koshigaya Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="278975"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AZURE</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="239585"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALTAIR</ProtocolAcronym><ProtocolTitle>Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="217442"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Efficacy of Aflibercept in Neovascular Age-Related Macular Degeneration (wAMD) With Refractory of Ranibizumab</ProtocolTitle><Sponsor>Nagoya City University Graduate School of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="137925"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Rio-CF</ProtocolAcronym><ProtocolTitle>Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="88">Cystic fibrosis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="198974"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DIGIT</ProtocolAcronym><ProtocolTitle>Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="478">Raynauds disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="156395"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESCUE</ProtocolAcronym><ProtocolTitle>Riociguat in Scleroderma Associated Digital Ulcers</ProtocolTitle><Sponsor>University of Michigan</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1105">Scleroderma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="273025"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Multiple-Doses of BAY-63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1105">Scleroderma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="17236"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT-2</ProtocolAcronym><ProtocolTitle>Long-term, Extension Study in Patients With Pulmonary Arterial Hypertension</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49223"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3511">Left heart disease pulmonary hypertension</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHEST-2</ProtocolAcronym><ProtocolTitle>BAY63-2521 - Long-Term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer Vital GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="56923"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RACE</ProtocolAcronym><ProtocolTitle>Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic Thrombo-embolic Pulmonary Hypertension</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="249143"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GRID</ProtocolAcronym><ProtocolTitle>Study of Regorafenib as a Third-Line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73625"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64193"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects with Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231443"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Georgetown University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="226385"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC</ProtocolTitle><Sponsor>Clinical Research Support Center Kyushu, Kyushu Study Group of Clinical Cancer</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="215638"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, two-period, multiple-dose, fixed-sequence study to evaluate the effect of linagliptin on the steady-state pharmacokinetics of Microgynon in healthy, premenopausal female subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65486"></Trial><Drug id="55852">linagliptin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the Neuroinflammation Pattern of BAY-85-8102 (F-18 DPA-714) in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F-18 DPA-714 in Healthy Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="61695"></Trial><Drug id="62600">BAY-85-8102</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Long Term Follow Up of Relapsing Remitting Multiple Sclerosis Patients Who Have Been Treated With Intereron Beta-1b (Betaferon) at Least Five Years</ProtocolTitle><Sponsor>Bayer Oy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="141416"></Trial><Drug id="63787">interferon beta-1b, Novartis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1747">Splenic marginal zone lymphoma</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="220374"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI HD-M</ProtocolAcronym><ProtocolTitle>Maintenance Treatment of Renal Anemia in Dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="341588"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIGARO-DKD</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Queen Mary Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="239986"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of Vilaprisan in Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="327209"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 6</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="302733"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY-1002670 (Vilaprisan)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="291965"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 2</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="232028"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODENZA</ProtocolAcronym><ProtocolTitle>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</ProtocolTitle><Sponsor>Cancer Campus, Grand Paris, Institut Gustave Roussy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="316586"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="320087"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="285513"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Naproxen Sodium ER Pharmacokinetic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81718"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Naproxen Sodium Extended-Release Actual Use Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="81716"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Morpheus/DPH</ProtocolAcronym><ProtocolTitle>Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="192851"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VENICE</ProtocolAcronym><ProtocolTitle>Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="247276"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Study of SH-U04722 in Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="102711"></Trial><Drug id="83142">SH-U04722</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-Vaginal Ring</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="240273"></Trial><Drug id="90559">anastrozole + levonorgestrel (intravaginal ring, endometriosis), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CADA DIA</ProtocolAcronym><ProtocolTitle>A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY-1142524 in Patients With Type 2 Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="326998"></Trial><Drug id="91352">fulacimstat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AKRENDO1</ProtocolAcronym><ProtocolTitle>A Study to Test Whether Study Drug BAY-1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Doses Work Best</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="322739"></Trial><Drug id="92237">BAY-1128688</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="337">Ulcerative colitis</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="211447"></Trial><Drug id="93023">iberogast N (ulcerative colitis), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single Escalating Dose and Multiple Dose Study of BAY-1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="242381"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study for BAY-1251152 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="249187"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of BAY-2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1240">Mesothelioma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="337620"></Trial><Drug id="101864">BAY-2287411</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Investigate BAY-2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="326222"></Trial><Drug id="109257">BAY-2402234</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1830839: First in Man, Single Dose-Escalation, Safety and Tolerability and Pharmacokinetics</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="291">Rheumatoid arthritis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="341202"></Trial><Drug id="110323">BAY-1830839</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32233"></Trial><Drug id="13599">desogestrel + ethinylestradiol (monophasic), Organon/Merck &amp; Co/Barr</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of BAY-39-9624 in postmenopausal women, for potential treatment of osteoporosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2549">Postmenopausal osteoporosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50339"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SUSE</ProtocolAcronym><ProtocolTitle>Sorafenib in Urothelium Cancer of Bladder</ProtocolTitle><Sponsor>Association of Urogenital Oncology (AUO)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71022"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PRIGA</ProtocolAcronym><ProtocolTitle>Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis</ProtocolTitle><Sponsor>Fundaci Clnic Per A La Recerca Biomdica</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="86422"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="304890"></Trial><Drug id="46921">levonorgestrel + estrogen, Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of food on the pharmacokinetics of
once-daily prolonged-release tacrolimus</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3878">Organ transplant rejection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306883"></Trial><Drug id="54222">tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An exploratory study to prospectively evaluate the safety and maximum standardized uptake values of 18F-FPPRGD2 positron emission tomography in patients with glioblastoma multiforme</ProtocolTitle><Sponsor>Bayer AG, GE Healthcare, General Electric Co, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="311550"></Trial><Drug id="71662">peptide-based PET radiotracer (breast cancer), Stanford University Medical Center</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study of BAY-1082439 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1705">Endometrioid carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98541"></Trial><Drug id="77019">BAY-1082439</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pivotal Bioequivalence FDC Nifedipine/Candesartan versus Loose Combination of Single Components, Fed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77278"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, randomized, crossover study to evaluate the bioavailability of estradiol after single application of two different Climara estradiol transdermal systems (SH P00577F, 9.35 and 15 cm2) in healthy post-menopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1523">Menopause</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81081"></Trial><Drug id="12356">estradiol (transdermal, menopausal symptoms), Theramex</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effects of BAY-M-1099 and emiglitate on metabolic responses to a mixed meal in normal healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56987"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="19810"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of two contrast agents for magnetic resonance imaging in patients with liver cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="70">Liver cirrhosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169693"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety and Efficacy Study of Different Oral Doses of BAY-94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115003"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV study to evaluate the safety and efficacy of Yasmin for contraception</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="365">Menstruation disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46838"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="10271">palbociclib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II, multicenter, dose-escalating study to evaluate the pharmacokinetics, safety and efficacy of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic melanoma</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53035"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLANTIC</ProtocolAcronym><ProtocolTitle>Randomized, Double-masked, Sham-controlled, Phase IV Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Association for Innovation and Biomedical Research on Light and Image</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="234648"></Trial><Drug id="2622">verteporfin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="175285"></Trial><Drug id="2622">verteporfin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Angeliq and Prempro185 on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21720"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RIOPRED</ProtocolAcronym><ProtocolTitle>Riociguat in patients with respiratory disease hypoxia - a proof-of-concept study</ProtocolTitle><Sponsor>Newcastle upon Tyne Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="708">Pulmonary fibrosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="256782"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-myeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematological Disorders</ProtocolTitle><Sponsor>Beth Israel Deaconess Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="142">Hematological disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37434"></Trial><Drug id="5999">ciclosporin, Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein-PE</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6231"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Safety and Exploratory Skin Lesion Measurement of TR-701FA Study</ProtocolTitle><Sponsor>Trius Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3081">Abscess</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84345"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONFIRM-2</ProtocolAcronym><ProtocolTitle>Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Novartis AG, Queen Mary Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="37552"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, post marketing surveillance study to evaluate the safety and efficacy of Angeliq in postmenopausal women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="374">Estrogen deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78415"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="116253"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3471">Metastatic brain cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47142"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Test2Func</ProtocolAcronym><ProtocolTitle>Effects of Testosterone Undecanoate versus Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism</ProtocolTitle><Sponsor>Medical University of Vienna</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3288">Non alcoholic fatty liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="371095"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Finding Study of Gadovist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="556">Brain disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49081"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25586"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2975">Ewing sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of single-dose cerivastatin in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="246">Osteoporosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55035"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of lanthanum carbonate on coronary artery calcification in patients new to dialysis</ProtocolTitle><Sponsor>Kobe University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="149749"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3198">Larynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Docetaxel Dose-Escalation Trial</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28445"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="273">Myeloproliferative disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="23624">clofarabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, randomized, double-blind, placebo-controlled clinical trial to compare the safety and efficacy of 3- and 14-day regimen of ciprofloxacin for the treatment of acute urinary tract infection in patients with spinal cord injury</ProtocolTitle><Sponsor>University of Manitoba</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1009">Urinary tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71425"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54662">ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma</ProtocolTitle><Sponsor>Peking University Cancer Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3467">Metastatic renal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="103912"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARDINAL</ProtocolAcronym><ProtocolTitle>Adalat XL versus Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="20154"></Trial><Drug id="46078">diltiazem hydrocloride (once-daily), Bausch Health/Actavis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of sorafenib in combination with carboplatin and paclitaxel in patients with melanoma</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="205">Melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52773"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A safety and efficacy study of Kogenate for surgical procedures or in-hospital treatment of serious hemorrhage</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="75">Blood clotting disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51458"></Trial><Drug id="3091">octocog alfa, Genentech/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematological Malignancies</ProtocolTitle><Sponsor>St Jude Children's Research Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56238"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6153"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRIDGE</ProtocolAcronym><ProtocolTitle>Iloprost for Bridging to Heart Transplantation in PH</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233298"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Reno-protective effect of nisoldipine and lisinopril in type 1 diabetic nephropathy</ProtocolTitle><Sponsor>Steno Diabetes Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="100">Diabetic nephropathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9957"></Trial><Drug id="44601">lisinopril</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2749">Hematoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Copanlisib on Metformin PK and PD</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="351877"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Mass Balance Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="183109"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT-CHILD</ProtocolAcronym><ProtocolTitle>Riociguat in Children With Pulmonary Arterial Hypertension (PAH)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="570">Connective tissue disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241682"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pharmacodynamic Study Comparing Zegerid and Prilosec OTC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="48954"></Trial><Drug id="34063">omeprazole and bicarbonate (oral capsules), Santarus/GSK/Norgine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320705"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIGARO-DKD</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Queen Mary Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="239986"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single and multiple oral administration pharmacokinetic study of 2 mg dienogest in healthy Korean women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="150085"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Treatment Combination for Patients With Unresectable Stage III or IV Melanoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3256">Stage III melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25614"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to assess opem-label, safety and efficacy of BAY-85-8501 tablet formulation healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210862"></Trial><Drug id="84161">PHP-303</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="759">Central nervous system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FLORIMS</ProtocolAcronym><ProtocolTitle>Flupirtine as Oral Treatment in Multiple Sclerosis</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="186944"></Trial><Drug id="15418">flupirtine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="33708"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Nebidolocal</ProtocolAcronym><ProtocolTitle>Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate</ProtocolTitle><Sponsor>Hospital Santa Fe</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31571"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY-43-9006</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="41654"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Mount Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="271772"></Trial><Drug id="28035">cabazitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC</ProtocolTitle><Sponsor>Clinical Research Support Center Kyushu, Kyushu Study Group of Clinical Cancer</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="829">Fatigue</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215638"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone</ProtocolTitle><Sponsor>Abramson Cancer Center of the University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73243"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of BAY-59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="24955"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35683"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Ginseng for Patients on Regorafenib</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243766"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PECASO</ProtocolAcronym><ProtocolTitle>Study in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib</ProtocolTitle><Sponsor>Eli Lilly &amp; Co, University Hospital Muenster</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47958"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="357065"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MAIDEN</ProtocolAcronym><ProtocolTitle>Uncomplicated Pelvic Inflammatory Disease; Treatment With Moxifloxacin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3140">Pelvic inflammatory disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="22547"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="131">Gastrointestinal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-masked, prospective, safety and efficacy study of moxifloxacin compared to cefuroxime axetil in patients with community-acquired acute sinusitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2999">Acute sinusitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50297"></Trial><Drug id="44368">cefuroxime (antibacterial), GlaxoSmithKline</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, double-blind, multicenter study to evaluate the safety and efficacy of moxifloxacin when compared with cefuroxime axetil in the treatment of acute sinusitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2999">Acute sinusitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="30288"></Trial><Drug id="44368">cefuroxime (antibacterial), GlaxoSmithKline</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed-Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-Intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71680"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Herceptin and GM-CSF for Metastatic Breast Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44099"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY59-7939 Japanese in Atrial Fibrillation (Second)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60207"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRIFT</ProtocolAcronym><ProtocolTitle>Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="311747"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>Hypertension and Atrial Fibrillation treated by Rivaroxaban for the Morning and Night with Synergy with calcium antagonists</ProtocolTitle><Sponsor>Jichi Medical School, Sogo Rinsho Medefi Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273125"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AFIRE</ProtocolAcronym><ProtocolTitle>Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study</ProtocolTitle><Sponsor>Japan Cardiovascular Research Foundation</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249714"></Trial><Drug id="19001">prasugrel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Gynodian Depot in Women With Impaired Well-being</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1093">Amenorrhea</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="190575"></Trial><Drug id="65324">estradiol valerate + levomefolate calcium (contraception), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="3364">peginterferon alfa-2b</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>FDA Phase IV- Commitment- Retinal Function Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55315"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="385606"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS</ProtocolAcronym><ProtocolTitle>BAY-94-8862 Dose Finding Trial in Subjects with Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77024"></Trial><Drug id="46934">spironolactone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="356333"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CONSIGN</ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85150"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Determine Maximum Tolerated Dose of BAY-79-4620 in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62519"></Trial><Drug id="64356">BAY-79-4620</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers</ProtocolTitle><Sponsor>Loxo Oncology Inc, MEDPACE SINGAPORE PTE LTD</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="304549"></Trial><Drug id="101262">LOXO-195</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4299">Salivary gland cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of Three Treatment Cycles</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32238"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="55288">trametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of vardenafil when co-administered with cimetidine or ranitidine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52957"></Trial><Drug id="44398">cimetidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84321"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEIN-DVT</ProtocolAcronym><ProtocolTitle>Oral Direct Factor-Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism: Einstein-DVT Evaluation</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="7140"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="195416"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="203798"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="62282">trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25940"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The lowering effect of ezetimibe on serum lipids and serum lipoprotein in postprandial hyperlipidemia</ProtocolTitle><Sponsor>Nakakinen Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="584">Lipid metabolism disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="180271"></Trial><Drug id="11367">ezetimibe</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of sorafenib in combination with capecitabine in patients with advanced solid tumors</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83818"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>University of Colorado at Denver and Health Sciences Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46036"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="53133">dabrafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Sagopilone in Combination With Carboplatin and Bevacizumab in the First-Line Treatment of Patients With Stage IIIB/IV</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132432"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REACHIN</ProtocolAcronym><ProtocolTitle>Regorafenib Versus Placebo to Treat Cholangiocarcinoma</ProtocolTitle><Sponsor>Erasme Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="196636"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Regorafenib as A Single-Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="173006"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase IIa, Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="167394"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Penetration of moxifloxacin (BAY-12-8039) Into the Excretory Pancreatic Secret After Intravenous Application</ProtocolTitle><Sponsor>Albert-Ludwigs-Universitt Freiburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="250">Pancreatitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130354"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I safety, pharmacokinetic and pharmacodynamic study of BAY 59-7939 (rivaroxaban) in subjects with extreme body weight</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6130"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study of the effects of BAY 59-7939 (rivaroxaban) on thrombin generation, in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="626">Heart disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6118"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1054">Testis tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOMUNE</ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors</ProtocolTitle><Sponsor>Institut Bergonie</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="333808"></Trial><Drug id="83065">avelumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GALILEO-4D</ProtocolAcronym><ProtocolTitle>Comparison of a Rivaroxaban-Based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)</ProtocolTitle><Sponsor>European Commission against Racism and Intolerance</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265742"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35591"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAND</ProtocolAcronym><ProtocolTitle>Radium 223 Following Intermittent ADT</ProtocolTitle><Sponsor>Canadian Urology Research Consortium</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="251104"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="89175"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Veeda Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45720"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="57735"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative 12 Month Study of Menstrually-Signalled Use of a Combined Contraceptive Pill Versus a Combined Contraceptive Vaginal Ring</ProtocolTitle><Sponsor>Family Planning Association New South Wales</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="125349"></Trial><Drug id="13615">etonogestrel + ethinylestradiol (vaginal ring, contraceptive), Merck &amp; Co</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADVISE</ProtocolAcronym><ProtocolTitle>Low-Dose Nifedipine-Valsartan Combination Compared to Up-Titrated Valsartan Monotherapy in Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61043"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of YAZ for dysmenorrhea</ProtocolTitle><Sponsor>Saitama Medical University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3835">Adenomyosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="214349"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, cross-over study to evaluate the efficacy and tolerability of BAY-M-1099 and BAY-O-1248 in patients with IDDM (insulin dependent diabetes mellitus)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56971"></Trial><Drug id="3035">emiglitate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bleeding Pattern and User Satisfaction During Second Consecutive Mirena in Contraception and Treatment of Menorrhagia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32167"></Trial><Drug id="5312">misoprostol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnevist Injection Enhanced MRA at Two Dose Levels Compared to Non-contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169935"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CKD-FGF23</ProtocolAcronym><ProtocolTitle>CKD-FGF23 Study</ProtocolTitle><Sponsor>Daikosunadabashi Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3796">Renal osteodystrophy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212377"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 12-month, double-blind, randomized, comparartive, multi-center study to evlauate the the efficacy, cycle control and tolerance of two low-dose of SH-543 and Femodene</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51976"></Trial><Drug id="47516">gestodene + estrogen (oral), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="231217"></Trial><Drug id="17735">sipuleucel-T</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-escalation Trial of BAY-1187982 in Subjects with Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="223770"></Trial><Drug id="90875">BAY-1187982</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2726">Neuroblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3866">Metastatic ovary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36011"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="629">Hepatobiliary system tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5033"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARI2</ProtocolAcronym><ProtocolTitle>Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration</ProtocolTitle><Sponsor>Centre Hospitalier Intercommunal Creteil</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="194367"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Switching to Aflibercept in Patients With Neovascular Age-Related Macular Degeneration Not Responding to Anti-VEGF Treatment: A Pilot Study</ProtocolTitle><Sponsor>Bayer AG, Radboud University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="157869"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and antitumor activity of afeletecan in patients with recurrent or metastatic inoperable colorectal cancer (CRC) resistant to irinotecan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Suspended</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88784"></Trial><Drug id="27970">afeletecan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for Antiphospholipid Antibody Syndrome</ProtocolTitle><Sponsor>St Josephs Healthcare Hamilton</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2065">Antiphospholipid syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="182239"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCKET AF</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation</ProtocolTitle><Sponsor>Bayer HealthCare AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="65">Stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4937"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMINI ACS 1</ProtocolAcronym><ProtocolTitle>A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="216173"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effect of age and gender on pharmacokinetics and bioavailability of cerivastatin in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="55038"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Phase III Trial of Leukine Versus Neupogen in Patients Receiving Cisplatin &amp; Gemcitabine for Urothelial Cancer</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44754"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NEXIRI</ProtocolAcronym><ProtocolTitle>Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation</ProtocolTitle><Sponsor>Institut Regional Du Cancer De Montpellier</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60844"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Penetration of moxifloxacin (BAY-12-8039) Into the Excretory Pancreatic Secret After Intravenous Application</ProtocolTitle><Sponsor>Albert-Ludwigs-Universitt Freiburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3912">Necrotizing acute pancreatitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130354"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia, Splenic Lymphoma or Lymphoplasmacytic Lymphoma</ProtocolTitle><Sponsor>Taunton and Somerset Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53391"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 7</ProtocolAcronym><ProtocolTitle>Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2991">Uterine hemorrhage</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343659"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMMANDER HF</ProtocolAcronym><ProtocolTitle>A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure</ProtocolTitle><Sponsor>Janssen Pharmaceuticals Inc, Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="143374"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="48946">dasatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of BAY-M-1099 and emiglitate on glycemic and hormonal responses in patients with insulin dependent diabetes mellitus (IDDM)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="836">Insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56995"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect on Primary Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="172041"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOBONE</ProtocolAcronym><ProtocolTitle>A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2588">Chondroma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="224631"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="36630">ipilimumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IOPAC study</ProtocolAcronym><ProtocolTitle>Iopamiron Abdominal and Cardiac CT enhancement study</ProtocolTitle><Sponsor>Kumamoto University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="303153"></Trial><Drug id="44295">iopamidol</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of BAY-1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="790">Diabetic foot ulcer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="296031"></Trial><Drug id="96958">BAY-1193397</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation for the effect of riociguat on right ventricular function</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="279682"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of food on the pharmacokinetics of
once-daily prolonged-release tacrolimus</ProtocolTitle><Sponsor>University of Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3878">Organ transplant rejection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306883"></Trial><Drug id="4510">tacrolimus</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation, safety study of ZK-304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36323"></Trial><Drug id="45637">ZK-304709</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of two contrast agents for magnetic resonance imaging in patients with liver cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="70">Liver cirrhosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="169693"></Trial><Drug id="11862">gadoterate meglumine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, pilot study to assess the safety and tolerability of intracoronary local paclitaxel delivery by X-ray contrast media for in-stent restenosis</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="330">Restenosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="139969"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I trial of P2X3 receptor antagonist, for the potential treatment of endometriosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="322453"></Trial><Drug id="106990">BAY-1902607</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADVISE</ProtocolAcronym><ProtocolTitle>Low-Dose Nifedipine-Valsartan Combination Compared to Up-Titrated Valsartan Monotherapy in Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61043"></Trial><Drug id="2773">valsartan</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPARIOS 1</ProtocolAcronym><ProtocolTitle>BAY-98-7196 Dose-Finding/POC Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215042"></Trial><Drug id="90559">anastrozole + levonorgestrel (intravaginal ring, endometriosis), Bayer</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, intra-individual comparison, four-period crossover study to evaluate the safety and efficacy of MR angiography using variable dosages, concentrations and injection speed of SH-L-562 in healthy subjects</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342678"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, double-blind, parallel-group, placebo-controlled, dose-escalation study to evaluate the single-dose tolerability of SH-L-562 in healthy young male subjects</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342677"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51091"></Trial><Drug id="3072">etoposide phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled study evaluating safety and efficacy sorafenib in combination with capecitabine in patients with advanced metastatic HER-2 negative breast cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="59091"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients</ProtocolTitle><Sponsor>Bayer AG, Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="182002"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multinational, randomized, non-blinded study of moxifloxacin, compared to co-amoxiclav in adult patients with acute exacerbations of chronic bronchitis (AECB)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="509">Respiratory tract infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50281"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label, Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-Tumor Activity</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="76673"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Nebidolocal</ProtocolAcronym><ProtocolTitle>Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate</ProtocolTitle><Sponsor>Hospital Santa Fe</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="31571"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="56544">cobimetinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, double-blind comparative study to evaluate the safety and efficacy of ramatroban and terfenadine in patients with perennial allergic rhinitis</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3201">Perennial allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29585"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="148972"></Trial><Drug id="77107">BAY-1125976</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="7934">doxorubicin (liposomal, STEALTH), Alza</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="344881"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status</ProtocolTitle><Sponsor>Medica Scientia Innovation Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="283222"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-DVT</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor BAY-59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44583"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Refametinib (BAY-86-9766) in Combination With Regorafenib (Stivarga, BAY-73-4506) in Patients With Advanced or Metastatic Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198547"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Timing of Complete Polyp Regression Following Aflibercept Treatments in Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Bayer Thai Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="364737"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="175285"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53861"></Trial><Drug id="3130">filgrastim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1770">Nephroblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="2871">irinotecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the effect of ramatroban on bronchial hyperresponsiveness to methacholine in patients with asthma</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="31">Asthma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="29587"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of bromerguride in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="282">Psychotic disorder</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="55739"></Trial><Drug id="2686">bromerguride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32379"></Trial><Drug id="2716">alemtuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I pharmacokinetic and pharmacodynamic study of oral cicaprost in healthy volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56015"></Trial><Drug id="2813">cicaprost</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS-TIMI 46</ProtocolAcronym><ProtocolTitle>Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes</ProtocolTitle><Sponsor>Bayer AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="5154"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>7</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATLAS ACS 2 TIMI 51</ProtocolAcronym><ProtocolTitle>An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE), Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC, Johnson &amp; Johnson Sdn Bhd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38869"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMINI ACS 1</ProtocolAcronym><ProtocolTitle>A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="216173"></Trial><Drug id="2836">clopidogrel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="276">Prostate tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MADONNA</ProtocolAcronym><ProtocolTitle>Randomized, Double-Blind, Phase II Study of Docetaxel + Sorafenib (Nexavar) Versus Docetaxel + Placebo in First-Line Treatment of Patients With HER2-Negative, Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, University Hospital Heidelberg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="142525"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SH-T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose-Finding and Placebo-Controlled Comparative Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53838"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>SH-T00186 in the Treatment of Primary Dysmenorrhea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="105">Dysmenorrhea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53783"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20-Week Elimination Phase of Folate</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="73422"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open-label, uncontrolled, phase III trial to evaluate the safety and efficacy of Yasminelle in the prevention of pregnancy in women</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46679"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III trial to evaluate the efficacy of Yasminelle compared to Mercilon in the prevention of pregnancy in subjects</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46670"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53861"></Trial><Drug id="3072">etoposide phosphate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate the Maximum Tolerated Dose of BAY-1000394 When Given Together with Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small-Cell Lung Cancer)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="86332"></Trial><Drug id="3072">etoposide phosphate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRUST</ProtocolAcronym><ProtocolTitle>A Phase II/III Trial to Evaluate the Efficacy and Safety of BAY-86-6150</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88568"></Trial><Drug id="3089">eptacog alfa (activated)</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, comparative, open, randomized study to evaluate the efficacy of tanomastat versus gemcitabine in the treatment of patients with advanced or metastatic pancreatic adenocarcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3669">Metastatic pancreas cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51025"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the risk factors for poor adherence to betaferon treatment including early discontinuation and omitting dose in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="288502"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Betaferon/Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="671">Myocardial disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="4401"></Trial><Drug id="3362">interferon beta-1b, Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, safety and efficacy study of pemetrexed in combination with carboplatin in patients with platinum-sensitive recurrent ovarian or primary peritoneal cancer</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Eli Lilly &amp; Co, GlaxoSmithKline plc, Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="85458"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, double-blind, placebo-controlled to evaluate the effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="19790"></Trial><Drug id="3629">miglitol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Accelerated Community Oncology Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31715"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="74576"></Trial><Drug id="3792">oxaliplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation of Oral BAY-1161909 in Combination With Intravenous Paclitaxel</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="187561"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalating Study With BAY-43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64882"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone</ProtocolTitle><Sponsor>SELARL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="96177"></Trial><Drug id="4119">tadalafil</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EINSTEINJr</ProtocolAcronym><ProtocolTitle>Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="217784"></Trial><Drug id="4476">fondaparinux sodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25722"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246805"></Trial><Drug id="4529">temozolomide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-Cell Lymphoma After Six Cycles of CHOP</ProtocolTitle><Sponsor>Mahidol University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46928"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ZEVALLO</ProtocolAcronym><ProtocolTitle>Safety of Ibritumomab Tiuxetan (Zevalin) in Combination With a Fudarabine-Based Reduced Intensity Conditioning (RIC) Regimen</ProtocolTitle><Sponsor>University Hospital, Bordeaux</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48232"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIT Trial</ProtocolAcronym><ProtocolTitle>Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25574"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, single-arm, open-label, non-randomized, multicenter phase II safety and efficacy trial of yttrium-90 ibritumomab tiuxetan as a second-line treatment for eladerly patients with diffuse large B-cell lymphoma (DLBCL) who are not eligible for stem cell transplantation</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="49402"></Trial><Drug id="4705">ibritumomab tiuxetan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Three-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85719"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy of Acarbose, Metformin, Sitagliptin Combination Treatment in DM Patients</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83240"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, randomized, controlled, cross-over trial of metabolic effects of acarbose or repaglinide when added to a double oral antidiabetic treatment with sulphonylureas and metformin in type 2 diabetic patients</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63005"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="32379"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25586"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>OFOCIR</ProtocolAcronym><ProtocolTitle>An Australian, phase II , multicenter, randomized, open-label, dose intensification study of three patient cohorts, investigating varying dose schedules, each of 6 x 28 day cycles, with monitoring continuing for 12 months into the post-treatment period</ProtocolTitle><Sponsor>Australasian Leukaemia and Lymphoma Group, Bayer AG, Roche Holding AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="121012"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HIGHCARE-ANDES</ProtocolAcronym><ProtocolTitle>High Altitude Cardiovascular Research in the ANDES</ProtocolTitle><Sponsor>Istituto Auxologico Italiano</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="121584"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53861"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma</ProtocolTitle><Sponsor>Hopital Maisonneuve-Rosemont</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38444"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FIT Trial</ProtocolAcronym><ProtocolTitle>Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="25574"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48255"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>OFOCIR</ProtocolAcronym><ProtocolTitle>An Australian, phase II , multicenter, randomized, open-label, dose intensification study of three patient cohorts, investigating varying dose schedules, each of 6 x 28 day cycles, with monitoring continuing for 12 months into the post-treatment period</ProtocolTitle><Sponsor>Australasian Leukaemia and Lymphoma Group, Bayer AG, Roche Holding AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="121012"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="53861"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="186877"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MIYABI HD-M</ProtocolAcronym><ProtocolTitle>Maintenance Treatment of Renal Anemia in Dialysis Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="341588"></Trial><Drug id="7413">darbepoetin alfa</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Accelerated Community Oncology Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="31715"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalating Study With BAY-43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="64882"></Trial><Drug id="8047">bevacizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PATENT PLUS</ProtocolAcronym><ProtocolTitle>Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and other Safety Parameters</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="69059"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2164">Rosacea</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85702"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study of the safety, pharmacokinetics and preliminary efficacy of vatalanib in combination with oxaliplatin/5-FU/leucovorin (FOLFOX-4) in patients with treatment-naive metastatic colorectal cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="38140"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A dose-escalation, phase I trial of vatalanib in patients with newly diagnosed or relapsed/refractory AML or advanced MDS</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="38016"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EPCAT</ProtocolAcronym><ProtocolTitle>Extended Prophylaxis Comparing Low Molecular Weight Heparin (LMWH) to Aspirin in Total Hip Arthroplasty</ProtocolTitle><Sponsor>Dalhousie University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="136012"></Trial><Drug id="9291">dalteparin sodium</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of BAY-77-1931 Granule</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1003">Hyperphosphatemia</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63541"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of TS-1 and Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Chiba University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="133019"></Trial><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety and pharmacokinetics study of nikkomycin Z after oral administration of single doses to healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="53">Candida albicans infection</Indication><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Trial id="16772"></Trial><Drug id="10351">nikkomycin Z</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A trial to evaluate the efficacy of progestogen dienogest in female volunteers with laparoscopically proven endometriosis</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51515"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of Dienogest for the Treatment of Endometriosis in Chinese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="113">Endometriosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="118752"></Trial><Drug id="11378">dienogest</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44334"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)</ProtocolTitle><Sponsor>Accelerated Community Oncology Research Network</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="48633"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Gadobutrol on background parenchymal enhancement in breast dynamic MRI</ProtocolTitle><Sponsor>Sagara Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="289942"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="45128"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LEADER75</ProtocolAcronym><ProtocolTitle>Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="60">Central nervous system disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="347577"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label study to evaluate the efficacy of SH-L-562 in patients with primary cancers outside the CNS with brain metastases</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="342679"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Efficacy,Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Quantitative evaluation of brain perfusion MRI with gadobutrol</ProtocolTitle><Sponsor>Hokkaido University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="760">Brain tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="291038"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SEARCH</ProtocolAcronym><ProtocolTitle>Nexavar-Tarceva Combination Therapy for First-Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="55235"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="11961">erlotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="28057"></Trial><Drug id="12150">vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open, randomized trial to compare the effect of Meliane and Femodene on lipid metabolism</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="51961"></Trial><Drug id="12164">ethinylestradiol + gestodene (oral), Schering AG</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III study of gadofosveset for the imaging of aorto-iliac occlusive disease, in patients with known or suspected PVD or abdominal aortic aneurysm</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="260">Peripheral vascular disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="8554"></Trial><Drug id="12526">gadofosveset</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A follow-up extension study to evaluate the CSF acetylcholinesterase activity in Alzheimer's disease patients after chronic treatment with metrifonate</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="8466"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="9107"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SPEED</ProtocolAcronym><ProtocolTitle>Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="21620"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="428">Clostridium infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1819">Chlamydia pneumoniae infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2227">Salpingitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, randomized, double-masked, prospective, safety and efficacy study of moxifloxacin compared to cefuroxime axetil in patients with community-acquired acute sinusitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2999">Acute sinusitis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="50297"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Advanced Solid Tumors Selected on Molecular Targets</ProtocolTitle><Sponsor>Southern European New Drug Organization</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Suspended</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="71514"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="346325"></Trial><Drug id="13600">etonogestrel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RECORD2</ProtocolAcronym><ProtocolTitle>Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-Blind, Randomized Study of BAY-59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd, Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="4877"></Trial><Drug id="13928">enoxaparin sodium</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to assess the safety of tanomastat in colorectal and breast cancer patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="51041"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetics study of tanomastat in patients with knee effusions due to osteoarthritis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="245">Osteoarthritis</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="51057"></Trial><Drug id="14217">tanomastat</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF Japan</ProtocolAcronym><ProtocolTitle>Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="157446"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety and Efficacy Study of Different Oral Doses of BAY-94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="115003"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>LCS-12 Versus ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="79353"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>JANESS</ProtocolAcronym><ProtocolTitle>Immediate Versus Delayed Initiation of Intrauterine System</ProtocolTitle><Sponsor>Sheba Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="357142"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of BAY-59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="24955"></Trial><Drug id="16631">ortataxel (intravenous, cancer), Spectrum</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vardenafil ODT (Orally Disintegrating Tablet)-Nifedipine Interaction Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="77192"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of vardenafil in men with mild to severe impaired erectile function</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52962"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RESTORE</ProtocolAcronym><ProtocolTitle>Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="34369"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>POTENT I</ProtocolAcronym><ProtocolTitle>Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31424"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="31230"></Trial><Drug id="21994">vardenafil hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of tomeglovir in healthy male volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="89">Cytomegalovirus infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="16762"></Trial><Drug id="22437">tomeglovir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Hysterectomy is Planned</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="319800"></Trial><Drug id="23239">ulipristal</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Trial id="25606"></Trial><Drug id="24087">entinostat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARDINAL</ProtocolAcronym><ProtocolTitle>Adalat XL versus Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="20154"></Trial><Drug id="24189">irbesartan + hydrochlorothiazide (oral, hypertension), Sanofi</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety of afeletecan for treatment of cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="651">Cancer</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="49171"></Trial><Drug id="27970">afeletecan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="28532">pertuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RELIEF</ProtocolAcronym><ProtocolTitle>Comparison of Sequential iv/po Moxifloxacin With iv Piperacillin/Tazobactam Followed by po Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="485">Bacterial skin infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10316"></Trial><Drug id="29446">piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multinational, Double-Blind, Randomized, Phase IIb, Cooperative-Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Fondazione Michelangelo</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="246017"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1055">Rectal tumor</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="78450"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Newly Diagnosed High Grade Glioma</ProtocolTitle><Sponsor>Hopitaux Universitaires De Geneve</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1108">Glioma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="52545"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52861"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1262">Non-small-cell lung cancer</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="45855"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and 5-azacitidine in Acute Leukemia + Myelodysplastic Syndrome</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="72898"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Idarubicin, Cytarabine and Sorafenib (BAY-43-9006)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="29318"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="206309"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Idarubicin, Cytarabine and Sorafenib (BAY-43-9006)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1731">Acute myelogenous leukemia</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="29318"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="186912"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HATT</ProtocolAcronym><ProtocolTitle>Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="65341"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety, tolerability and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="52669"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SPACE</ProtocolAcronym><ProtocolTitle>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47918"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>HCC</ProtocolAcronym><ProtocolTitle>Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Combined Military Hospital, Pakistan</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="46462"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of BAY-43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28441"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SHARP</ProtocolAcronym><ProtocolTitle>A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28091"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of TS-1 and Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Chiba University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="133019"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="225976"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Trial of 'Chemo-Switch' Regimen to Treat Advanced Melanoma</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="27630"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients Undergoing Surgery for Stage II, III, or IV Kidney Cancer</ProtocolTitle><Sponsor>UNC Lineberger Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44847"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28453"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28383"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1267">MRSA infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="158534"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-confirmatory Bridging Study in Total Hip Replacement</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="70599"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I multiple-dose, safety, pharmacokinetic and pharmacodynamic study of BAY-59-7939 (rivaroxaban) in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6126"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODIXa-DVT</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor BAY-59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis</ProtocolTitle><Sponsor>Bayer AG, Bayer Australia Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="574">Deep vein thrombosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44583"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein-PE</ProtocolAcronym><ProtocolTitle>Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="6231"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>BARIVA</ProtocolAcronym><ProtocolTitle>Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="339268"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Einstein VTE III and Einstein Extension</ProtocolAcronym><ProtocolTitle>The effect of oral rivaroxaban in treating and in the long term prevention in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism</ProtocolTitle><Sponsor>Bayer Australia Ltd, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="267386"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>IRIVASC</ProtocolAcronym><ProtocolTitle>Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="174098"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EinsteinChoice</ProtocolAcronym><ProtocolTitle>Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE (Venous Thromboembolism)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1078">Lung embolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="173902"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over Three Treatment Cycles in Healthy, Young Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="70509"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Birth Control Patch Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="60670"></Trial><Drug id="34860">ethinylestradiol + gestodene (transdermal), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of oral fasudil in patients with stable angina</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="5525"></Trial><Drug id="35320">fasudil (oral), Asahi</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Prospective, Pharmacodynamic Study to Compare Platelet Reactivity in Black versus White Patients with Acute Coronary Syndrome (ACS) Treated with Ticagrelor</ProtocolTitle><Sponsor>Amgen Inc, Bayer AG, Daiichi Sankyo Co Ltd, Eli Lilly &amp; Co, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="317040"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEMINI ACS 1</ProtocolAcronym><ProtocolTitle>A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3258">Acute coronary syndrome</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="216173"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EUCLID</ProtocolAcronym><ProtocolTitle>A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="99397"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="39209">axitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study of artemisone as a potential oral treatment of plasmodium infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="268">Plasmodium infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="9199"></Trial><Drug id="39618">artemisone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to assess the safety and tolerability of artemisone against plasmodium infection</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="268">Plasmodium infection</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="9190"></Trial><Drug id="39618">artemisone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="64317"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ALSYMPCA</ProtocolAcronym><ProtocolTitle>A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="33301"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="231217"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane/Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="212741"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>eRADicAte</ProtocolAcronym><ProtocolTitle>Open-Label, Phase II Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration Resistant (Hormone Refractory) Prostate Cancer Subjects With Bone Metastasis</ProtocolTitle><Sponsor>Carolina Research Professionals, LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="179595"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status</ProtocolTitle><Sponsor>Medica Scientia Innovation Research</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="283222"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alpharadin Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton</ProtocolTitle><Sponsor>Algeta ASA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="28004"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>InReTel</ProtocolAcronym><ProtocolTitle>The Influence of Telmisartan on Insulin Resistance and Fatty Liver in Patients Suffer from Hypertension</ProtocolTitle><Sponsor>Klinikum Chemnitz Gmbh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="120057"></Trial><Drug id="44372">bisoprolol fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>QUIP</ProtocolAcronym><ProtocolTitle>BAY-0-9867 Cipro Pediatric Use Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="40">Bacterial infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="53001"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Testosterone, Metformin, or Both, for Hypogonadism in Obese Males</ProtocolTitle><Sponsor>Bayer AG, Fundacion Publica Andaluza para la Investigacion de Malaga en Biomedicina y Salud</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3494">Male hypogonadism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="236616"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="89116"></Trial><Drug id="45857">dienogest + estradiol valerate (oral contraceptive), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study to evaluate the safety and utility of F-18-CCR1 as a brain-imaging biomarker for the early detection and tracking of disease progression of Alzheimer's disease (AD)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="54326"></Trial><Drug id="46179">F-18-CCR1</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="63597"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the safety and efficacy of bendamustine in combination with rituximab in the treatment of patients with advanced low-grade and mantle cell lymphomas with unfavorable prognosis</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="49436"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1745">Follicle center lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="47000">bendamustine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pivotal Bioequivalence FDC Nifedipine/Candesartan versus Loose Combination of Single Components, Fed</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="77278"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed-Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-Intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="71680"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to test the effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adults with high blood pressure whose blood pressure is not well controlled with tablets containing Nifedipine</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="157359"></Trial><Drug id="47178">nifedipine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Comparative, Open-Label Treatment With Double-Blind, Placebo-Controlled Periods Within Treatment Study to Evaluate the Efficacy and Safety of a Once-a-Week Prophylaxis Treatment With BAY-79-4980 Compared to Once-a-Week Prophylaxis Treatment and to on-Demand Treatment With rFVIII-FS Reconstituted With Water for Injection in Previously Treated Patients With Severe Hemophilia A</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="134515"></Trial><Drug id="51391">recombinant Factor VIII (PEGylated liposomal), Bayer/Zilip</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="85148"></Trial><Drug id="52725">ciprofloxacin (inhaled, lung infection/COPD), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FOXTROT</ProtocolAcronym><ProtocolTitle>Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="325">Thromboembolism</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="312046"></Trial><Drug id="52967">apixaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VENERA</ProtocolAcronym><ProtocolTitle>Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG. Safety of the Drug and Patients Tolerability of the Drug Injection is Also Studied</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="134">Glaucoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="350837"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The efficacy of intravitreal aflibercept given in a treat and extend regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion</ProtocolTitle><Sponsor>Centre For Eye Research Australia</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2656">Retinal venous occlusion</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="229334"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VISTA DME</ProtocolAcronym><ProtocolTitle>Study of Intravitreal Aflibercept Injection (IAI; EYLEA; BAY-86-5321) in Patients With Diabetic Macular Edema</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="77822"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIVID-DME</ProtocolAcronym><ProtocolTitle>Intravitreal Alfibercept Injection in Vision Impairment Due to DME</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="76222"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection</ProtocolTitle><Sponsor>University of Indonesia</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="331480"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of the T and E protocol with IVA in combination with retinal photocoagulation in DME patients (extension study)</ProtocolTitle><Sponsor>Shinshu University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="303556"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The efficacy of Eylea to treat proliferative diabetic retinopathy/preproliferative diabetic retinopathy in patients with diabetic macular edema</ProtocolTitle><Sponsor>Kyorin University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="281981"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The efficacy of the treat and extend protocol with aflibercept for diabetic macula edema</ProtocolTitle><Sponsor>Kyoto Prefectural University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2659">Diabetic macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="275019"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MYRROR</ProtocolAcronym><ProtocolTitle>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathological Myopia (mCNV)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3138">Choroidal neovascularization</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="72667"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NEUTON</ProtocolAcronym><ProtocolTitle>Study to evaluate the effectiveness of aflibercept in patients with macular edema secondary to central retinal vein occlusion</ProtocolTitle><Sponsor>Fundacin Retinaplus+</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="292450"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Modified treat and extend regimen of aflibercept to branch retinal vein occlusion with cystoid macular edema</ProtocolTitle><Sponsor>Aoki Eye Clinic, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Jichi Medical University Hospital, Okubo Eye Clinic, Saito Eye Clinic, Takahashi Eye Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="277534"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CENTERA</ProtocolAcronym><ProtocolTitle>Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3352">Macular edema</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="263357"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MATE</ProtocolAcronym><ProtocolTitle>Treating neovascular age-related Macular degeneration with Aflibercept</ProtocolTitle><Sponsor>York Hospitals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="247461"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of second year aflibercept in patients with wAMD</ProtocolTitle><Sponsor>Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Jichi Medical School</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="223268"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>VIEW 2</ProtocolAcronym><ProtocolTitle>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</ProtocolTitle><Sponsor>Bayer AG, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="18499"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Switching to Aflibercept in Patients With Neovascular AMD Not Responding to Anti-VEGF Treatment</ProtocolTitle><Sponsor>Radboud University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="160028"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AAA Study</ProtocolAcronym><ProtocolTitle>To investigate the role of intravitreal aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment</ProtocolTitle><Sponsor>Auckland District Health Board (ADHB), Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="3354">Wet age related macular degeneration</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="155583"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 in Combination With Enzalutamide</ProtocolTitle><Sponsor>All Ireland Cooperative Oncology Research Group, Cancer Trials Ireland</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="209043"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Upfront Combination Pulmonary Arterial Hypertension Therapy</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="367069"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3513">Chronic thromboembolic pulmonary hypertension</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE II</ProtocolAcronym><ProtocolTitle>A Study of Regorafenib in Refractory Advanced Gastro-Esophageal Cancer</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="260950"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Regorafenib as A Single-Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="173006"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Continuous Dosing of BAY-73-4506 in Patients With Advanced Malignancies</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="66133"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGONIVO</ProtocolAcronym><ProtocolTitle>Regorafenib and Nivolumab Simultaneous Combination Therapy</ProtocolTitle><Sponsor>National Cancer Center Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="326836"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGORA</ProtocolAcronym><ProtocolTitle>The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib</ProtocolTitle><Sponsor>Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="263264"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A non-randomized, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY-734506 in patients with advanced solid tumors refractory to standard treatment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="38559"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RE-ARRANGE</ProtocolAcronym><ProtocolTitle>Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC</ProtocolTitle><Sponsor>Grupo de Tratamiento de los Tumores Digestivos</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="265924"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="162134"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REFRAME</ProtocolAcronym><ProtocolTitle>Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="138996"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGARD</ProtocolAcronym><ProtocolTitle>Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="131104"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="359275"></Trial><Drug id="54804">nivolumab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 4-week, dose-finding study to evaluate the efficacy of MENT in both normal and hypogonadal men</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Population Council</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2639">Testosterone deficiency</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="56212"></Trial><Drug id="54914">MENT subdermal implant (male contraceptive/ hormone replacement), Population Council/Schering AG</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1744">Mantle cell lymphoma</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="373629"></Trial><Drug id="55237">ibrutinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Refametinib in Patients With RAS Mut Hepatocellular Carcinoma (HCC)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1767">Hepatocellular carcinoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="164739"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-86-9766 Plus Gemcitabine Phase I Study in Asian</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="104379"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-86-9766 Plus Gemcitabine Phase I Study in Asian</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="104379"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A proof of mechanism, phase 0 study to assess the efficacy, pharmacokinetics, safety and tolerability of florbetaben (18F) in patients with Alzheimers disease and healthy controls</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="14">Alzheimers disease</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="67487"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CogniMS</ProtocolAcronym><ProtocolTitle>Cognition, Fatigue, Depression and HR-QoL in Early Multiple Sclerosis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="148343"></Trial><Drug id="63787">interferon beta-1b, Novartis</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-1</ProtocolAcronym><ProtocolTitle>Open-label, Uncontrolled, Phase II Trial of Intravenous PI3K Inhibitor BAY-80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Bayer HealthCare Limited</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="90005"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="220374"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II, Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Trial id="226848"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1772">Osteosarcoma</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="331813"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI3(Phosphoinositol 3)-kinase Inhibitor BAY-80-6946 With Paclitaxel in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="79862"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese BAY-80-6946 Monotherapy Phase I Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="79601"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-80-6946, Open-label, Phase I Study in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="59742"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo or Peritoneal Dialysis Compared to Healthy Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="17">Anemia</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="217836"></Trial><Drug id="69012">molidustat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 5</ProtocolAcronym><ProtocolTitle>Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="308273"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole (ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C] Vilaprisan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="230626"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ASTEROID 1</ProtocolAcronym><ProtocolTitle>BAY-1002670, Fibroids, Safety and Efficacy EU, US, Canada, Japan</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1780">Uterine fibroids</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="185475"></Trial><Drug id="69015">vilaprisan</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARAMIS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG, Orion Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Trial id="206573"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DISTINCT</ProtocolAcronym><ProtocolTitle>Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="75238"></Trial><Drug id="70045">nifedipine + candesartan (essential hypertension), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="326220"></Trial><Drug id="74146">naproxen sodium (extended-release, pain), Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="297918"></Trial><Drug id="75484">vericiguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY-1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1778">Female contraception</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="234174"></Trial><Drug id="82773">levonorgesterol (3-year intrauterine contraceptive system), Bayer Healthcare</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study for Acarbose/Metformin FDC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="98656"></Trial><Drug id="83247">acarbose + metformin (fixed-dose combination, type 2 diabetes), Bayer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ROCOCO</ProtocolAcronym><ProtocolTitle>Phase I Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="338906"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rogaratinib (BAY-1163877) in Chinese Patients</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China, CordenPharma International GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="363508"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="385629"></Trial><Drug id="95768">BAY-1093884</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Tolerability of BAY-1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="244237"></Trial><Drug id="99698">BAY-1862864</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Repeat Doses of BAY-1817080 in Healthy Males and Proof of Concept in Chronic Cough Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="82">Cough</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="316056"></Trial><Drug id="102704">BAY-1817080</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple-Dose Study of BAY-1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="281">Psoriasis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="335852"></Trial><Drug id="105371">BAY-1834845</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple-Dose Study of BAY-1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="291">Rheumatoid arthritis</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="335852"></Trial><Drug id="105371">BAY-1834845</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38773"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, multicenter, placebo-controlled, phase Ib study to determine the effect of rivaroxaban on the biomarkers of hypercoaguability (F1.2, D-dimer [DD] and thrombin-antithrombin III complex [TAT]) in patients with chronic heart failure (CHF) when given in addition to concurrent CHF therapy</ProtocolTitle><Sponsor>Bayer Schering Pharma AG, Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="75">Blood clotting disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62306"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FORT-1</ProtocolAcronym><ProtocolTitle>Study of Rogaratinib (BAY-1163877) versus Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="327002"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study to evaluate the influence of naproxen on the safety, pharmacokinetics and pharmacodynamics of BAY-59-7939 (rivaroxaban), in healthy male subjects</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6131"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematological Diseases</ProtocolTitle><Sponsor>NPO Center for Supporting Hematology-Oncology Trials</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3795">Febrile neutropenia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32155"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib and Sildenafil for Advanced Solid Tumors</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="231570"></Trial><Drug id="8713">sildenafil citrate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>RISE-IIP</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2976">Bronchiolitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187482"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of vardenafil when co-administered with cimetidine or ranitidine</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="186">Erectile dysfunction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52957"></Trial><Drug id="44398">cimetidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1261">Small-cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="159612"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3462">Metastatic liver cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="320087"></Trial><Drug id="70667">pembrolizumab</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, pilot study to compare the efficacy of cilostazol plus aspirin with aspirin alone in preventing  early neurological deterioration in patients with non-cardioembolic ischemic stroke</ProtocolTitle><Sponsor>Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Co Ltd, Otsuka Pharmaceutical Co Ltd, Sanofi KK, Schering-Plough KK</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3676">Ischemic stroke</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85816"></Trial><Drug id="13482">cilostazol</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, open-label, crossover study to compare the pharmacokinetics and bioequivalence tablets 'acarbose', JSC 'GOSNIISINTEZBELOK' (Russia) and the reference drug tablets 'Glucobay' company 'Bayer Healthcare AG' (Germany)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="168026"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="6386">trastuzumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>INTEGRATE</ProtocolAcronym><ProtocolTitle>A Randomized, Phase II, Double-Blind Study of Regorafenib or Placebo in Refractory Advanced Esophago-Gastric Cancer (AOGC)</ProtocolTitle><Sponsor>Australasian Gastro-Intestinal Trials Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3667">Metastatic esophageal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="130456"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rivaroxaban in Bariatric Surgery</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2979">Surgical procedure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="229033"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-4</ProtocolAcronym><ProtocolTitle>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="248251"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, randomized, double-blind, multicenter, inter-individual comparison study of Gd-EOB-DTPA (SH-L-569) and Gd-BOPTA in MRI with a corresponding blinded reading in patients with known or suspected focal liver lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="201">Liver disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84885"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>REGOVAR</ProtocolAcronym><ProtocolTitle>Regorafenib versus Tamoxifen in Patients With Platinum-sensitive Ovarian Carcinoma and Isolated Biological Progression</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="799">Ovary tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243698"></Trial><Drug id="44314">tamoxifen</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Switching Study From Warfarin to Rivaroxaban</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83871"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study in Healthy Subjects, 2 x 5 mg Tablets Rivaroxaban Versus 1 x 10 mg Tablet Rivaroxaban</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="80894"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rivaroxaban Hypericum Trial</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="365829"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>GEYSER</ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3202">Seasonal allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77734"></Trial><Drug id="2752">cetirizine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PRIGA</ProtocolAcronym><ProtocolTitle>Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis</ProtocolTitle><Sponsor>Fundaci Clnic Per A La Recerca Biomdica</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="70">Liver cirrhosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="86422"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3512">Lung disease pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigate Impact of Yasmin Versus Microgynon on Hemostasis Parameters in Healthy Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45042"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32233"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPAN-ORL06</ProtocolAcronym><ProtocolTitle>Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="264936"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3673">Metastatic head and neck cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 Mg/DRSP 3 Mg) on Quality of Life</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="365">Menstruation disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45040"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="740">Uterus tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25940"></Trial><Drug id="7121">sargramostim</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II study to evaluate the effect of ramatroban on nasal obstruction caused by PGD2 in allergic rhinitis patients</ProtocolTitle><Sponsor>Bayer Yakuhin Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1107">Allergic rhinitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="29566"></Trial><Drug id="2594">ramatroban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First-in-human Study of ATR Inhibitor BAY-1895344 in Patients With Advanced Solid Tumors and Lymphomas</ProtocolTitle><Sponsor>Almac Group, Bayer AG, Bayer Healthcare Co Ltd China</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="301760"></Trial><Drug id="105767">BAY-1895344</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PLANET</ProtocolAcronym><ProtocolTitle>Aflibercept in Polypoidal Choroidal Vasculopathy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="183545"></Trial><Drug id="2622">verteporfin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers</ProtocolTitle><Sponsor>Loxo Oncology Inc, MEDPACE SINGAPORE PTE LTD</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="304549"></Trial><Drug id="101262">LOXO-195</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1272">Myelodysplastic syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="53932"></Trial><Drug id="3364">peginterferon alfa-2b</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI-3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3083">Peritoneal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81893"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pharmacokinetic study of two isomers of rolipram (+/-), administered orally and intravenously, in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16906"></Trial><Drug id="4268">rolipram</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="65206"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naive Patients With Locally Advanced or Metastatic Urothelial Carcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2380">Bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="46031"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ODM-201 Versus Androgen Deprivation Therapy in Hormone Naive Prostate Cancer</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="280153"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, dosimetric and pharmacokinetic study of the anti fibronectin 131-I-L19-small immunoprotein (SIP), in patients with solid tumors</ProtocolTitle><Sponsor>Philogen SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1648">Adrenal cortical carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36556"></Trial><Drug id="43218">131I-radretumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64589"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="55798">crizotinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI3(Phosphoinositol 3)-kinase Inhibitor BAY-80-6946 With Paclitaxel in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="79862"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARCS-Multi</ProtocolAcronym><ProtocolTitle>Phase Ib, Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer (Singapore) Pte Ltd, Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="293132"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of BAY-1834942 in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3658">Metastatic colorectal cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="347143"></Trial><Drug id="110220">BAY-1834942</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III multicenter, single-blind, randomized, inter-individually controlled MRI study to evaluate the safety and efficacy of Gadovist and Magnevist (single iv injection) in patients with known or suspected renal lesions</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc, Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="742">Vascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75857"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A single-center, randomized, unblinded, cross-over study to evaluate the effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate, in healthy Caucasian volunteers</ProtocolTitle><Sponsor>Bayer Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8225"></Trial><Drug id="12555">metrifonate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Gynodian Depot in Women With Impaired Well-being</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="364">Hormone deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="190575"></Trial><Drug id="65324">estradiol valerate + levomefolate calcium (contraception), Bayer</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LDS</ProtocolAcronym><ProtocolTitle>Lipids in Diabetes Study</ProtocolTitle><Sponsor>Bayer plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="119376"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BLT-T2D</ProtocolAcronym><ProtocolTitle>Final Version 30th Dec 2007 Clinical and Biochemical Improvement in Type 2 Diabetic Parameters in Type 2 Diabetic Men With Symptomatic Testosterone Deficiency Syndrome (TDS). A Double-Blind, Placebo-Controlled Study of Depot Testosterone Undecanoate (Nebido) Versus Placebo in a Primary Care Setting</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="174033"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Inhaled A1AT in Adult Stable Bronchiectasis</ProtocolTitle><Sponsor>Hospital Vall D'Hebron</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2432">Bronchiectasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="323899"></Trial><Drug id="46884">Prolastin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>LAVALIER</ProtocolAcronym><ProtocolTitle>Lanthanum versus Calcium Carbonate for Vascular Abnormalities in Patients with CKD and Hyperphosphatemia</ProtocolTitle><Sponsor>Osaka University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3251">End stage renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210182"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-risk Fever and Neutropenia in Children With Cancer: safety and Efficacy of Oral Antibiotics in an Outpatient Setting</ProtocolTitle><Sponsor>Swiss Pediatric Oncology Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1833">Fever</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32141"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="62282">trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of PI3 (Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY-86-9766) in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="79185"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3511">Left heart disease pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="25940"></Trial><Drug id="6408">vinorelbine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TEREPINS</ProtocolAcronym><ProtocolTitle>Testosterone Replacement in Non-Alcoholic Steatohepatitis</ProtocolTitle><Sponsor>Sheffield Teaching Hospitals NHS Foundation Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="149757"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single Dose Ciprofloxacin in the Treatment of Childhood Cholera: Randomized, Controlled Clinical Trial</ProtocolTitle><Sponsor>International Centre For Diarrhoeal Disease Research, Bangladesh</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="343">Vibrio cholerae infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="8624"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="795">Nasopharynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="259309"></Trial><Drug id="7934">doxorubicin (liposomal, STEALTH), Alza</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF</ProtocolAcronym><ProtocolTitle>Phase IIb, Safety and Efficacy Study of Different Oral Doses of BAY-94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115003"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NiraRad</ProtocolAcronym><ProtocolTitle>Phase Ib Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1829">Bone metastases</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290785"></Trial><Drug id="61287">niraparib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, placebo-controlled three way crossover study to evaluate the pharmacodynamics and pharmacokinetics of BAY-X-7195 in healthy volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="30848"></Trial><Drug id="5541">BAY-X-7195</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide, Fludarabine and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27592"></Trial><Drug id="6156">fludarabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TeLoDe12</ProtocolAcronym><ProtocolTitle>Late-onset hypogonadism (LOH) and depressive mood changes - a double-blind, placebo-controlled study with intramuscular application of testosterone undecanoate</ProtocolTitle><Sponsor>Martin-Luther-Universitaet</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="981">Hypogonadism</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="185683"></Trial><Drug id="45617">testosterone undecanoate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2726">Neuroblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study of BAY-1082439 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98541"></Trial><Drug id="77019">BAY-1082439</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91191"></Trial><Drug id="100129">topotecan hydrochloride (oral, small-cell lung cancer), Novartis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, randomized, parallel control study to investigate the efficacy and safety of isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) and acarbose combination therapy in elderly diabetic patients, evaluate whether acarbose in insulin-treated patients can reduce glycemic variability and shorten injection-meal interval</ProtocolTitle><Sponsor>Chinese PLA General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="92231"></Trial><Drug id="45317">human insulin, Novo Nordisk A/S</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation Of Effect Of Chemotherapy For Depiction Of Metastatic Liver Tumor On Gadoxetate Disodium Enhanced MRI</ProtocolTitle><Sponsor>Hiroshima University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3462">Metastatic liver cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132894"></Trial><Drug id="33591">lapatinib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRUST</ProtocolAcronym><ProtocolTitle>A Phase II/III Trial to Evaluate the Efficacy and Safety of BAY-86-6150</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1228">Factor IX deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88568"></Trial><Drug id="52200">BAY-86-6150</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38773"></Trial><Drug id="12205">capecitabine</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Angeliq and Prempro185 on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="178">Hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="21720"></Trial><Drug id="4157">sodium estrone sulfate + sodium equilin sulfate + medroxyprogesterone acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADRRAD</ProtocolAcronym><ProtocolTitle>Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer</ProtocolTitle><Sponsor>Belfast Health &amp; Social Care Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="235876"></Trial><Drug id="7290">triptorelin acetate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NiraRad</ProtocolAcronym><ProtocolTitle>Phase Ib Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Cancer Center, Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="290785"></Trial><Drug id="61287">niraparib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Dose-escalation Study of OMP-54F28 in Subjects With Solid Tumors</ProtocolTitle><Sponsor>OncoMed Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="87980"></Trial><Drug id="76435">ipafricept</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36139"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Research for the Adheerence and QOL for Oral Anti-coagulants(OAC) in Patients With Atrial Fibrillation</ProtocolTitle><Sponsor>KKR Takamatsu Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="168764"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, multicenter, dose-escalating, phase II study of CDP-571 to assess safety, pharmacokinetics, immune response and influence of the antibody on cytokine concentrations in patients with septic shock</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="114">Sepsis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="16885"></Trial><Drug id="2731">CDP-571</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, open-label, non-randomized, single-arm study to evaluate the efficacy of 1.0 M gadobutrol in the diagnosis of patients with unilateral carotid artery stenosis and/or unilateral cerebral infarct by comparing regional cerebral blood to SPECT</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="62">Cerebral infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="345222"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-risk Fever and Neutropenia in Children With Cancer: safety and Efficacy of Oral Antibiotics in an Outpatient Setting</ProtocolTitle><Sponsor>Swiss Pediatric Oncology Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1833">Fever</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32141"></Trial><Drug id="44438">ciprofloxacin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC</ProtocolTitle><Sponsor>Clinical Research Support Center Kyushu, Kyushu Study Group of Clinical Cancer</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="829">Fatigue</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215638"></Trial><Drug id="6104">lansoprazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gadobutrol MRA of abdomen-lower extremity in healthy volunteers</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="284738"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODENZA</ProtocolAcronym><ProtocolTitle>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</ProtocolTitle><Sponsor>Cancer Campus, Grand Paris, Institut Gustave Roussy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="316586"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY-94-8862</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="82461"></Trial><Drug id="14603">eplerenone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, dosimetric and pharmacokinetic study of the anti fibronectin 131-I-L19-small immunoprotein (SIP), in patients with solid tumors</ProtocolTitle><Sponsor>Philogen SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1766">Renal cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36556"></Trial><Drug id="43218">131I-radretumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SURPRISE</ProtocolAcronym><ProtocolTitle>Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux</ProtocolTitle><Sponsor>GWT-TUD GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1845">Phlebothrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83592"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) Drug-Drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212225"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnevist Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="4996"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Dose-Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1770">Nephroblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177466"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="19001">prasugrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of BAY-1436032 in IDH1-mutant Advanced Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="258833"></Trial><Drug id="101614">BAY-1436032</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="432">Dyspepsia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="177117"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COSMOS</ProtocolAcronym><ProtocolTitle>Copanlisib and Gemcitabine in Relapsed/Refractory PTCL</ProtocolTitle><Sponsor>Bayer Korea Ltd, Chonnam National University Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="311">T-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="288180"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>RAPSON</ProtocolAcronym><ProtocolTitle>Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer</ProtocolTitle><Sponsor>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="306965"></Trial><Drug id="2953">docetaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="165927"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study to evaluate the safety and efficacy of fludarabine and paclitaxel in patients with non-Hodgkins lymphoma</ProtocolTitle><Sponsor>Jacobi Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="73461"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer</ProtocolTitle><Sponsor>Houston Methodist</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35202"></Trial><Drug id="44299">ketoconazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="10309">abiraterone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="106382"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation Of Effect Of Chemotherapy For Depiction Of Metastatic Liver Tumor On Gadoxetate Disodium Enhanced MRI</ProtocolTitle><Sponsor>Hiroshima University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3462">Metastatic liver cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132894"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>06-882 A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer</ProtocolTitle><Sponsor>New York University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45857"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib/Carboplatin/Paclitaxel in Patients With Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="27986"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54469">vemurafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of Angeliq on skin and hair of female healthy postmenopausal volunteers</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78436"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cycle Control and Safety of E2-DRSP</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="197170"></Trial><Drug id="22275">estradiol valerate + drospirenone (oral, HRT), Bayer Schering</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Magnevist (SH-L-451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3471">Metastatic brain cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44481"></Trial><Drug id="12347">gadopentetate dimeglumine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bleeding Pattern and User Satisfaction During Second Consecutive Mirena in Contraception and Treatment of Menorrhagia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2051">Menorrhagia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="32167"></Trial><Drug id="5312">misoprostol</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="195533"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, prospective, randomized, double-blind, comparative, multicenter clinical trial to compare	 safety and efficacy of moxifloxacin compared with piperacillin + tazobactam and amoxicillin + clavulanate for the treatment of complicated intra-abdominal infections</ProtocolTitle><Sponsor>Case Western Reserve University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="68863"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and Pharmacokinetics of Single-dose Intravenous Moxifloxacin in Pediatric Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="746">Infectious disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="63500"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="307">Squamous cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="35591"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II study to evaluate the safety, efficacy and tolerability of bendamustine in combination with mitoxantrone and rituximab in patients with symptomatic stage III/IV indolent lymphomas</ProtocolTitle><Sponsor>Jenapharm GmbH &amp; Co KG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="203">Lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="49427"></Trial><Drug id="11519">mitoxantrone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Second Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="247966"></Trial><Drug id="3536">pemetrexed disodium</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple-Dose Study of BAY-1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="281">Psoriasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="335852"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52615"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (Mirena)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2991">Uterine hemorrhage</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75160"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="22965">temsirolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY-43-9006)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58925"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Treating Patients With Advanced Malignant Solid Tumors</ProtocolTitle><Sponsor>University of California Davis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3713">Advanced solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38949"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib in Patients With Advanced Myeloid Malignancies</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="273">Myeloproliferative disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="287296"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="427">Uterine cervix tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ATMOS</ProtocolAcronym><ProtocolTitle>This Study Tests the Safety of Inhaled BAY-1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="361572"></Trial><Drug id="105762">BAY-1237592</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3146">Gallbladder tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma</ProtocolTitle><Sponsor>Spectrum Health Hospitals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2726">Neuroblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="191428"></Trial><Drug id="4577">topotecan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, safety, dosimetric and pharmacokinetic study of the anti fibronectin 131-I-L19-small immunoprotein (SIP), in patients with solid tumors</ProtocolTitle><Sponsor>Philogen SpA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="989">Colorectal tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="36556"></Trial><Drug id="43218">131I-radretumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="39209">axitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3672">Metastatic colon cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>BARIVA</ProtocolAcronym><ProtocolTitle>Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery</ProtocolTitle><Sponsor>University Hospital Inselspital, Berne</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1076">Thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="339268"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib (BAY-80-6946) Drug-Drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="212225"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-3</ProtocolAcronym><ProtocolTitle>Copanlisib and Rituximab in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma (iNHL)</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222423"></Trial><Drug id="6736">rituximab</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Tolerability of BAY-1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="244237"></Trial><Drug id="99698">BAY-1862864</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006: Phase II in Advanced Breast Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28782"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-1238097, First in Man</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="230">Neoplasm</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222585"></Trial><Drug id="91106">BET inhibitors (oral, cancer), Bayer HealthCare AG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ADVISE</ProtocolAcronym><ProtocolTitle>Low-Dose Nifedipine-Valsartan Combination Compared to Up-Titrated Valsartan Monotherapy in Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="61043"></Trial><Drug id="6587">nifedipine (once daily, OROS), Alza</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BRUISECONTROL2</ProtocolAcronym><ProtocolTitle>Strategy of Continued Versus Interrupted novel oral anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events</ProtocolTitle><Sponsor>Ottawa Heart Institute Research Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2749">Hematoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90553"></Trial><Drug id="24343">dabigatran etexilate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A post-marketing, five-year, prospective, multi-center, randomized study to evaluate the efficacy of Helixate in treatment of children with hemophilia A</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="51454"></Trial><Drug id="3091">octocog alfa, Genentech/Bayer</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PI-3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1516">Biliary cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="81893"></Trial><Drug id="3199">gemcitabine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Safety and Efficacy of an OC Preparation versus Placebo for Six Treatment Cycles in Women With Moderate Acne</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="64327"></Trial><Drug id="2963">drospirenone + ethinylestradiol, Schering AG</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3471">Metastatic brain cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/II study to evaluate the efficacy, safety, pharmacokinetic and pharmacodynamic effect of midazolam, omeprazole and dextromethorphan on sorafenib in metastatic melanoma patients</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3257">Stage IV melanoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52766"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PEACE III</ProtocolAcronym><ProtocolTitle>Phase III Radium 223 mCRPC</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210276"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Re-Treatment Safety of Radium-223 Dichloride in Castration-Resistant Prostate Cancer With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="153754"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>8+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CARE-MS I</ProtocolAcronym><ProtocolTitle>Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study 1</ProtocolTitle><Sponsor>Sanofi Genzyme</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="213">Multiple sclerosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="6755"></Trial><Drug id="2752">cetirizine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib in Combination With RAD-001 in Patients With Advanced Neuroendocrine Tumors</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1128">Neuroendocrine tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="58975"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study of BAY-1082439 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="98541"></Trial><Drug id="77019">BAY-1082439</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>X-VERT</ProtocolAcronym><ProtocolTitle>Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Non-valvular Atrial Fibrillation Scheduled for Cardioversion</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="57">Cardiovascular disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="90547"></Trial><Drug id="44375">warfarin</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>Eylea IIT</ProtocolAcronym><ProtocolTitle>Outcomes of intravitreal aflibercept (Eylea) treatment for treatment-nave contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed with intravitreal ranibizumab in the first eye</ProtocolTitle><Sponsor>Bayer Korea Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1226">Age related macular degeneration</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="314090"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Riociguat on Bone Metabolism</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3510">Pulmonary artery hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47886"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib Drug-Drug Interaction Study in Healthy Male Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="219462"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>BAY-43-9006 in Previously Untreated Patients With Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="47939"></Trial><Drug id="3803">paclitaxel</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A double-blind, placebo-controlled, randomized study to determine the influence of age on the safety, tolerability, and pharmacokinetics (PK) of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="109132"></Trial><Drug id="2595">cerivastatin</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Copanlisib Pharmacodynamic Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="193917"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, open-label, single-arm study to evaluate the efficacy of gadobutrol in the treatment of hospitalized patients with tumor in the liver, pelvis, or bone and soft tissue</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3378">Soft tissue sarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="343144"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3466">Metastatic bladder cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43433"></Trial><Drug id="44383">carboplatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="4299">Salivary gland cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Iloprost in Patients with Eisenmenger Syndrome</ProtocolTitle><Sponsor>Royal Brompton &amp; Harefield NHS Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2087">Eisenmenger syndrome</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342099"></Trial><Drug id="6149">iloprost (inhaled nebulizer formulation, pulmonary hypertension), Bayer Schering/Actelion</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>EICAR</ProtocolAcronym><ProtocolTitle>Contrast Enhancement on Coronary Computed Tomographic Angiography</ProtocolTitle><Sponsor>Maastricht University Medical Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="80">Coronary artery disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="231276"></Trial><Drug id="6685">iopromide</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="552">Bleeding</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="19001">prasugrel</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="38773"></Trial><Drug id="9174">vatalanib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>AMOUR</ProtocolAcronym><ProtocolTitle>Aflibercept for Macular Edema With Underlying Retinitis Pigmentosa (AMOUR) Study</ProtocolTitle><Sponsor>Moorfields Eye Hospital, Moorfields Eye Hospital Nhs Trust</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2004">Retinitis pigmentosa</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="251579"></Trial><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TRUST</ProtocolAcronym><ProtocolTitle>A Phase II/III Trial to Evaluate the Efficacy and Safety of BAY-86-6150</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="121">Factor VIII deficiency</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88568"></Trial><Drug id="52200">BAY-86-6150</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="50">Bronchitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARASENS</ProtocolAcronym><ProtocolTitle>ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="263277"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>RDEA-119 and Sorafenib Combination Dose-Escalation Study</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1134">Thyroid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34206"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="12973">sunitinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Phase I, Dose-Escalation Study With BAY-1143572 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="49">Breast tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="154135"></Trial><Drug id="87787">atuveciclib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ACE</ProtocolAcronym><ProtocolTitle>Acarbose Cardiovascular Evaluation Trial</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="224">Myocardial infarction</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="43326"></Trial><Drug id="6051">acarbose</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1264">Macroglobulinemia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="220374"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NOVEL</ProtocolAcronym><ProtocolTitle>Nifedipine On Coronary Vascular Function After Drug Eluting Stent Implantation</ProtocolTitle><Sponsor>Tohoku University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="23">Angina</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="210503"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess</ProtocolTitle><Sponsor>KAOHSIUNG VETERANS GENERAL HOSPITAL</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="2994">Liver abscess</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="54535"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIa, randomized, double-blind, placebo-controlled, safety, efficacy and pharmacokinetic study of KN-38-7271 in patients with severe traumatic brain injury (TBI)</ProtocolTitle><Sponsor>KeyNeurotek Pharmaceuticals AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="834">Brain injury</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="7213"></Trial><Drug id="22439">KN-38-7271</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of effect of rivaroxaban in patients with non-valvular atrial fibrillation</ProtocolTitle><Sponsor>Yamaguchi University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1587">Coronary thrombosis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="221453"></Trial><Drug id="32677">rivaroxaban</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the effects of atorvastatin high-dose and atorvastatin/ezetimibe combination therapy</ProtocolTitle><Sponsor>Misaki Naika Clinic</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="837">Non-insulin dependent diabetes</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="284962"></Trial><Drug id="11367">ezetimibe</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, Dose-Escalation Study for BAY-1251152 in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249187"></Trial><Drug id="100352">BAY-1251152</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open, Multiple-Dose Titration Study In Patients With Pulmonary Hypertension</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5158"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A two part, phase II, safety, tolerability and pharmacokinetic study of BAY-63-2521 in patients with pulmonary artery hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1867">Pulmonary hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="5157"></Trial><Drug id="54614">riociguat</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, dose-escalation study to evaluate the safety, efficacy and pharmacokinetics of sorafenib in combination with docetaxel and prednisone for the treatment of chemo-naive patients with metastatic castration-resistant prostate cancer</ProtocolTitle><Sponsor>Bayer AG, Clinique Universitaires Saint-Luc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91174"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of lanthanum carbonate on coronary artery calcification in patients new to dialysis</ProtocolTitle><Sponsor>Kobe University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1083">Calcification</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="149749"></Trial><Drug id="9819">lanthanum carbonate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>MaxSep</ProtocolAcronym><ProtocolTitle>Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem plus Moxifloxacin) in the Treatment of Severe Sepsis and Septic Shock</ProtocolTitle><Sponsor>Kompetenznetz Sepsis</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="114">Sepsis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11415"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="287715"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY-1841788 (ODM-201)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="270840"></Trial><Drug id="69844">darolutamide</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PERI</ProtocolAcronym><ProtocolTitle>Primovist/Eovist in Renally Impaired Patients</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3245">Nephrogenic fibrosing dermopathy</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="56387"></Trial><Drug id="10536">gadoxetate disodium</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>PIONEER AF-PCI</ProtocolAcronym><ProtocolTitle>A Study Exploring Two Strategies of Rivaroxaban (JNJ-39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Janssen Scientific Affairs, Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1542">Atrial fibrillation</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="115251"></Trial><Drug id="36332">ticagrelor</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DISTINCT</ProtocolAcronym><ProtocolTitle>Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="75238"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed-Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-Intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3366">Essential hypertension</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="71680"></Trial><Drug id="4522">candesartan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="2454">Glioblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="24791"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers</ProtocolTitle><Sponsor>Loxo Oncology Inc, MEDPACE SINGAPORE PTE LTD</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3769">Anaplastic thyroid cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="304549"></Trial><Drug id="101262">LOXO-195</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-h Extended Release Tablet From Two Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="338941"></Trial><Drug id="3516">loratadine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1765">Cholangiocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="184038"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ZK-219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="3657">Metastatic breast cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45207"></Trial><Drug id="28176">sagopilone</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3153">Adenoid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="160243"></Trial><Drug id="89138">rogaratinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Orca</ProtocolAcronym><ProtocolTitle>Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="378616"></Trial><Drug id="44292">fluconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1011">Esophagus tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54449">afatinib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, open-label, parallel-group study to evaluate the safety, pharmacokinetics and dialysability of SH-L-562 in patients with renal failure</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="69">Renal failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342647"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="249">Pancreas tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="50935">cabozantinib S-malate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-lable, single-dose, single-center, parallel-group study to evaluate the safety and pharmacokinetics of SH-L-562 in healthy elderly subjects</ProtocolTitle><Sponsor>Bayer HealthCare Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="342675"></Trial><Drug id="11687">gadobutrol</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>16+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>DRUP</ProtocolAcronym><ProtocolTitle>The Drug Rediscovery Protocol</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="274411"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3666">Metastatic stomach cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265067"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to measure the serum cortisol levels in volunteers receiving extensive cutaneous application of methylprednisolone aceponate or mometasone furoate</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="109">Eczema</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="50602"></Trial><Drug id="13594">mometasone furoate (nasal), Merck &amp; Co</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1828">Multiple myeloma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="26282"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma</ProtocolTitle><Sponsor>Spectrum Health Hospitals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2533">Medulloblastoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="191428"></Trial><Drug id="4577">topotecan</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interaction With HIV Antiretroviral Agents</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="158">HIV infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="241152"></Trial><Drug id="63988">tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride (HIV-1 infection, fixed dose), Gilead Sciences</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SKADI</ProtocolAcronym><ProtocolTitle>Study for Long-Term Treatment of Acne Vulgaris With Skinoren Versus Differin</ProtocolTitle><Sponsor>University of Magdeburg</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="3040">Acne vulgaris</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="78992"></Trial><Drug id="9001">azelaic acid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Regorafenib in Patients With Advanced Myeloid Malignancies</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="287296"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1061">Sinusitis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9107"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>10+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>TAPUR</ProtocolAcronym><ProtocolTitle>Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</ProtocolTitle><Sponsor>American Society of Clinical Oncology</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254403"></Trial><Drug id="16063">olaparib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1771">Transitional cell carcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="262770"></Trial><Drug id="54624">regorafenib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2243">Fallopian tube cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ODENZA</ProtocolAcronym><ProtocolTitle>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</ProtocolTitle><Sponsor>Cancer Campus, Grand Paris, Institut Gustave Roussy</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1069">Metastasis</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="316586"></Trial><Drug id="53981">enzalutamide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>SCOUT</ProtocolAcronym><ProtocolTitle>A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children</ProtocolTitle><Sponsor>Bayer AG, Bayer Consumer Care AG CH, Loxo Oncology Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2445">Fibrosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="249218"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>NAVIGATE</ProtocolAcronym><ProtocolTitle>A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="2445">Fibrosarcoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="243052"></Trial><Drug id="86278">larotrectinib sulfate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride Long-Term Follow-Up Program</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1012">Bone tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="218250"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression</ProtocolTitle><Sponsor>University of Colorado at Denver and Health Sciences Center</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="365">Menstruation disorder</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88156"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="286">Renal disease</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="106382"></Trial><Drug id="5800">pantoprazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>COPAN-ORL06</ProtocolAcronym><ProtocolTitle>Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss</ProtocolTitle><Sponsor>The UNICANCER Group</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3198">Larynx tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="264936"></Trial><Drug id="10388">cetuximab</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies</ProtocolTitle><Sponsor>H Lee Moffitt Cancer Center and Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91191"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I dose-escalating study to evaluate the safety, efficacy and pharmacokinetics of sorafenib in Japanese patients with solid tumors</ProtocolTitle><Sponsor>Onyx Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="52925"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics (PK) Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors</ProtocolTitle><Sponsor>Sarah Cannon Research Institute</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="45864"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="725">Solid tumor</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="28448"></Trial><Drug id="29831">sorafenib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="2399">Adenocarcinoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="254741"></Trial><Drug id="70824">anetumab ravtansine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radium-223 Dichloride (BAY-88-8223) in Castration-resistant (Hormone-refractory) Prostate Cancer Patients With Bone Metastases</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="3664">Metastatic prostate cancer</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="84317"></Trial><Drug id="40115">radium Ra 223 dichloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Ketoconazole on the Pharmacokinetics of Refametinib</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication></Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="151309"></Trial><Drug id="56559">refametinib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Proportionality Study With BAY-94-8862 IR (Immediate Release) Tablets</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91819"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>FINESSE-HF</ProtocolAcronym><ProtocolTitle>Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensation</ProtocolTitle><Sponsor>Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="253339"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ARTS-HF Japan</ProtocolAcronym><ProtocolTitle>Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="55">Cardiac failure</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="157446"></Trial><Drug id="69013">finerenone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>ESPARIOS 1</ProtocolAcronym><ProtocolTitle>BAY-98-7196 Dose-Finding/POC Study</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="215042"></Trial><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the efficacy of BAY-94-9172 in humans</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2678">Frontotemporal dysplasia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34633"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study to evaluate the efficacy of PET imaging with BAY-94-9172 in healthy subjects, Alzheimers disease (AD) patients and patients with frontotemporal lobar degeneration (FTLD)</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="2678">Frontotemporal dysplasia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="34586"></Trial><Drug id="57021">florbetaben (18F)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-Ventilated Patients With Nosocomial Pneumonia</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1815">Bacterial pneumonia</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="62317"></Trial><Drug id="44937">amikacin (inhaled, Aeroneb), Bayer</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>CHRONOS-2</ProtocolAcronym><ProtocolTitle>Phase III Copanlisib in Rituximab-refractory iNHL</ProtocolTitle><Sponsor>Bayer AG, Bayer HealthCare AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="316">B-cell lymphoma</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="222628"></Trial><Drug id="64231">copanlisib hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>